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Abstract: Das Epstein-Barr-Virus (EBV) ist ein ubiquitäres Virus, mit welchem über 95% aller Menschen
infiziert sind. Die meisten Träger des Pathogens bleiben während ihrer frühen Kindheit asymptomatisch.
Eine Minderheit derer, die zu einem späteren Zeitpunkt infiziert werden, durchlaufen als symptomatis-
che Primärinfektion die infektiöse Mononukleose (IM). Nach einer lytischen Replikation während der
Primärinfektion bleibt EBV latent und lebenslang in B-Zellen des betroffenen Organismus. Die Mehrheit
der EBV-Träger ist durch das Virus nicht beeinträchtigt. Allerdings ist für einen Teil der EBV-Infektionen
und im besonderen der IM eine Assoziation mit einer Vielzahl von Krankheiten beschrieben. Zu diesen
Erkrankungen zählen das Burkitt- und Hodgkin-Lymphom, proliferative Krankheiten nach Transplan-
tationen und das Nasopharynxkarzinom. Zusätzlich liegen zahlreiche Hinweise für einen Zusammen-
hang von EBV mit verschiedenen Autoimmunkrankheiten wie beispielsweise der Multiplen Sklerose (MS)
und Myasthenia Gravis (MG) vor. Der genaue Mechanismus von EBV in diesen autoimmun medi-
ierten Erkrankungen ist noch nicht vollständig geklärt. Um die Rolle des Virus im Pathomechanismus
dieser Erkrankungen zu verstehen, führten wir drei Studien durch, die den Zusammenhang zwischen
EBV Infektion und Autoimmunität untersuchen sollten. Hierbei konzentrierten wir uns auf die drei
Erkrankungen IM, MS und MG. Grundlage der ersten Studie war die Hypothese, dass während einer
fulminanten IM- Infektion anhaltende autoreaktive humorale und zelluläre Reaktionen generiert werden,
die zu toimmunpathologien im späteren Leben führen. Wir fanden eine erhöhte humorale Immunant-
wort, die mit der EBV-Viruslast positiv korrelierte. Dies legt nahe, dass die mit EBV in Verbindung
stehende humorale Antwort zur Immunpathologie im späteren Leben beiträgt. Als nächstes untersuchten
wir, ob eine Behandlung mit IFN-￿ bei MS-Patienten die EBV-spezifische Immunantwort beeinflusst.
Wir fanden in MS-Patienten eine reduzierte zelluläre Antwort auf EBNA1, jedoch keine Veränderung
der Immunantwort auf andere EBV Antigene. Dies ist ein Indiz dafür, dass EBNA1-spezifische T-Zellen
in der Pathogenese der MS eine Rolle spielen. Unsere dritte Studie hatte zum Ziel, die Kontroverse
um den Zusammenhang von EBV und MG zu klären. Trotz Berichten über aktive EBV-Infektionen
im Thymus von MG Patienten konnten wir nur geringe Anzeichen von EBV-Infektionen auf DNA- und
Proteinlevel finden. Folglich konnten wir nicht bestätigen, dass eine aktive EBV-Infektion in der Patho-
genese der MG eine Rolle spielt. Trotz zahlreicher Krankheiten, die mit EBV assoziiert sind, gibt es
derzeit keine Behandlung, welche auf latente EBV-Infektionen abzielt. In der letzten in dieser Arbeit
beschriebenen Studie lag der Fokus auf EBNA1, welches während der latenten Virusphase exprimiert
wird. Mit einem Hochdurchsatz-Screening identifizierten wir die Substanz Tiloron als einen Inhibitor
von EBNA1-Funktionen, der die Erhaltung und Replikation des Virus während EBV-Infektionen re-
duziert. Die Substanz zeigte zytotoxische und antiproliferative Effekte auf EBV-positive, jedoch nur in
geringem Maß auf EBV-negative Lymphom- Zelllinien. Des Weiteren führte Tiloron zu reduzierter EBV-
assoziierter Tumorlast in immungeschwächten Mäusen und wenig reduzierter EBV-Viruslast in EBV-
infizierten Mäusen mit einem humanen Immunsystem. Tiloron hat vielversprechendes Potential, nicht
nur im Hinblick auf eine Behandlung von EBV-Infektionen, sondern auch im Hinblick auf EBV-assoziierte
Erkrankungen. Zusammenfassend bekräftigen unsere Beobachtungen, dass es bei IM-Patienten und bei
IFN- ￿ behandelten MS-Patienten eine Assoziation von EBV und Autoimmunität gibt. Unsere Daten
betreffend autoreaktiven poly-spezifischen humoralen Immunantworten während der IM deuten darauf
hin, dass EBV bereits vor dem Krankheitsausbruch eine Rolle spielt. Das Hochdurchsatz-Screening hat
eine Substanz identifiziert, die das Potential hat, bei latenten EBV-Infektionen und EBV-assoziierten
Krankheiten eingesetzt zu werden. Mitte der 80er-Jahre nannte de-Thé EBV den „Stein von Rosette für
Verständnis von der Rolle von Viren in menschlicher Karziogenese“ [2]. Mit den in dieser Doktorarbeit
gewonnen Erkenntnissen glauben wir einen Schritt näher an die Entschlüsselung vom Stein von Rosette
gekommen zu sein im Bereich von virus-assoziierten Autoimmunerkrankungen und deren Behandlungen.
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SUMMARY	  
 
Epstein-Barr virus (EBV) is a ubiquitous pathogen that infects more than 95% of the human 
adult population. Most people acquire the virus asymptomatically early in their childhood, 
while a small percentage who acquire the virus later in life would develop symptomatic 
primary infection called infectious mononucleosis (IM). After lytically replicating in the early 
stages of the primary infection, EBV establishes latency in B cells and is maintained for a 
lifetime. Even though the majority of EBV carriers are not affected by the virus, EBV 
infection and particularly a history of IM have been associated with a number of malignancies 
such as Burkitt’s and Hodgkin’s lymphoma, posttransplant proliferative disease, and 
nasopharyngeal carcinomas among others. Moreover, accumulating evidence points towards 
an association of the virus with several autoimmune diseases such as multiple sclerosis (MS) 
and myasthenia gravis (MG). Despite a plethora of conflicting studies implicating EBV in the 
immuno-pathogenesis of these autoimmune diseases, the exact mechanism of causation has 
not yet been clearly elucidated. To address this issue we designed three studies that 
respectively looked at the association of the virus with autoreactivity during IM, EBV 
responses in IFN-β treated MS patients, and involvement of EBV in MG.  
In the first study, we hypothesized that during the fulminant infection of IM, 
persistent autoreactive humoral and cellular immune responses are generated that eventually 
lead to autoimmune-pathologies later in life. We discovered considerable humoral poly-
autoreactivity that positively correlated with EBV viral load. These results suggest a potential 
role of EBV-associated humoral immune responses in contributing to immunopathologies 
later in life. 
Next, we investigated whether IFN-β treatment affects EBV-specific immune 
responses in MS patients. We observed decreased cellular responses to EBNA1 but not to 
other EBV antigens in MS patients who responded to IFN-β treatment, which hinted at the 
role of EBNA1-specific T cells in the pathogenesis of the disease. 
 Our third study aimed at clarifying the controversial association of EBV in MG. 
Despite reports of active EBV infection in MG thymi, we found only rarely signs of EBV 
infection on DNA and protein level. Therefore, we could not confirm that active EBV 
infection is implicated in the pathogenesis of MG. 
 Despite the considerable number of diseases associated with EBV, currently no 
treatment exists that targets latent EBV infection. In the last study described in this thesis, we 
targeted EBNA1, a viral antigen expressed during all latency stages of the virus. With a high-
throughput screening we were able to identify Tilorone as an inhibitor of EBNA1’s functions 
to maintain and replicate latent EBV infection. The compound had cytotoxic and anti-
SUMMARY 
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proliferative effects on EBV-positive but to a lesser extent on EBV-negative lymphoma cell 
lines and reduced EBV-associated tumor burden in immunodeficient mice, but only 
marginally decreased EBV viral load in EBV-infected mice with reconstituted human 
immune system components. The compound might nevertheless constitute a promising lead 
compound to develop small molecules for the treatment of not only EBV infection but also 
EBV-associated diseases. 
 In conclusion, our observations in IM patients and IFN-β treated MS patients have 
reinforced the association of EBV and autoimmunity pointing at early involvement of EBV in 
the development of autoreactive poly-specific humoral immune responses. Our high-
throughput screen on the other side has led to the identification of a compound that is a 
promising candidate against latent EBV infection and EBV-associated diseases.  
 In the mid 1980s, de Thé named EBV the ”Rosetta stone for understanding the role of 
viruses in human carcinogenesis” [2]; with the work described in this doctoral thesis we 
believe we have gone one step closer to deciphering the Rosetta stone of virus-associated 
autoimmune diseases and the strategies to treat them. 
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ZUSAMMENFASSUNG	  
 
Das Epstein-Barr-Virus (EBV) ist ein ubiquitäres Virus, mit welchem über 95% aller 
Menschen infiziert sind. Die meisten Träger des Pathogens bleiben während ihrer frühen 
Kindheit asymptomatisch. Eine Minderheit derer, die zu einem späteren Zeitpunkt infiziert 
werden, durchlaufen als symptomatische Primärinfektion die infektiöse Mononukleose (IM). 
Nach einer lytischen Replikation während der Primärinfektion bleibt EBV latent und 
lebenslang in B-Zellen des betroffenen Organismus. Die Mehrheit der EBV-Träger ist durch 
das Virus nicht beeinträchtigt. Allerdings ist für einen Teil der EBV-Infektionen und im 
besonderen der IM eine Assoziation mit einer Vielzahl von Krankheiten beschrieben. Zu 
diesen Erkrankungen zählen das Burkitt- und Hodgkin-Lymphom, proliferative Krankheiten 
nach Transplantationen und das Nasopharynxkarzinom. Zusätzlich liegen zahlreiche 
Hinweise für einen Zusammenhang von EBV mit verschiedenen Autoimmunkrankheiten wie 
beispielsweise der Multiplen Sklerose (MS) und Myasthenia Gravis (MG) vor. Der genaue 
Mechanismus von EBV in diesen autoimmun mediierten Erkrankungen ist noch nicht 
vollständig geklärt. Um die Rolle des Virus im Pathomechanismus dieser Erkrankungen zu 
verstehen, führten wir drei Studien durch, die den Zusammenhang zwischen EBV Infektion 
und Autoimmunität untersuchen sollten. Hierbei konzentrierten wir uns auf die drei 
Erkrankungen IM, MS und MG. 
Grundlage der ersten Studie war die Hypothese, dass während einer fulminanten IM-
Infektion anhaltende autoreaktive humorale und zelluläre Reaktionen generiert werden, die zu 
Autoimmunpathologien im späteren Leben führen. Wir fanden eine erhöhte humorale 
Immunantwort, die mit der EBV-Viruslast positiv korrelierte. Dies legt nahe, dass die mit 
EBV in Verbindung stehende humorale Antwort zur Immunpathologie im späteren Leben 
beiträgt. 
Als nächstes untersuchten wir, ob eine Behandlung mit IFN-β bei MS-Patienten die 
EBV-spezifische Immunantwort beeinflusst. Wir fanden in MS-Patienten eine reduzierte 
zelluläre Antwort auf EBNA1, jedoch keine Veränderung der Immunantwort auf andere EBV 
Antigene. Dies ist ein Indiz dafür, dass EBNA1-spezifische T-Zellen in der Pathogenese der 
MS eine Rolle spielen. 
Unsere dritte Studie hatte zum Ziel, die Kontroverse um den Zusammenhang von 
EBV und MG zu klären. Trotz Berichten über aktive EBV-Infektionen im Thymus von MG 
Patienten konnten wir nur geringe Anzeichen von EBV-Infektionen auf DNA- und 
Proteinlevel finden. Folglich konnten wir nicht bestätigen, dass eine aktive EBV-Infektion in 
der Pathogenese der MG eine Rolle spielt. 
ZUSAMMENFASSUNG 	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Trotz zahlreicher Krankheiten, die mit EBV assoziiert sind, gibt es derzeit keine 
Behandlung, welche auf latente EBV-Infektionen abzielt. In der letzten in dieser Arbeit 
beschriebenen Studie lag der Fokus auf EBNA1, welches während der latenten Virusphase 
exprimiert wird. Mit einem Hochdurchsatz-Screening identifizierten wir die Substanz Tiloron 
als einen Inhibitor von EBNA1-Funktionen, der die Erhaltung und Replikation des Virus 
während EBV-Infektionen reduziert. Die Substanz zeigte zytotoxische und antiproliferative 
Effekte auf EBV-positive, jedoch nur in geringem Maß auf EBV-negative Lymphom-
Zelllinien. Des Weiteren führte Tiloron zu reduzierter EBV-assoziierter Tumorlast in 
immungeschwächten Mäusen und wenig reduzierter EBV-Viruslast in EBV-infizierten 
Mäusen mit einem humanen Immunsystem. Tiloron hat vielversprechendes Potential, nicht 
nur im Hinblick auf eine Behandlung von EBV-Infektionen, sondern auch im Hinblick auf 
EBV-assoziierte Erkrankungen. 
Zusammenfassend bekräftigen unsere Beobachtungen, dass es bei IM-Patienten und bei IFN-
β behandelten MS-Patienten eine Assoziation von EBV und Autoimmunität gibt. Unsere 
Daten betreffend autoreaktiven poly-spezifischen humoralen Immunantworten während der 
IM deuten darauf hin, dass EBV bereits vor dem Krankheitsausbruch eine Rolle spielt. Das 
Hochdurchsatz-Screening hat eine Substanz identifiziert, die das Potential hat, bei latenten 
EBV-Infektionen und EBV-assoziierten Krankheiten eingesetzt zu werden. 
Mitte der 80er-Jahre nannte de-Thé EBV den „Stein von Rosette für Verständnis von 
der Rolle von Viren in menschlicher Karziogenese“ [2]. Mit den in dieser Doktorarbeit 
gewonnen Erkenntnissen glauben wir einen Schritt näher an die Entschlüsselung vom Stein 
von Rosette gekommen zu sein im Bereich von virus-assoziierten Autoimmunerkrankungen 
und deren Behandlungen. 	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aa   Amino acid 
7-AAD   7-Aminoactinomycin D 
AChR   Acetylcholin receptor 
ADP   Adenosine diphosphate 
APC (cell type)  Antigen-presenting cells 
APC (FACS)   Allophycocyanin 
BART   BamHI A rightward transcript 
Bax   Bcl-2 associated X protein 
Bcl-2   B-cell lymphoma 2 
BCR   B cell receptor 
bp   Base pair 
CD   Cluster of differentiation 
CFSE   Carboxyfluorescein succinimidyl ester 
CIS   Clinically isolated syndromes 
CMV   Cytomegalovirus 
CNS   Central nervous system 
CTL   Cytotoxic T lymphocytes 
Da   Dalton 
DC   Dendritic cells 
DMSO   Dimethyl sulfoxide 
DNA   Deoxyribonucleic acid 
DS   Dyad symmetry 
DTT   Dithiothreitol 
EAE   Experimental allergic encephalomyelitis 
EBER   EBV-encoded RNA 
EBNA1  EBV nuclear antigen 1 
EBV   Epstein-Barr virus 
E. coli   Escherichia coli 
EDSS   Expanded Disability Status Scale 
ELISA   Enzyme-linked immunosorbent assay 
ELISPOT  Enzyme-linked immunosorbent spot 
EMSA   Electrophoretic mobility shift assay 
EOMG   Early onset myasthenia gravis 
FCS   Fetal calf serum 
FR   Family of repeats 
g   Gravitational force 
GC   Germinal center 
Gd   Gadolinium 
gp   Glycoprotein  
HCl   Hydrogen chloride 
HEK   Human Embryonic Kidney 
HHV   Human herpes virus 
His   Histidine 
HL   Hodgkin’s lymphoma 
HLA   Human leukocyte antigen 
HRP   Horseradish peroxidase 
HTS   High-throughput screen 
IFN-β   Interferon beta 
IFN-γ   Interferon gamma 
IM   Infectious mononucleosis 
IRF   IFN regulatory factors 
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Ion   Ionomycin 
i.p.   Intraperitoneal 
IPTG   Isopropylthio-β-galactoside 
ITAM   Immunoreceptor tyrosine-based activation motifs 
i.v.    Intravenously 
kbp   Kilobase pairs 
KSHV   Kaposi’s sarcoma virus 
LB   Lysogeny broth 
LCL   Lymphoproliferative cell line 
LD50   Lethal dose, 50 percent kill 
LMP   Latency membrane protein  
MACS   Magnetic-activated cell sorting 
MFI   Mean fluorescence intensity 
MG   Myasthenia gravis 
MHC   Major histocompatibility  
MHV-68  Murine gamma-herpesvirus 68 
MOG   Myelin Oligodendrocyte glycoprotein 
MOI   Multiplicity of infection 
MRI   Magnetic resonance imaging 
MS   Multiple sclerosis 
Nab   Neutralizing antibody 
NaCl   Sodium chloride 
NFkB   Nuclear factor kappa B 
NK   Natural killer 
NOD   Non-obese diabetic 
NPC   Nasopharyngeal carcinoma 
NSG   NOD-SCID-gamma-chain-deficient 
OD   Optical density 
ORC   Origin recognition complex 
OriP   Origin of plasmid replication 
OriLyt   Origin of lytic replication 
PBMC   Peripheral blood mononuclear cell 
PCNA   Proliferating cell nuclear antigen 
PCR   Polymerase chain reaction 
PerCP    Peridinin chlorophyll 
PHA   Phytohaemagglutinin 
PMA   Phorbol 12-myristate 13-acetate 
pp   peptide pool 
PRR   Pattern recognition receptor 
RA   Rheumatoid arthritis 
RANA   Rheumatoid arthritis nuclear antigen 
RANK   Receptor activator of nuclear factor kappa B 
RIU   Raji infectious units 
RNA   Ribonucleic acid 
RRMS   Relapsing-remitting multiple sclerosis 
RS   Reed-Sternberg 
SCID   Sever combined immunodeficiency 
SDS-PAGE  Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SFU   Spot forming units 
SLE   Systemic lupus erythematosus 
TAP   Transporter associated with antigen processing 
TBM   3,3',5,5'-Tetramethylbenzidine 
TCR   T cell receptor 
TMEV    Theiler's murine encephalomyelitis virus 
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TMEV IDD   TMEV induced demyelinating disease 
TNF   Tumor necrosis factor 
TRAF   Tumor-necrosis-factor-receptor-associated factors 
TR-FRET   Time resolved fluorescence energy transfer 
VCA   Viral Capsid Antigen 
VZV   Varicella-zoster virus 
wo   Without stimulation 
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1.	  INTRODUCTION	  
 
1.1. Human Herpesvirus Family 
Herpesviridae comprises of a family of enveloped, double-stranded DNA viruses with large 
complex genomes. Eight varieties have been isolated from humans and have been grouped 
into three subfamilies (Table 1.1). The neurotropic alpha herpesvirus subfamily includes 
herpes simplex virus (HSV) type 1 and 2, and varicella-zoster virus (VZV). To the beta 
herpesviruses group belong cytomegalovirus (CMV) and human herpesvirus 6 and 7. Epstein-
Barr Virus (EBV) and Kaposi’s sarcoma herpesvirus (KSHV) form the gamma subfamily that 
establishes infection in B lymphocytes [3]. The gamma viruses are divided into two genera, 
gamma-1 and gamma-2. The gamma-2 genus comprises of KSHV and its relative murine 
gamma-herpesvirus 68 (MHV-68), which establish latency in B cell, however they have no 
independent capacity to drive B cell proliferation. On the other hand, the more recently 
evolved gamma-1 viruses, which EBV belongs to, are characterized by B cell growth 
transforming potential [4]. 
 
Table 1.1. Human herpesvirus subfamilies members, their tropism, and the diseases they cause.  
Subfamily Scientific name Common name Tropism Associated Diseases 
Alpha HHV-1 HSV-1 Neurotropic Facial, labial, ocular 
lesions 
HHV-2 HSV-2  Genital lesions 
HHV-3 VZV  Chickenpox and 
shingles 
Beta HHV-5 CMV Myelotropic Infectious 
mononucleosis 
HHV-6 -  
 
Mild early childhood 
roseola 
HHV-7 -  Mild early childhood 
roseola 
Gamma HHV-4 EBV Lymphotropic 
(B, T and NK 
cells), 
epithelial 
cells 
Infectious 
mononucleosis, 
cofactor in human 
cancers 
HHV-8 KSHV  Cofactor in Kaposi’s 
sarcoma 
 
 
1.2. Virion Structure of EBV 
All herpesvirus virions are comprised of four basic structures (Figure 1.1).  A single linear 
double-stranded DNA molecule is wrapped around a toroid-like protein core. The core is 
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surrounded by an icosahedral capsid composed of 162 capsomeres. The tegument fills up the 
space between the capsid and the envelope. The envelope is the outermost layer of the virion 
and consists of host membrane and viral transmembrane glycoproteins such as gp350/220 that 
mediate attachment and entry of the virus. 
 
Figure 1.1. Herpesviridae virion structure. 
 
 
1.3. EBV Genome 
EBV has a linear double-stranded genome of approximately 172 kilobase pairs (kbp) with 85 
to 95 open reading frames, and was the first large DNA virus to be sequenced [5]. The 
sequenced genome, B95-8, was derived from a EBV-infected marmoset cell line [6] which 
was later determined to contain a 12 kb deletion, that involves three open reading frames [7]. 
Still this EBV genome is the one used most often in laboratory experiments. While the genes 
expressed during lytic replication are highly conserved among the Herpesviridae family, 
those expressed during EBV latency are not found in other human herpesviruses. 
Two types of closely related EBV genomes, which differ predominantly in the 
sequence of their latency gene EBNA2, have been identified: EBV-1 and EBV-2 [8]. While 
EBV-1 isolates are more common in the United States, Europe, and Southeast Asia, EBV-2 is 
largely restricted to equatorial Africa and Papua New Guinea. Interestingly, HIV patients in 
the United States and Europe have higher frequency of EBV-2 infection [9]. 
 
 
1.4. EBV Life Cycle  
EBV infection usually occurs through salivary contact early in childhood and results in 
asymptomatic primary infection. After oral transmission, the virus lytically replicates in a 
permissive cell type of contested origin in the oropharynx (Figure 1.2). EBV gains entry into 
B cells by binding to CD21 (C3d complement receptor) through its major glycoprotein gp350 
[10]. Additionally, glycoprotein gp42 interacts with MHC Class II, which functions as an 
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EBV co-receptor. Epithelial cells do, however, not express CD21 and therefore it is thought 
that EBV enters epithelial cell through CD21-independent pathways. Tugizov et al. have 
shown that EBV entry could be mediated through three such pathways: (1) direct cell-to-cell 
contact of apical cell membranes with EBV-infected lymphocytes, (2) entry of cell-free 
virions through basolateral membranes that is mediated through the interaction of β1 or α5β1 
integrin and the EBV protein BMRF-2, (3) virus spread across lateral membranes to adjacent 
epithelial cells [11]. 
The lytic replication of the virus leads to large amounts of shed virus in the throat. 
The virus reaches mucosal B cells, infects them and initiates a latent growth-transforming 
program, which leads to substantial expansion of the EBV-transformed B cells many of which 
are later on killed by the immune response. However, EBV-infected B cells that downregulate 
viral antigen expression and enter into a resting state would be spared by the immune system 
and would persist as long-lived memory B cells that recirculate in the blood and pharyngeal 
lymphoid tissues. These latent EBV infection-harboring cells might be pushed towards lytic 
reactivation through antigen stimulation or plasma cell differentiation signals, which can lead 
to low-level virus shedding and novel infection of B cells [4]. 
 
 
Figure 1.2. Cellular responses to EBV infection. (Figure drawn based on Hislop et al. [4]) 
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1.4.1. Lytic Infection 
 
1.4.1.2. Lytic Viral Replication 
EBV is one of the few known viruses that have two completely independent genome 
replication systems: one system that is used by most herpesviruses to actively replicate the 
linear genome during lytic infection, and a second system that is unique to EBV and is 
essential to facilitate circular viral genome replication in synchrony with cellular replication 
during viral latency [12].   
Viral replication during lytic infection leads to the generation of thousands of viral 
copies produced in concatemers, which are subjected to further processing to generate 
cleaved, packaged, linear genomes bound to capsid polyamides [13], [14]. While the virus is 
dependent on cellular factors for the initiation phase, the process of replication itself is mainly 
self-reliant and homologous but not identical to the replication process of HSV. The EBV 
genome contains two lytic replication origins, oriLyt, located opposite each other on the viral 
episome, and characterized by 1055-bp core element, composed of two identical duplicate 
segments [15]. It should be noted that the commonly used laboratory EBV strain B95-8 has 
only one oriLyt copy due to a deletion (Figure 1.3A). 
 
Figure 1.3. (A) Physical map of B95-8 laboratory strain. The triangle designates the deletion site of 
B95-8 compared to other EBV strains. (B) OriLyt and its expanded core domain. (Figures adapted from 
Hammerschmidt and Sugden [16]) 
 
 
BZLF1, the master switch between latent and lytic EBV infection, is a key 
transcriptional regulator that binds to several sites on oriLyt (Figure 1.3B) and initiates lytic 
replication by supporting the expression of viral factors of lytic amplification. Moreover, 
BZLF1 interacts with members of the replication complex such as helicases and primases and 
A	   B	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the viral polymerase accessory factor BMRF1 [17], [18], [19], [20]. The mechanisms initiated 
at oriLyt include DNA replication and homologous recombination [21], and initiation of the 
recruitment of cellular recombination and DNA repair factors [22], [23], [24]. 
In summary, not only is lytic replication at oriLyt intricate because it involves two 
distinct but interdependent mechanisms of DNA replication and homologous recombination, 
but also because it uses a complex repertoire of viral and poorly defined cellular components 
to execute these processes.  
 
1.4.1.2. Lytic Gene Expression 
The EBV genome encodes about 90 genes expressed during lytic viral replication. Their 
products are classified as immediate-early, early, and late proteins. Immediate-early proteins 
such as BZLF1 and BRLF1 function as transcriptional activators of viral genes. Early genes 
involved in the viral DNA replication include DNA polymerase and thymidine kinase, 
proteins involved in apoptosis inhibition, soluble cytokine receptors, and activators of early 
gene expression. Late proteins such as viral capsid antigen (VCA), gp350, gp42, and gp85 are 
major components of the viral capsid and envelope and are essential for viral entry into B 
cells. One interesting late EBV protein is BCRF1, also termed viral IL-10 for its close 
homology to human IL-10. This protein provides the virus with an immune evasion strategy 
not only to reduce dendritic cell (DC) activation and subsequent CD8+ T cells responses, but 
also to stimulate growth of B cells [25].  
 
 
1.4.2. Latent Infection 
 
1.4.2.1. Origin of Latent Replication 
 OriP, the origin of latent EBV replication is a DNA fragment of 1.7 kbps that 
supports the autonomous replication and maintenance of the latent EBV episome. Latent viral 
replication is initiated in synchrony with the tightly regulated replication of the host cell 
chromosomal DNA and is mediated by the cellular replication machinery [12]. Even though 
EBV’s genome encodes more than 100 gene products, EBV nuclear antigen 1 (EBNA1) is the 
only viral protein that is essential for latent EBV replication and maintenance. EBNA1 binds 
site-specifically to OriP and is instrumental for episome maintenance, recruitment of the 
cellular replication machinery and initiation of latent replication. EBNA1 and its DNA 
binding sites are discussed in detail in the following three sections. 
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1.4.2.2. Family of Repeats Region 
The Family of repeats (FR) is an array of 20 non-conserved tandem repeats of 30bp size that 
is located on the OriP and is essential for episomal maintenance (Figure 1.4) [12]. EBNA1 
can bind with high affinity as a dimer to 20 motifs in the FR; however, only seven of the 20 
motifs need to be occupied by EBNA1 for efficient episomal maintenance to occur [12]. The 
carboxyl terminus of EBNA1 binds specifically to FR, while its amino terminus bind AT-rich 
chromosomal sequences. In this way EBNA1 tethers the episome to condensed mitotic 
chromosomes as they segregate during mitosis and ultimately it minimizes episomal loss in 
proliferating cells. Recent live-cell image studies have shown that 88% of newly synthesized 
episomes are segregated equally to the daughter cells, while the rest are segregated in a poorly 
understood random manner [26].  
 
Figure 1.4. Depiction of OriP and its EBNA1 binding sites. (Figure drawn based on Hammerschmidt 
et al. [16]) 
 
 
1.4.2.3. Dyad Symmetry Region 
The dyad symmetry (DS) is a 65 bp region on OriP located about 1 kbps downstream of FR 
and is the minimal replicator element of episomal EBV. The region consists of two pairs of 
low affinity EBNA1-binding sites [12], [16]. The sites within one pair are spaced exactly 21 
bp apart so that they fall in the same helical phase, a characteristic essential for their function 
as replicator that is not required for EBNA1 binding at the FR region [27]. It was shown that 
only one pair of binding sites is sufficient to initiate replication, however, the upstream 
presence of FR region is indispensable for the initiation of bidirectional DNA synthesis at the 
DS element [12], [28], [29]. The efficacy of initiation of replication at DS has been linked, 
but not fully understood, to the presence of proximal auxiliary elements one of which has 
been shown to bind telomere-associated proteins [30], [31]. 
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 Downstream of DS lies the Rep* element (Figure 1.4), which is a 300 bps motif that 
was identified as an alternative EBNA1-dependent lower activity replicator [32], [16]. Rep* 
maintains only short-term replication of plasmids, however multimers of the motif have been 
shown to support long-term plasmid replication [33].  
 Interestingly, chromatin structure is suspected to influence replication at OriP since 
spacing and modification of the nucleosomes surrounding DS have been observed to be cell 
cycle-dependent [34], [35]. 
 
1.4.2.4. EBV-Nuclear Antigen 1 (EBNA1) 
During latency EBV dramatically reduces the number of expressed viral gene products. 
EBNA1 is the only viral protein that is expressed in all forms of viral latency and in all EBV-
associated tumors, which reinforces its position as one of the most essential viral products. It 
has three essential functions: (1) to maintain the EBV genome in dividing cells, (2) to initiate 
latent episomal replication by recruiting the cellular replication machinery at OriP, (3) to 
transactivate gene expression. Purified EBNA1 has been shown, however, to lack ATPase or 
DNA helicase activity [36] suggesting that the functions of EBNA1 are mediated through its 
interaction with cellular components [12]. Learning more about the structure of EBNA1 can 
facilitate the understanding of its properties and interactions.  
A 160 amino acid stretch at the carboxyl terminus of EBNA1 facilitates the 
dimerization of the protein and enables site-specific DNA binding to OriP (Figure 1.5) [37]. 
Crystallographic studies have revealed the presence of four antiparallel beta strands that when 
dimerized form eight-stranded beta barrels with projecting alpha helices that establish DNA 
contacts [38], [39]. The structure of the carboxyl terminus of EBNA1 closely resembles the 
dimerization and DNA-binding domain of the E2 protein of papillomaviruses [40], [39]. 
Additional similarity between the two proteins lies in their ability to bend DNA upon site-
specific binding [27], [33].  
UR1 is another functional component of EBNA1 that bears resemblance to a similar 
domain of the E2 protein and spans 25 amino acids between the glycine-arginine and the 
glycine-alanine repeat motifs. This region contains two cysteine residues that facilitate the 
coordinated binding of two EBNA1 monomers to Zinc, a process that is instrumental for the 
transcriptional transactivation potential of EBNA1 [41], [42]. 
Moreover, clusters of DNA-bound EBNA1 dimers, such as at the FR region, have the 
propensity to adhere to other EBNA1/DNA complexes forming a DNA loop [43], [44]. This 
linking and looping activity of EBNA1 is mediated by the LR1 and LR2 that are segments 
rich in arginine and glycine residues. In addition, the presence of arginine-glycine repeats 
promotes the binding of EBNA1 to AT-rich DNA sequences [45]. This binding promotes the 
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attachment of EBNA1 to AT-rich chromosomal DNA and the maintenance of the EBV 
episome in latently infected cells. A third function of the LR1 and LR2 regions is to bind G-
rich RNA, which facilitates the recruitment of the human origin recognition complex (ORC) 
at the DS segments, however the precise mechanisms of how that happens is not yet clearly 
understood [16]. 
A hallmark of EBNA1 is the 200 amino acid glycine-alanine repeat region that has no 
link to the genome maintenance and replication function of EBNA1 but has been shown to 
reduce EBNA1 antigen processing by limiting its proteasomal degradation, ribosomal 
translation and eventually minimizing MHC class I presentation of EBNA1 epitopes [46], 
[47]. This is presumably one of the main reasons for the success of EBV infection: EBNA1, 
an essential viral protein that is expressed during all latency stages of EBV is at the same time 
poorly recognized by CD8+ T cells. Nevertheless, EBNA1 epitopes have been shown to be 
presented on MHC class II molecules after autophagosomal degradation, which resulted in 
the generation of EBNA1-specific CD4+ T cell responses [48]. 
 
Figure 1.5. Schematic structure of EBNA1. (Figure adapted from Hammerschmidt et al. [16]) 
 
 
1.4.2.5. Latency Programs and Latency-Associated Proteins 
Characteristic for EBV latency is the drastic reduction of viral gene expression from about 
100 genes to only 11 latently expressed genes. These include six EBNA genes (EBNA1, 
EBNA2, EBNA3A, EBNA3B, EBNA3C, and EBNA-LP), two latent membrane proteins 
(LMP1 and LMP2), two EBV-encoded RNAs (EBER1 and EBER2), and BamHI A rightward 
transcript (BART). Among these, only EBNA1 and LMP1 are also expressed during lytic 
infection. Depending on the number of expressed genes, EBV latency can be categorized into 
4 programs (Table 1.2). 
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Table 1.2. EBV latency programs, associated protein expression pattern and diseases. 
Latency Program Proteins expressed Affected B cell Associated disease 
0  EBER, BART Memory B cell Peripheral blood B 
lymphocytes 
I EBNA1, EBER, 
BART 
Memory B cell Burkitt lymphoma 
II  EBNA1, LMP1, 
LMP2, EBER, BART 
Germinal center 
centroblast 
Nasopharyngeal 
carcinoma, 
Hodgkin’s disease 
III  EBNA1, EBNA2, 
EBNA3, LMP1, 
LMP2, EBER, BART 
Immunoblast Infectious 
mononucleosis, LCLs 
 
LMP1 and LMP2 are multiple-membrane spanning molecules that act as 
constitutively activated ligand-independent receptors and provide survival signals to stimulate 
B cells to enter into memory state [49], [50]. LMP1 has extensive functional homology with 
CD40 and is able to interact with a number of tumor-necrosis-factor-receptor-associated 
factors (TRAFs) that trigger downstream NFkB activation and promote survival and 
proliferation of B cells [51], [52], [53]. CD40 is expressed on germinal center B cells and is 
activated upon interaction with its T cell ligand, CD40L (CD154). LMP2, on the other hand, 
is a B cell receptor (BCR) homolog that contains immunoreceptor tyrosine-based activation 
motifs (ITAM) motifs [54]. It provided tonic survival signals in EBV-infected B cells that 
lack surface expression of immunoglobulins [49].   
 
1.5. Immune Response to EBV Infection 
 The immune responses targeting EBV have been best studied in patients with primary 
symptomatic EBV infection, also known as infectious mononucleosis (IM). Therefore, the 
following sections will elucidate the innate and adaptive EBV-specific immune response in 
the setting of IM.  
 
1.5.1. Innate Immune Responses 
Natural killer (NK) cells provide the first defense against microbial invaders and are 
involved in tumor immunosurveillance through their ability to secrete IFN-γ. NK cells 
expand during IM and their number has been shown to inversely correlate with viral load 
[55]. Tonsillar NK cells are known to be particularly strong IFN-γ producers that can inhibit 
in vitro resting B cell transformation in the presence of DCs as IL-12 producers [56]. 
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Moreover, NK cells may provide a defense against the virally induced HLA class I 
donwregulation on infected cell [57].  
 
 
1.5.2. Adaptive Immune Responses 
 
1.5.2.1. CD8+ T Cell Responses 
Oligoclonal populations of EBV-specific CD8+ T cells arise early in IM, reaching frequencies 
of 1-40% of total CD8+ T cell population that are mainly directed against immediate early and 
early antigens [58], [4]. Reactivity to latent proteins is minor, accounting for 0.1-5 % of the 
CD8+ T cell population and mainly directed against members of the EBNA3 family [4]. 
Characteristic of the EBV-directed CD8+ T cells is their strong cytotoxicity and activation 
state. These cells are positive for perforin and exhibit cytotoxic activity ex vivo [59], [58], 
[60]. The cells express molecules that characterize them as cells that recently encountered 
antigen such as the activation marker CD38, cell cycling marker Ki-67, and CD45RO isoform 
[60], [61], [4]. If no antigen stimulation is provided in vitro, these cells will undergo rapid 
apoptosis since they express low levels of anti-apoptotic molecules such as Bcl-2 and Bcl-x 
and high levels of the pro-apoptotic Bax molecules [60], [62]. This explains the rapid 
reduction in CD8+ T cell numbers in late IM when the antigen availability becomes scares. 
CD8+ T cells directed against lytic antigens are reduced dramatically both in absolute 
numbers and in percentages. On the other hand the latent antigen-specific CD8+ T cells are 
also reduced in numbers but to a much lower extend than the T cells targeting lytic antigens 
[4]. The surviving CD8+ T cells then lose their activation status, i.e. they lack CD38 and 
CD69 expression, and upregulate Bcl-2 [63], [64].  
Long-term asymptomatic EBV carriers who did not develop IM shed very low or 
absent levels of virus and carry 1-50 EBV-infected B cells per million total B cells. These 
healthy carriers develop CD8+ memory responses to an array of epitopes: 0.2-2% of all CD8+ 
T cells are directed against lytic antigens, while 0.05-1% against latent epitopes [4], which 
signifies the importance of CD8+ T cells in controlling asymptomatic EBV infection even in 
EBV healthy carriers.  
Curiously, characteristic for EBV-specific CD8+ T cell responses is that despite the 
variety of HLA types, infected people develop immune responses towards a limited number 
of immunodominant antigens. Among the lytic antigens the immunodominant epitopes are 
derived from the immediate early BZLF1 or BRLF1, from some of the early proteins such as 
BMLF1, BMRF1, BALF2, or BALF5, and very rarely from late lytic proteins [4]. This 
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skewing of the immune responses towards immediate early and early epitopes and away from 
late proteins together with the observation of reduced HLA class I surface levels on lytically 
infected cells [65] suggests of an immunoevasion strategy by the virus. Indeed, the early EBV 
protein BNLF2a has been shown to interfere with HLA class I antigen presentation by 
blocking TAP1/TAP2 peptide transport [4].  
 
1.5.2.2. CD4+ T Cell Responses 
EBV-specific CD4+ T cell responses have been much less well characterized than the CD8+ 
responses mostly due to the difficulty of generation of MHC class II tetramers and the lack of 
massive oligoclonal expansion of CD4+ T cells during IM [66], [67]. Nevertheless, EBV-
directed CD4+ T cell responses are of a comparable magnitude to CD4+ responses to other 
viral infections and peak during acute IM. The responses are directed to both lytic and latent 
antigens and are rapidly reduced few weeks post the peak of disease. One study that evaluated 
responses to a limited set of antigens determined that most common in the lytic antigen 
repertoire were epitopes from the immediate early BZLF1 protein, while responses to EBNA1 
were less frequent [68].  Another study that looked at the CD4+ memory T cells determined 
that these cells secrete IFN-γ and TNF-α, limited levels of IL-2 and express CD45RO, CD27 
and CD28, which significantly differs from the phenotype of CMV-specific memory T cells 
which lack CD27 and CD28 [67].  
In contrast to the CD8+ T cell responses, CD4+ memory lytic T cell responses 
encompass immediate early, early, and late proteins along with envelope glycoproteins that 
rarely elicit CD8 responses [4]. The latent antigens are derived similarly to the CD8 responses 
from EBNA3 proteins, however the largest proportion of CD4 responses is targeted to 
EBNA1 and EBNA2, proteins that elicit only limited CD8 responses [4]. 
Interestingly, the virus has developed an evasion strategy to prevent infected cells 
from CD4 responses by shedding large amounts of a truncated form of gp42, an envelope 
protein that binds MHC class II and serves as a co-receptor for viral entry. The truncated form 
masks MHC class II molecules on the surface of infected cells and interferes with CD4+ T cell 
recognition [69]. 
 
1.5.2.3. B Cell Responses 
Generation of EBV-specific antibody responses has been best studied during acute IM and the 
detection of IgM and IgG targeted against the viral capsid antigen (VCA), early antigen, and 
EBNA1 are used in the clinical diagnosis of IM [70]. IgM responses to VCA appear at the 
time of IM symptoms presentation and resolve 1-2 months after (Figure 1.6). While no IgM 
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responses can be detected in chronic viral carriers, IgG response to VCA develop at the time 
of IM diagnosis and persist at reduced levels for life [70].  
 Antibodies against the early lytic protein, early antigen D, develop during the peak of 
IM and resolve 3-6 months later, however in about 20% of individuals they can persist for 
life. EBNA1 IgG antibodies appear only several weeks after IM and persist for life [70]. 
 
Figure 1.6. EBV-specific antibody responses during and after infectious mononucleosis. (Figure 
copied from Luzuriaga et al. [70])  
 
 
1.6. EBV-Associated Diseases 
 
1.6.1. Infectious Mononucleosis  
More than 95% of the adult population is carrier of latent EBV infection. The majority of 
individuals acquire EBV infection during the first 5 years of life. However, in the 
industrialized and developed world about 50% of the population acquires the virus later in life 
[70]. That predisposes between 30-50% of the individuals who acquire EBV between 15 and 
24 year of age to develop symptomatic primary infection or infectious mononucleosis (IM) 
[70]. IM symptoms appear 30-50 days post viral exposure and constitute of pharyngitis, fever, 
and lymphadenopathy [70]. The symptoms typically resolve one month after diagnosis. 
However, cervical lymph node enlargement and fatigue might persist for a longer time period. 
IM is associated with a risk of mild hematologic complications as well as rare severe 
neurological complications. The disease is rarely fatal, however, male patients with X-linked 
lymphoproliferative disease, who carry a mutation that results in uncontrolled CD8+ T cell 
expansion, suffer from very severe or even fatal IM [71].   
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 Interestingly, a history of IM has been associated with four-fold increased risk of 
development of Hodgkin’s lymphoma, and a two-fold risk for development of multiple 
sclerosis later in life. The suspected molecular mechanisms behind these associations are 
discussed below.  
 
1.6.2. EBV-Associated Malignancies 
Even though animal studies from the early 1900s had already implicated the role of viruses in 
tumorigenesis, it was not until the identification of EBV in Burkitt lymphoma biopsies in 
1964 that established the role of viruses in human cancer [72]. This is why EBV is commonly 
referred to as the Rosetta stone of viral tumorigenesis. The virus encodes for proteins that 
share close homology to anti-apoptotic factors, cytokines, and signal transducers that are used 
by the virus to promote infection, transformation and immortalization of the infected cells. 
Due to these characteristics the virus is associated with a number of lymphoproliferative 
disorders that include B cell, as well as T/NK cell malignancies, and carcinomas some of 
which will be briefly reviewed below. 
 
1.6.2.1. Burkitt’s Lymphoma 
Three variants of Burkitt’s lymphoma exist: endemic, affecting children in equatorial Africa 
and New Guinea; sporadic, affecting children and young adults worldwide; and 
immunodeficiency-related, affecting mainly HIV patients. The majority of endemic cases are 
EBV-associated, while only 15-20% of the sporadic cases, and 30-40% of the 
immunodeficiency-related cases are linked to EBV [73]. The lymphoma is highly 
proliferative and is a result of translocation of the c-myc oncogene under the control of the 
immunoglobulin heavy or light chain loci [74]. The exact mechanism of the association of 
EBV and the c-myc translocation has not yet been elucidated, however it has been suggested 
that the translocation happens as an error to somatic hypermutation in the germinal centers 
[74]. Yet, EBV genes, associated with induction and maintenance of proliferation, are not 
expressed in EBV-infected Burkitt’s lymphoma cells. Being in latency I, these cells express 
constitutively only EBNA1. Moreover, Kennedy et al. determined that EBNA1 provides 
survival signals to the infected cells since inhibition of EBNA1 led to decreased cell survival 
[75].  
 
1.6.1.2. Hodgkin’s Lymphoma 
Hallmarks of the classical form of Hodgkin’s lymphoma (HL) are giant multinuclear 
Hodgkin’s and Reed-Sternberg (RS) cells, which are transformed B cells that originated from 
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pre-apoptotic germinal center B cells [73]. They are characterized by constitutive NFkB 
activation that provides survival signals to the transformed cells. The activation can be 
induced by members of the classical NFkB activation pathway such as CD30, CD40, and the 
receptor activator of nuclear factor kB (RANK) all of which are expressed on RS cells. About 
40% of all classical HL cases are associated with EBV infection. EBV infected cells express 
LMP1, which acts as a CD40 homolog and stimulates NFkB activation [73]. 
 
1.6.1.3. Non-B Cell Lymphomas 
Besides B cell lymphomas, EBV is also associated with a number of T and NK cell 
malignancies such as peripheral T-cell lymphomas, angioimmunoblastic T cell lymphoma, 
extranodal nasal type NK/T-cell lymphoma, enteropathy-type T cell lymphoma, gamma delta 
T cell lymphomas, T cell lymphoproliferative disorders after chronic EBV infection, EBV-
associated cutaneous T cell lymphoproliferative disorders, and aggressive NK cell leukemia 
[73]. 
 The virus is also associated with 95% of nasopharyngeal carcinoma (NPC) cases. 
NPC is a squamous cell carcinoma that is predominant among isolated populations such as in 
southern Chinese, the Inuits of Alaska, and native Greenlanders [76].  
 
1.6.1.4. Other Lymphoproliferative Diseases 
There are three main categories of EBV-associated lymphoproliferative lymphomas: ones that 
occur in primary immunodeficiencies such as X-linked lymphoproliferative disease, ones that 
occur due to immunosuppressive treatment post organ transplantation, and lymphomas 
associated with AIDS. 
 
 
1.6.3. EBV-Associated Autoimmune Diseases  
 
1.6.3.1. Mechanisms of EBV-Induced Autoimmunity 
The following text is adapted from Kakalacheva et al., 2011 and partially from Münz et al., 
2009. 
Several mechanisms have been proposed to explain how pathogens such as viruses might 
trigger autoreactive immune responses in autoimmune diseases. These include virus-induced 
general activation of the immune system and the provision of viral gene products that 
specifically stimulate immune responses that cross-react with self-antigen (Figure 1.7). 
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Figure 1.7. Molecular mechanisms of pathogen-induced autoimmunity. (Figure adapted from 
Kakalacheva et al. [77]) 
  
1.6.3.1.1. Mechanisms of Bystander Activation 
Infectious agents express specific pathogen-associated molecular patterns (PAMPs). These 
are recognized by immune cell receptors leading to cellular activation, which increases the 
antigen-presenting capacity and the expression of costimulatory molecules of antigen-
presenting cells (APCs). This also leads to APC production of type I interferons, pro-
inflammatory cytokines and chemokines, which in turn initiate and direct the immune 
response against the invading pathogen. Thus, EBV, when recognized by the immune system 
can mediate activation of APCs that at the same time contain self-antigens obtained from 
dying cells or damaged tissue. In this way the activated APCs can not only activate EBV-
specific lymphocytes but also cross-activate autoreactive T and B cells. Alternatively, the 
Th1-driven environment during viral infection could facilitate activation of autoreactive 
bystander T and B cells via proinflammatory cytokine production. One would assume that 
that is the case during acute IM infection when massive activation of virus-specific T cells 
leads to bystander activation of EBV non-specific lymphocytes (Figure 1.7A and B). 
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1.6.3.1.2. Mechanisms of Molecular Mimicry 
Polyspecific antigen recognition has emerged as a fundamental feature of adaptive cellular 
immune responses. Mathematical models indicated that the TCR repertoire is not large 
enough to give functional protection against all possible foreign epitopes on the basis of a one 
TCR–one epitope model, and several groups consistently have demonstrated that there can be 
considerable flexibility in TCR recognition of peptide–major histocompatibility complex 
(MHC) complex, [78], [79], [80]. Polyspecific or so-called degenerate TCR recognition is 
considered to represent a compromise between the need to provide host protection against 
virtually any pathogen-derived epitope and, at the same time, the need to ensure thymic 
positive selection and peripheral maintenance of this T cell repertoire via intermediate affinity 
recognition of self-peptides that are presented by self-MHC molecules. Such degenerate 
specificity, however, also carries a certain risk for autoimmunity under special circumstances, 
e.g., strong innate immune activation (Figure 1.7D).  
 
1.6.3.1.3. Mechanisms of Epitope Spreading 
In addition to one TCR being engaged by different MHC/peptide complexes, one TCR 
specificity can set free epitopes for other TCRs and lead to a process called epitope spreading. 
Epitope spreading describes the phenomenon observed in animal models of autoimmune 
diseases and cancer patients in which responses to immunodominant epitopes are elicited 
first, followed by responses to less dominant epitopes [81], [82], [83], [84], [85]. Although 
these examples document epitope spreading within autoantigens and to additional 
autoantigens, the inflammatory environment of EBV infection could also support these 
immune response cascades by increasing the presentation of autoantigens, thereby spreading 
immune responses from foreign to self-antigens (Figure 1.7E). 
 
1.6.3.1.4. Emerging Mechanisms 
The mechanisms of bystander activation, polyspecific antigen recognition/molecular mimicry, 
and epitope spreading are not the only ways by which EBV might trigger or accelerate 
autoimmunity. Viral infections could also directly maintain autoreactive effector T cells or 
autoantigen-presenting cells. For example, Theiler's murine encephalomyelitis virus (TMEV)-
induced demyelinating disease (TMEV-IDD) is a model of MS in which intracerebral TMEV 
infection of mice leads to an autoimmune demyelinating disorder 30–40 days after infection 
[86]. Persistent infection of microglial cells with TMEV has been shown to upregulate 
expression of MHC and costimulatory molecules and to enhance the ability of these cells to 
function as effective APCs [87]. Furthermore, EBV immortalizes B cells and assists in their 
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differentiation into long-lived memory B cells. These mechanisms could support the survival 
of autoreactive B cells or of a reservoir of APCs that can present autoantigens to promote 
autoimmunity [88], [89]. 
The evidence for a biological role of these mechanisms mainly stems from 
experimental autoimmune disease models. Testing whether these mechanisms are indeed 
relevant in human autoimmune diseases is challenging because of a number of reasons 
including the following: (1) Chronic autoimmune diseases are likely to become clinically 
apparent only after a considerable period of subclinical autoreactivity, at which time the 
pathogen might have already been cleared and/or the antiviral immune responses might have 
subsided. (2) The proposed mechanisms by which a pathogen or a number of pathogens 
potentially initiate and sustain MS are likely dynamic, not mutually exclusive and might 
occur simultaneously or sequentially. A simple ‘one organism–one disease’ or ‘one 
mechanism–one disease’ paradigm might not apply to complex and heterogeneous diseases. 
(3) The flip side of the idea that autoimmunity is driven by viral infections is that autoreactive 
immune responses, or even only a predisposition to the development of these responses, 
might affect the ability of the host to control infections and to regulate antiviral immune 
responses. (4) The argument that infections contribute to disease development is strong for 
autoimmune conditions associated with one or two specific infectious agents such as 
Guillain–Barré syndrome, which is frequently preceded by Campylobacter jejuni infection or 
Rheumatic fever after Streptococcus infection. In contrast, other complex autoimmune 
diseases have been associated with a number of infectious agents and the data is still 
inconclusive.  
The suggested role of EBV in multiples sclerosis, myasthenia gravis, systemic lupus 
erythematosus, and rheumatoid arthritis is extensively discussed in the following sections. 
 
1.6.3.2. Multiple Sclerosis 
The following text is adapted from Kakalacheva et al. 2011. 
Evidence for a potential role of EBV in the development of multiple sclerosis (MS) arises 
from reports on the positive correlation between clinical history of IM and MS occurrence 
[90], [91]. The risk of MS has been suggested to increase after IM and to persist for at least 
30 years post infection [92]. Ramagopalan et al. compared more than 14 000 MS cases and 7 
000 spouse controls. Their study found a positive correlation of MS disease with history of 
IM, while no such association was observed for history of symptomatic measles, mumps, 
rubella, and varicella infections, or with history of measles, mumps, rubella, hepatitis B, and 
influenza vaccination [93]. A recent meta-analysis confirmed these findings by reviewing 14 
studies, 11 case–control and 3 cohort studies, which investigated the association of IM and 
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MS. The analysis concluded that the combined relative risk for development of MS after IM 
was 2.3-fold and in HLA-DR2-positive individuals even 7-fold [94], suggesting that 
symptomatic EBV infection is a risk factor for MS [95].  
Serological studies have demonstrated close to 100% EBV seropositivity in MS 
patients. However, high seropositivity, ranging between 90% and 95%, is also detected in the 
healthy adult population. A more prominent difference in seropositivity was observed in 
children with MS, 83% of which were reported to be seropositive for EBV, compared to 42% 
of healthy age-matched controls [96]. Moreover, no significant difference in seropositivity 
was observed between the two groups for cytomegalovirus, parvovirus B19, and VZV. These 
results were confirmed by a German study, showing 98.6% EBV seropositivity in children 
with MS in contrast to 72.1% in age-matched healthy controls [97]. Comparable results were 
observed by a more recent study that identified broadened and augmented recognition of the 
latency-associated EBV nuclear antigen 1 (EBNA1), suggesting dysregulation of EBV-
specific immune responses in pediatric MS [98]. 
An age-dependent relationship was suggested between alterations in EBV-specific 
immune responses and clinical manifestation of MS [99]. A longitudinal study in 69 matched 
case–control sets of US military personnel investigated the presence of EBV antibodies 
before MS onset. While EBV-specific antibody titers were similar between people who 
developed MS before the age of 20, a two- to three-fold increase in EBV-specific antibody 
titers was observed in MS cases after the age of 25. The strongest risk factor, rising MS 
susceptibility ten-fold, was increased titers of serum antibodies to EBV-derived nuclear 
antigens (EBNA) and in particular to EBNA1 [99], [100]. A recent study confirmed these 
results by reporting that EBNA1-specific antibody responses occurred 15 to 20 years before 
the onset of symptoms in MS patients [101]. Although these observations suggest an EBV-
specific immune dysregulation preceding MS onset, one limitation of the abovementioned 
studies is that they compared EBV-specific responses only to CMV responses and not to 
those towards other viruses, suspected in MS association. 
A more recent study determined immune responses to EBV, HHV-6, CMV, influenza 
virus, and measles virus antigens in a cohort of 147 patients with clinically isolated 
syndromes suggestive of MS (CIS) with a mean follow-up of 7 years compared to 50 
demographically matched controls [102]. CIS patients showed increased humoral and cellular 
immune responses to EBNA1 but not to other EBV-derived proteins. IgG responses to other 
viral antigens and frequencies of T cells specific for CMV and influenza virus gene products 
were unchanged in CIS patients. Furthermore, EBNA1 was the only viral antigen with which 
immune responses correlated with number of clinical disability and MRI metrics during the 
follow-up period. The authors therefore concluded that increased EBNA1-specific IgG 
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responses in CIS patients predicted conversion to clinically definite MS. Higher IgG 
responses to EBNA1 in patients with CIS and relapsing-remitting MS (RRMS) were also 
reported to correlate with increased frequencies of EBV-specific CD8+ T cells [103]. In line 
with the results of the former study, Farrell et al. found higher IgG responses to EBNA1 in 
CIS and RRMS patients, whereas responses to lytic EBV capsid antigens, CMV, and measles-
virus encoded proteins were unchanged compared to healthy blood donors. In these patients, 
elevated EBNA1-specific IgG responses were associated with the development of 
gadolinium-enhancing (Gd+) lesions and predictive for T2 lesion volume change and clinical 
disability for a period of 5 years [104]. 
EBNA1 is the most consistently recognized EBV-specific antigen, which stimulates 
CD4+ T cell responses in healthy virus carriers and selective expansion of T cells specific for 
EBNA1 was observed in MS patients [105], [98]. Moreover, a small subset of these cells has 
been shown to cross-react with myelin antigens, supporting the hypothesis that clonally 
expanded EBNA1-specific T cells could be actively involved in MS immunopathology by 
stimulating cross-recognition through molecular mimicry [106]. 
Molecular mimicry is one of the classical paradigms for infection-induced 
autoimmunity and there is solid evidence from a number of animal models transgenic for 
human autoreactive T cell receptors that microbial peptides can induce MS-like disease 
through mechanisms of molecular mimicry [107], [108], [109]. An alternative hypothesis for 
the association of EBV infection and autoimmune diseases is based on the virus' ability to 
immortalize B cells and to assist in their differentiation into long-lived memory B cells. 
Indeed, there is evidence that the EBV-encoded proteins LMP1 and LMP2 mimic signals of T 
cell help and B cell receptor engagement, respectively, possibly rendering autoreactive B cells 
less susceptible to tolerance control in the periphery [110]. These mechanisms could support 
the survival of autoreactive B cells or of a reservoir of APCs that can present autoantigens to 
promote autoimmunity [88], [89].  
B cells are now recognized to play a critical role in the pathogenesis of MS, and an 
increasing number of compounds that deplete B cells or target pathways essential for B cell 
development and function are currently being tested for their potential use as MS 
therapeutics. Serafini et al. found that EBV-infected B cells expressing viral antigens are 
significantly enriched in postmortem brain samples from patients with MS, but not in brain 
samples from patients with other inflammatory CNS diseases [111]. Activated CD8+ T cells 
were also present close to EBV-infected B cell foci, suggesting that EBV-specific lymphocyte 
responses may be involved in MS immunopathologies. However, these findings could not be 
reproduced in several subsequent studies [112], [113], [114]. Further research should clarify 
the source of this discrepancy. At present, the aforementioned conflicting data on the 
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presence of EBV in MS brain tissue do not allow to draw definite conclusions on the 
frequency and potential function of EBV-infected B cells in the CNS of patients with MS. 
Taken together, there is strong epidemiological evidence for a link between 
symptomatic EBV infection and MS development. The immune-modifying function of EBV 
suggests that this virus is, indeed, a major candidate for triggering MS. The mechanisms 
responsible for this association are, however, far from understood. 
 
1.6.3.3. Myasthenia Gravis 
The following text is adapted from Kakalacheva et al. 2011. 
Myasthenia gravis (MG) was the first neurological disease to be classified as antibody-
mediated. It is characterized by loss of acetylcholine receptors (AChR) on the neuro-muscular 
junction. This antibody-mediated loss results in reduced muscle contraction and even life-
threatening muscle weakness [115]. More than 80% of patients with early onset myasthenia 
gravis (EOMG; age <40 years) show medullary thymic infiltrates. They include T cell areas 
and lymphoid follicles closely resembling those found in reactive lymph nodes, with germinal 
centers (GC) and rare native AChR-expressing myeloid cells nearby [115], [116]. The EOMG 
thymus behaves like a target organ. Not only is production of pathogenic autoantibodies to 
the AChR selectively activated there, but AChR-specific B cells undergo antigen-driven 
clonal proliferation and somatic hypermutation and thus help to maintain and diversify the 
patients’ autoimmune responses [117]. Infections with common viruses are long-suspected 
environmental risk factors for MG but no specific candidates have yet been firmly implicated 
[115], [118], [119]. EBV is an interesting candidate since it is able to infect and transform B 
cells. Cavalcante and colleagues investigated recently thymi from 17 MG patients including 
12 with hyperplasia and reported high frequencies of EBV-infected thymus-infiltrating B 
cells [120]. All the investigated MG thymi showed evidence of active, i.e. replicative, EBV 
infection as defined by the presence of lytic and latent viral transcript and protein expression 
[120]. Their findings however were contested by others and us and will be further explained 
in the Sections 3.3. and 4.3 of this thesis. 
 
1.6.3.4. Systemic Lupus Erythematosus 
Similarly to MS, Systemic lupus erythematosus (SLE) is a complex multifactorial 
autoimmune disease with heterogeneous clinical presentation, which affects more often 
women than men. It is characterized by the generation of autoantibodies targeting nuclear 
components that form immunocomplexes which interfere with the function of vital organs. 
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The disease has been associated with genetic predisposing factors, however environmental 
factors are also thought to play a role.  
SLE patients have been shown to have increased frequency of EBV early antigen 
antibodies and high but comparable to healthy donors titers to EBNA1 [121], [122]. 
Interestingly, it was shown that EBNA1-specific antibodies produced in immunized mice 
cross-react with common SLE antigens such as dsDNA and Sm [123], [124]. One study 
showed elevated EBV-specific CD69+ CD4+ T cells producing IFN-γ post EBV stimulation 
[125]. A different study looked at a larger cohort of patients determined significantly higher 
EBV viral loads in both active and inactive SLE patients compared to healthy controls [126]. 
Interestingly, the authors observed that less EBV-specific CD8+ T cells have polyfunctional 
characteristics in terms of secretion of IFN-γ, TNF-α, IL-2, and MIP-1beta and have reduced 
cytotoxic function as measured by CD107a and granzyme B expression. The authors, 
however, observed that contrary to expectations EBV reactivation is an aggravating 
consequence rather than a cause to SLE since EBV reactivation followed disease flares. 
Moreover, longitudinal studies that looked at patients with history of IM, found no elevated 
risk in those patients for development of SLE [127]. 
 EBV has been suggested to play different roles in SLE predisposition; however, 
many of the studies led to inconclusive conclusions. SLE patients have higher level of early 
antigen antibody titers and elevated EBV viral load after disease activity peak, which might 
suggest more frequent viral reactivation as a result of the disease, rather than a causative 
function of EBV in SLE.  
 
1.6.3.5. Rheumatoid Arthritis 
Rheumatoid arthritis (RA) is a complex autoimmune disease characterized by chronic joint 
inflammation that leads to bone erosion and cartilage destruction. RA has been historically 
linked to EBV since RA patient serum was found to react to an antigen expressed on EBV-
infected B cells that was termed rheumatoid arthritis nuclear antigen (RANA) that was later 
on determined as EBNA1 [128]. Interestingly, the glycine-alanine repeat typical for EBNA1 
are also expressed in cytoskeletal proteins such as cytokeratin and type 2 collagen [129]. This 
finding suggests that molecular mimicry could be a hypothetical mechanism of EBV and RA 
association.  
 The virus has been shown to be found in RA PBMCs, saliva, synovial fluid or 
synovial membrane more frequently than for healthy donors [128]. Moreover, patients who 
had both the susceptibility allele HLA-DR4 and presence of EBV DNA in the synovium had 
41-fold increased risk for development of RA compared with subject with no EBV DNA 
[130]. Similarly to SLE patients, RA patients have elevated, about ten-fold higher, levels of 
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EBV DNA compared to healthy controls. However, yet again it is hard to say whether the 
elevated levels of EBV are sign of causation or rather due to the high inflammatory 
environment in the course of both diseases. The question remains unanswered if EBV is 
reactivated and functions as additional exacerbator of the disease, but not as its cause. 
 
 
1.6.4. Treatment Strategies 
In the majority of individuals EBV infection is asymptomatic, however, commonly it leads to 
fulminant symptomatic infection called infectious mononucleosis that has been associated 
with the development of malignant and autoimmune diseases. Furthermore, 
immunocompromised individuals such as post-transplantation patients, and individuals with 
hereditary or acquired immunodeficiency syndrome are at particular risk of developing EBV-
associated diseases like lymphoproliferative diseases. Currently, there is no medication that 
inhibits latent EBV infection. EBV associated disease are commonly treated with antiviral 
agents such as aciclovir, ganciclovir, and vidarabine, which are general inhibitors of herpes 
viral DNA polymerases [128]. Table 1.3 summarizes the most common treatment strategies 
against EBV-associated diseases.   
 
Table 1.3. Therapeutic strategies for EBV-associated diseases. (Table adapted from Toussirot et al. 
[128]) 
EBV-Associated Disease Pathogenic Mechanism Therapeutic Strategies 
Burkitt lymphoma, 
Nasopharyngeal carcinoma 
Proliferation of latently 
infected cells 
Surgery; chemotherapy; 
irradiation 
Primary or hereditary 
immunodeficiency syndrome 
(X-linked 
lymphoproliferative 
syndrome, Wiskotte Aldrich 
syndrome) 
Proliferation of latently 
infected cells 
Immunoglobulin; monoclonal 
antibodies targeting B cells (anti-
CD20); hematopoietic stem cell 
transplantation; EBV-specific 
CTL 
Acquired immunodeficiency 
syndrome: transplant 
recipients, AIDS 
 
Proliferation of latently 
infected cells 
Cessation or decrease of 
immunosuppressive drugs; 
antiviral agents; monoclonal 
antibodies against CD20, CD21, 
CD24, and IL-6; Hydroxyurea 
Oral hairy leukoplakia (in 
AIDS) 
Replication of EBV in 
infected cells 
Aciclovir; ganciclovir; 
vidarabine 
Severe infectious 
mononucleosis in 
immunocompromised 
hemophagocytic 
lymphohistiocytosis 
Immune response against 
EBV-infected cells 
Corticosteroids; 
immunoglobulin; cyclosporine; 
etoposide; plasmapheresis; bone 
marrow transplantation, 
monoclonal antibodies against 
CD20 and TNF-α 
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As seen from Table 1.3 very few of the agents target EBV specifically and the ones 
that do so affect only lytic EBV infection and have no effect on the latent maintenance or 
replication of the virus. It is tempting to say that a drug that targets latent infection would 
provide a very effective treatment strategy for all EBV-associated disease. However, that 
should be speculated with caution since EBV might be the initiator early on during the 
disease onset, while the role of the virus in the late stages of the EBV-associated diseases is 
unclear. 
 
1.6.5. Vaccination Strategies 
A major difficulty for the design and testing of an EBV vaccination strategy is the lack of 
appropriate animal models and the scarcity of knowledge on immune correlates of protection 
against EBV infection. Another challenge for performing preventive clinical trials is the long 
period of time between EBV infection and occurrence of malignancies. Despite these 
difficulties there are few EBV vaccination strategies that show limited promise.  
 Vaccination trials performed in the cotton-top tamarin, now an endangered species, 
with the major viral protein, gp350, showed remarkable protection capacity of the vaccine 
from EBV-associated B cell lymphomas post parenteral challenge [131]. However, several 
caveat of this model organism are that EBV is not a natural pathogen of the cotton-top 
tamarin and the animals cannot be infected orally, they do no develop persistent infection and 
lack expression of MHC class I molecules [132]. 
Another good model for EBV vaccine efficacy studies is the rhesus macaque, whose 
natural virus, the rhesus lympocryptovirus is genetically homologous to EBV. Infection with 
the virus leads to viral persistency and long-term viral shedding and if immunosuppressed the 
animals can acquire virus-associated malignancies [133]. This model was used to compare 
three types of EBV vaccines: soluble gp350, virus-like replicon particles that express gp350, 
and a combination of gp350-expressing virus-like replicon particles and EBNA3A and 
EBNA3B. The study concluded that soluble gp350 provided the optimal protection from oral 
EBV challenge [134]. 
Not many EBV vaccine trials have been done in humans. One study performed with 
nine EBV seronegative children in China showed that only one-third of the gp350-expressing 
vaccinia virus immunized children became seropositive at 16 months compared to 100% of 
the unvaccinated children [135]. The only double-blind randomized Phase 2 clinical trial 
performed to date involved 181 seronegative adults who received either soluble gp350 in 
alum and monophosphoryl lipid A or placebo. The gp350-vaccinated individuals showed 78% 
reduction in the rate of IM, however there was no difference in the infection rate between the 
groups [136].  
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As mentioned earlier, a major burden for the development of an EBV vaccine is the 
lack of appropriate model organism. However, the development of severely 
immunosuppressed mice with reconstituted human immune system components poses new 
opportunities for study and development of novel EBV vaccine as well as therapeutic agents. 
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2.	  MATERIALS	  AND	  METHODS	  
 
2.1. Generation of Autoreactive Humoral and Cellular Immune Responses during 
Infectious Mononucleosis  	  
2.1.1. EBV Viral Load Quantification 
Quantitative analysis of serum EBV DNA was performed by the Medical Virology 
department at the University of Zurich using a TaqMan® (Applied Biosystems) real-time PCR 
technique [137] with modified primers for the BamHI W fragment (5’-
CTTCTCAGTCCAGCGCGTTT-3’ and 5’-TCTAGGGAGGGGGACCACTG-3’) and the 
fluorogenic probe (5′-(FAM)-CGTAAGCCAGACAGCAGCCAATTGTCAG-(TAMRA)-3′). 
PCR of duplicate samples were performed using ABI Prism 7700 Sequence Detector 
(Applied Biosystems). 
 
2.1.2. VCA and Vimentin ELISAs 
Viral capsid antigen (VCA)-specific IgG and anti-vimentin IgM and IgG antibodies were 
assessed using commercially available ELISA kits: VCA (p23/p28) IgG (Immunolab GmbH), 
and anti-vimentin IgM and anti-vimentin IgG (VIDIA). Standards and controls provided by 
the ELISA kits were used to quantitatively evaluate the results in arbitrary units (U/mL) for 
the VCA kit and as positivity index for the vimentin ELISA as recommended by the 
manufacturers.  
 
2.1.3. Quantification of Serum Antibodies Reactive to Myelin Oligoglycoprotein  
Human oligodendroglial cell line MO3.13 lentivirally transduced with human full-length 
MOG and protocols were generously provided by Fabienne Brilot-Turville (University of 
Sydney). MO3.13 cells lentivirally transduced with a MOG-negative vector were used as 
control cell line. The cells were cultured in high-glucose DMEM media (Gibco) 
supplemented with 10% FCS (Sigma), 1:100 GlutaMax (Invitrogen), and 1:100 
Penicillin/Streptomycin (Sigma). The cells were washed with PBS and harvested using 
Versene (Invitrogen) and seeded at 5x104 cells per well in a V-bottom 96-well plate. Human 
sera at a 1:50 dilution was added to the cells diluted in PBS + 2% FCS and incubated for one 
hour at room temperature. The cells were then washed with PBS + 2% FCS and 50 µl of 
secondary antibody goat anti-human IgG Alexa Fluor 647 (Invitrogen) 1:100 dilution was 
added and incubated for 1 hour at room temperature in the dark. The cells were then stained 
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with a Live/Dead Fixable APC-Cy7 Dead Cell Stain Kit (Invitrogen) and acquired on a FACS 
Canto (BD Biosciences). The results are presented as delta MFI that was calculated as the 
MFI signal obtained for the MOG expressing cell line minus the MFI signal obtained for the 
control MOG-negative cell line. The positivity threshold was determined as three standard 
deviations above the mean of the healthy control samples. 818C5 anti-MOG antibody was 
used as positive control, while secondary antibody only was used as negative control of the 
assay. 
 
2.1.4. Serum Autoreactivity  
Human anti-nuclear antibodies were detected by indirect immunofluorescence microscopy, 
using slides coated with HEp2 cells and cryostat tissues of rat kidney, liver and stomach 
(Eurommun), that were incubated at room temperature with patients’ serum samples at an 
starting dilution of 1:40, followed by incubation with FITC – labeled conjugates: anti-
IgG/A/M, anti-IgM, anti-IgG (Euroimmun). The reaction was visualized by fluorescence 
microscopy, and subsequent titration was performed for positive samples. Background was 
adjusted for with negative control samples. Slides were viewed with a LEICA DLMB 
microscope using Leica objectives HC PL Fluotar 20x/0.5 and HCX PL Fluotar 40/0.75. 
Images were acquired using a Leica camera DFC 420C and were processed with Application 
Suite 3.4.0 imaging software (Leica). Additionally, serum reactivity to SS-A (anti-Ro) and 
citrullinated protein (CCP2) was quantified according to the standard protocols of the Clinical 
Immunology Unit at the University Hospital Zurich. 
 
2.1.5. IFN-γ ELISPOT  
Frozen PBMCs were thawed and seeded at 2x105 cell density per well on MultiScreen 96-
well plate (Millipore) pre-coated with human IFN-γ antibody 1D1K (Mabtech). The cells 
were then stimulated with peptide pools of EBNA1 (Tables 2.2.1), latent EBV (Tables 2.2.2), 
lytic EBV (Tables 2.2.3), myelin, and pro-insulin with concentration of individual peptides at 
5 µM. PMA/Ionamycin was used as positive control, while 0.01% DMSO was used as 
negative control. After 18-20 hours of incubation at 37oC, the wells were washed and 
incubated with detection antibody 7B6-Biotin (Mabtech) at 1:1 000 dilution in PBS + 0.5% 
FCS. After 2 hours incubation at room temperature, the plate was washed and incubated with 
Streptavidin-ALP at a 1:2 000 dilution. After one hour of incubation and thorough washing, 
BCIP/NBT substrate (Mabtech) was added and developed for 45 minutes before the reaction 
was stopped by washing the plate with water. The plate was read and analyzed 24 hours later 
with an ELISpot reader and software (AID). 
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2.1.6. Cloning of EBNA1-Reactive T Cells 
Frozen PBMCs were thawed and resuspended in H5 media composed of RPMI 1640 (PAA) 
containing 5% pooled human AB-serum (Invitrogen) and Penicillin/Streptomycin (1:100). 
First, the EBNA1-reactive T cells, seeded at 2x105 cells per well in a 96-well U bottom plate, 
were expanded for 12 days according to the schedule in Table 2.1.1 and as described by 
Scherrenburg et al. [138]. On day 12 the cells were washed and rested for 24 hours.  
 
Table 2.1.1. Schedule for IL-2 and EBNA1 peptide pool addition for expansion of EBNA1-reactive 
clones.  
Time IL-2 concentration (U/mL) EBNA1 (µM, concentration 
of individual peptides) 
Day 0 - 2.5 
Day 2 10 - 
Day 6 10 10 
Day 9 10 - 
Day 12 - - 
 
 
The EBNA1-reactive cells were then stimulated again with EBNA1 peptide pool with 
individual concentration of each peptide at 2.5 µM and the IFN-γ secreting cells were 
captured using the IFN-γ Secretion Assay – Detection Kit (Miltenyi) according to 
manufacturer’s recommendations. The selected cells were then seeded at cell densities of 0.03 
cells/well, 0.3 cells/well, 3 cells/plate, or 30 cells/plate and cultured with irradiated feeders 
comprising of three types of LCLs (irradiated with 200 Gray) and 3 different PBMC donors 
cells (irradiated with 60 Gray) and pre-pulsed with EBNA1 peptide pool. The wells that 
proliferated were checked for EBNA1-reactivity through IFN-γ ELISA.  The selected 
EBNA1-reactive cells were supplemented with 100 U/mL IL-2 every 5 days and every 2 
weeks with new feeders pre-pulsed with EBNA1 peptides. All assays measuring antigen-
specific activity were performed 2 weeks after the addition of feeders to minimize the 
background signal.  
 
2.1.8. IFN-γ ELISA 
T cell clone cultures were stimulated with EBNA1, EBV latent, EBV lytic, myelin, and pro-
insulin peptide pools (as described in Section 2.1.5) over 18-20 hours. The culture 
supernatants were then collected and incubated on MaxiSorb plate (Nunc) that was pre-coated 
with anti IFN-γ antibody (Mabtech). Serial dilutions of human IFN-γ (Mabtech) at a 
concentrations ranging from 2000 pg/mL to 31.25 pg/mL were incubated on the same plate as 
the samples and were used as standards in the assay. After 2 hours of incubation at room 
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temperature, the plate was washed and incubated with biotinylated anti-IFN-γ antibody 
(Mabtech) for one hour at room temperature, then washed again and incubated with 
Streptavidin-HRP antibody at 1:1 000 dilution. After 30 minutes incubation the plate was 
thoroughly washed and TBM substrate was added to the plates and incubated for 40 minutes 
until blue color developed. Then the reaction was stopped with 1M HCl and the plate was 
immediately measured at OD450.  
 
2.1.9. Statistical Analysis 
The non-parametric Mann Whitney test was used unless otherwise stated. A p-value of less 
than 0.05 was considered significant. Correlation analysis and graphs were generated by 
Prism software (GraphPad Software). 
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2.2. EBV-Specific Immune Responses in Patients with Multiple Sclerosis Responding to 
IFN-β Therapy 
 
The following section is adapted from Comabella, Kakalacheva et al. Mult Scler. 2012 
May;18(5):605-9. 
 
2.2.1. Patient Demographics 
In total, 28 patients with MS who showed a clinical response to IFN-β were included in the 
study. A clinical response to IFN-β was defined by the absence of relapses and lack of 
progression on the Expanded Disability Status Scale (EDSS) score during the first 2 years of 
treatment. Since paired peripheral blood mononuclear cells (PBMC) and serum samples were 
not available in all of the 28 patients included in this study, we determined antibody responses 
in a total of 24 patients and cellular immune responses in a total of 18 patients. The study was 
approved by the local ethics committee and patients gave their informed consent. 
 
2.2.2. CFSE Proliferation 
Immune responses were evaluated at baseline before application of IFN-β and after 1 year of 
treatment. T cell responses were determined by CFSE dilution as described previously [139]. 
Overlapping peptides of 12–22 aa length (average of 15 aa length) with 11 aa overlap were 
designed for the EBNA1400–641 sequence of the B95-8 EBV strain (Table 2.2.1). For CD8+ T 
cell epitopes from EBV and CMV, we synthesized nonamer peptides that are part of the CEF 
control peptide pool of the National Institutes of Health AIDS Research and Reference 
Reagent Program (Table 2.2.2). Peptides were used at a 5 μM individual concentration. 
Samples were measured on an LSRFortessa (BD Biosciences) flow cytometer. Gating and 
calculations for precursor frequencies were performed with FlowJo software. The frequencies 
of proliferating antigen-specific T cells were determined by subtracting the background 
frequency from the frequency of antigen-stimulated positive samples. A positive response 
was defined as a stimulation index of at least two-fold increase in peptide-stimulated cells 
compared to non-stimulated cells.  
 
2.2.3. ELISA for Detection of Antiviral Immune Responses 
Virus antigen-specific IgG antibodies were assessed using commercially available ELISA 
kits: EBV-encoded nuclear antigen 1 (EBNA1) (p72 encoded by BKRF1) IgG (Biotest), viral 
capsid antigen (VCA) (p23/p28) IgG (Immunolab GmbH), and human cytomegalovirus 
(CMV) IgG antigens in lysates of infected versus control cells (Diamedix Corporation). 
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Standards and controls provided by the VCA and EBNA1 ELISA kits were used to 
quantitatively evaluate the results in arbitrary units (U/mL), while antibody (Ab) indices were 
calculated by dividing the OD450 value of each sample by the control cut-off value, as 
recommended by the manufacturer. 
 
Table 2.2.1. EBNA1 peptide pool. 
Antigen Sequence Length (aa) 
EBNA1 (400-414) 
EBNA1 (405-418) 
EBNA1 (409-422) 
EBNA1 (413-429) 
EBNA1 (420-434) 
EBNA1 (425-439) 
EBNA1 (430-451) 
EBNA1 (435-451) 
EBNA1 (442-458) 
EBNA1 (449-461) 
PGRRPFFHPVGEADY 
FFHPVGEADYFEYH 
VGEADYFEYHQEGG 
DYFEYHQEGGPDGEPDV 
EGGPDGEPDVPPGAI 
GEPDVPPGAIEQGPA 
PPGAIEQGPADDPGEGPSTGPR 
EQGPADDPGEGPSTGPR 
PGEGPSTGPRGQGDGGR 
GPRGQGDGGRRKK 
15 
14 
14 
17 
15 
15 
22 
17 
17 
13 
EBNA1 (452-465) 
EBNA1 (456-469) 
EBNA1 (460-474) 
EBNA1 (465-478) 
EBNA1 (469-482) 
EBNA1 (473-487) 
EBNA1 (478-491) 
EBNA1 (482-496) 
EBNA1 (487-503) 
EBNA1 (494-508) 
GQGDGGRRKKGGWF 
GGRRKKGGWFGKHR 
KKGGWFGKHRGQGGS 
FGKHRGQGGSNPKF 
RGQGGSNPKFENIA 
GSNPKFENIAEGLRA 
FENIAEGLRALLAR 
AEGLRALLARSHVER 
ALLARSHVERTTDEGTW 
VERTTDEGTWVAGVF 
14 
14 
15 
14 
14 
15 
14 
15 
17 
15 
EBNA1 (499-510) 
EBNA1 (501-514) 
EBNA1 (505-518) 
EBNA1 (509-522) 
EBNA1 (513-527) 
EBNA1 (519-532) 
EBNA1 (523-536) 
EBNA1 (527-541) 
EBNA1 (532-544) 
EBNA1 (535-548) 
DEGTWVAGVFVY 
GTWVAGVFVYGGSK 
AGVFVYGGSKTSLY 
VYGGSKTSLYNLRR 
SKTSLYNLRRGTALA 
NLRRGTALAIPQCR 
GTALAIPQCRLTPL 
AIPQCRLTPLSRLPF 
RLTPLSRLPFGMA 
PLSRLPFGMAPGPG 
12 
14 
14 
14 
15 
14 
14 
15 
13 
14 
EBNA1 (539-554) 
EBNA1 (545-559) 
EBNA1 (549-563) 
EBNA1 (554-566) 
EBNA1 (557-571) 
EBNA1 (562-576) 
EBNA1 (566-580) 
EBNA1 (571-584) 
EBNA1 (575-588) 
EBNA1 (579-593) 
LPFGMAPGPGPQPGPL 
PGPGPQPGPLRESIV 
PQPGPLRESIVCYFM 
LRESIVCYFMVFL 
SIVCYFMVFLQTHIF 
FMVFLQTHIFAEVLK 
LGTHIFAEVLKDAIK 
FAEVLKDAIKDLVM 
LKDAIKDLVMTKPA 
IKDLVMTKPAPTCNI 
16 
15 
15 
13 
15 
15 
15 
14 
14 
15 
   MATERIALS AND METHODS 
	   47 
EBNA1 (584-597) 
EBNA1 (588-600) 
EBNA1 (591-604) 
EBNA1 (595-609) 
EBNA1 (600-614) 
EBNA1 (605-619) 
EBNA1 (610-625) 
EBNA1 (616-629) 
EBNA1 (620-634) 
EBNA1 (625-639) 
EBNA1 (630-641) 
MTKPAPTCNIRVTV 
APTCNIRVTVCSF 
CNIRVTVCSFDDGV 
VTVCSFDDGVDLPPW 
FDDGVDLPPWFPPMV 
DLPPWFPPMVEGAAA 
FPPMVVEGAAAEGDDG 
EGAAAEGDDGDDGDE 
EGDDGDDGDEGGDGD 
DDGDEGGDGDEGEEG 
GGDGDEGEEGQE 
14 
13 
14 
15 
15 
15 
16 
15 
15 
15 
12 
 
 
Table 2.2.2. Latent EBV peptide pool. 
Antigen Sequence HLA restriction Virus  
EBNA3A (158-166) QAKWRLQTL HLA-B8 EBV 
EBNA3A (325-333) FLRGRAYGL HLA-B8 EBV 
EBNA3A (379-387) RPPIFIRRL HLA-B7 EBV 
EBNA3A (458-466) YPLHEQHGM HLA-B35 EBV 
EBNA3A (603-611) RLRAEAQVK HLA-A3 EBV 
EBNA3B (416-424) IVTDFSVIK HLA-A11 EBV 
EBNA3C (258-266) RRIYDLIEL HLA-B27 EBV 
EBNA3C (281-290) EENLLDFVRF HLA-B44 EBV 
 
 
Table 2.2.3. Lytic EBV peptide pool. 
Antigen Sequence HLA restriction Virus  
BZLF1 (190-197) RAKFKQLL HLA-B8 EBV 
BRLF1 (28-37) DYCNVLNKEF HLA-A24 EBV 
BRLF1 (134-143) ATIGTAMYK HLA-A11 EBV 
BRLF1 (148-156) RVRAYTYSK HLA-A3 EBV 
BMLF1 (259-267) GLCTLVAML HLA-A2 EBV 
 
 
Table 2.2.4. CMV peptide pool. 
Antigen Sequence HLA restriction Virus  
pp65 (417-426) TPRVTGGGAM HLA-B7 HCMV 
pp65 (495-503) NLVPMVATV HLA-A2 HCMV 
pp65 (512-521) EFFWDANDIY HLA-B44 HCMV 
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Table 2.2.5. Myelin peptide pool. 
Peptide Sequence Number of 
amino acids 
MBP13–32 KYLATASTMDHARHGFLPRH 20 MBP83–99 ENPVVHFFKNIVTPRTP 17 
MBP111–129 LSRFSWGAEGQRPGFGYGG 19 
MBP131–155 ASDYKSAHKGLKGVDAQGTLSKIFK 25 
MBP146–170 AQGTLSKIFKLGGRDSRSGSPMARR 25 
PLP40–60 TGTEKLIETYFSKNYQDYEYL 21 
PLP89–106 GFYTTGAVRQIFGDYKTT 18 
PLP139–154 HCLGKWLGHPDKFVGI 16 
PLP178–197 NTWTTCQSIAFPSKTSASIG 20 
PLP190–208 SKTSASIGSLCADARMYGVLP 20 
MOG1–20 GQFRVIGPRHPIRALVGDEV 20 
MOG11–30 PIRALVGDEVELPCRISPGK 20 
MOG35–55 MEVGWYRPPFSRVVHLYRNGK 21 
CNP343–373 EVGELSRGKLYSLGNGRWMLTLAKNMEVRAI 31 
CNP356–388 GNGRWMLTLAKNMEVRAIFTGYYGKGKPVPTQG 33 
 
 
2.2.4. Statistical Analysis 
The non-parametric Wilcoxon test was used to compare antibody and T cell responses before 
and during IFN-β treatment. A p-value of less than 0.05 was considered significant. 
  
   MATERIALS AND METHODS 
	   49 
2.3. Intrathymic Epstein-Barr Virus Infection in Patients with Myasthenia Gravis 
The following section is adapted from Kakalacheva et al., Ann Neurol. 2011;70:508–514. 
2.3.1. Patient Demographics  
With informed consent and ethical committee approval, we cryo-stored patients’ plasma, 
peripheral blood mononuclear cells (PBMCs), and thymic cells that were taken before any 
immunosuppressive drug treatments in 15 out of 16 cases. Thymi were dispersed 
mechanically in every case, and in 7 out of 16 cases dispase and/or collagenase were used to 
maximize recovery of GC, stromal and plasma cells [140]. After washing, thymic cells were 
frozen and stored at –180°C, and later thawed for testing as described below. Antiviral 
immune responses in patients were compared to those in 15 demographically matched healthy 
subjects (mean age 28 ± 4; 8 female, 7 male). 
 
2.3.2. Flow Cytometry Staining and MACS Separation of Thymi Suspensions 
Cryo-preserved thymic suspensions were thawed and then stained according to 
manufacturers’ recommendations with Live/Dead Fixable Aqua Stain (Invitrogen), CD45-
Pacific blue (BD Biosciences), CD3-APC (BD Biosciences), CD19-PeCy7 (BD Biosciences), 
CD27-PE (BD Biosciences) and acquired on FACSCanto (BD Biosciences). B cells were 
identified as live, CD45+CD3-CD19+ cell population. Memory B cells were identified as the 
frequency of CD27+ cells from total CD19+ cell population.  
 In order to separate CD19+ B cells from total thymi cells, we incubated the thymi 
suspensions with CD19+ MicroBeads (Miltenyi) and isolate them by positive selection with 
an AutoMACS Pro Separator (Miltenyi) according to manufacturer’s recommendation. 
 
2.3.2. EBV Detection by Real-Time PCR  
DNA was extracted using QIAamp DNA Blood Mini Kit (Qiagen). EBV DNA was quantified 
from thymic cells, cell lines, and EBV-positive tonsil samples by quantitative PCR using a 
TaqMan PCR kit (Roche) and a Model 7500 Sequence Detector (Applied Biosystems) as 
described previously [105]. All samples were tested at least in triplicates, and mean results 
were determined. 
 
2.3.3. Histochemistry 
Serial cryo-sections of EOMG thymi were in situ stained for EBV-encoded RNA (EBER), 
EBNA2, and CD20. The staining was performed independently at the Department of 
Pathology at the University Hospital Zurich. For in situ hybridization the slides were 
pretreated with Enzyme 1 (Leica). FITC-labeled EBER-Probe (Leica) was used and detected 
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with anti-FITC antibody (Dako) and detection-kit Refine-AP (Leica). 
 Sections for CD20 and EBNA2 staining were pretreated at 100°C with EDTA-Buffer 
(Leica). Rabbit anti-mouse IgG F(ab)2 (Epitomics) was used as secondary antibody. All 
incubations were performed on BondMax (Leica) with the detection Kit Refine HRP 
according to the manufacturer’s guidelines. EBV-positive tonsil samples were used as 
positive controls. 
 
2.3.4. ELISA for Detection of Antiviral Immune Responses 
Virus antigen-specific IgG antibodies were assessed using commercially available ELISA 
kits: EBNA1 (p72 encoded by BKRF1) IgG (Biotest), viral capsid antigen (VCA) (p23/p28) 
IgG (Diamedix Corporation), VCA IgM (Immunolab GmbH), human cytomegalovirus 
(CMV) IgG (Immunolab GmbH). Values are presented as antibody indices, which were 
calculated by dividing the OD450 value of each sample by the cut-off value as recommended 
by the kit manufacturers. IgG reactivity towards EBV-encoded VCA antigen defined 
persistent EBV infection, i.e. EBV carrier status. The majority of individuals tested for EBV-
specific T cell responses as well as for EBV viral loads had detectable levels of VCA-specific 
IgG antibodies. 
 
2.3.5. Intracellular Cytokine Staining  
PBMC at a cell density of 2×106 cells per 0.5 ml were cultured in RPMI 1640 medium (PAA) 
containing 5% pooled human AB-serum (Invitrogen) and were stimulated with (or without) 
viral peptide mixtures (final concentration of 5 μM per peptide per reaction) or 
PMA/Ionomycin (Sigma) for 6 hours in the presence of 1 μg/mL of co-stimulatory 
monoclonal antibodies to CD28 and CD49d (BD Biosciences), and Brefeldin A (Sigma) at a 
concentration of 10 μg/mL as previously described [105], [141]. The peptide mixtures 
included EBV latent- (n =8) (Table 2.2.2.) and lytic- (n = 5) (Table 2.2.3.) as well as CMV 
phosphoprotein 65- (n = 3) (Table 2.2.4.) derived immunodominant epitopes for CD8+ T 
cells, as well as overlapping peptides (n = 51) derived from the most consistently recognized 
EBV-encoded CD4+ T-cell antigen, the EBNA1 (Table 2.2.1.) [105], [141]. Positive 
responses were characterized as frequencies at least 2-fold above background (no antigen) 
and at least 10 IFN-γ+ events. The frequencies of antigen-specific T-cells were determined by 
subtracting background frequencies from those of antigen-stimulated positive samples  
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2.4 Identification of a Novel Inhibitor of Latent EBV Infection 
 
2.4.1. EBNA1 Protein Expression  
DE3BL21 bacteria expressing recombinant EBNA1458-641 were streaked from frozen stock 
onto LB-Ampicillin plates and grown overnight at 30oC. The next day, two colonies were 
picked and grown separately in 100 mL LB-Ampicillin pre-culture. The flasks were left 
overnight shaking at 30oC. The next day, 2.5 mL flasks were taken containing 500 mL fresh 
LB-Ampicillin media. 5 mL of the pre-culture was added and grown at 30oC. OD600 
measurements were taken at every hour, and the cultures were induced with 1 mM IPTG once 
an OD600 of 0.6-0.7 was reached. The cultures were then left overnight to express the 
recombinant protein.  Next day, the cultures were spun for 30 minutes at 5 500g at 4oC. The 
supernatant was removed and the pellet was resuspended in PBS, and then again spun at 4 
000 g for 40 minutes at 4oC. Then, every mL of pellet was resuspended in 5 mL of lysis 
buffer including 1 mg/mL freshly added lysozyme and protease inhibitor (Roche) in 20 mM 
Imidazole in PBS. The mixture was incubated for 30 minutes on ice and then the cells were 
lysed with cell harvester. The cell lysate was then spun at 30 000g for 60 minutes at 4oC. The 
supernatant was then filtered through a 0.4 µm filter without applying high pressure. 
 
2.4.2. EBNA1 Protein Purification 
A 5 mL nickel-chelated HiTrap HP column (GE Healthcare) was used with a maximal flow 
of 5 mL/min and maximal back pressure of 0.3 MPa. All buffers were filtered before use. 100 
mL lysate was loaded at 2.5 mL/min flow rate. The flow-through was collected and later re-
loaded on the column. 40 mM Imidazole was used as washing buffer until the UV signal was 
clean. Three-step elusion was then performed. Unspecific bacterial products were eluted with 
100 mM Imidazole in 7 fractions of 10 mL volume. Then, 2 fractions of 3 mL volume with 
250 mM Imidazole were used to eliminate all other leftover contaminants. The EBNA1 
recombinant protein was eluted with 500 mM Imidazole in 15 fraction of 5 mL volume. The 
fractions with the highest protein concentrations, based on the UV signal, were selected and 
dialyzed overnight in PBS buffer. The purity of the fractions was then determined through 
SDS-PAGE and Silver stain (Pierce Silver Stain Kit, used according to manufacturers 
recommendations) of pre-purification bacterial lysate, flow-through while loading, flow-
through during washing, and all elution fractions. After determination of purity and 
specificity, the fractions of interest were aliquoted and stored at -20oC. 
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2.4.3. Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE)  
30 µl of each purification fraction was incubated with loading dye for 5 minutes at 95oC and 
loaded onto a 0.75 mm 12.5% resolving gel containing 1 cm long 4% stacking gel. The gel 
was run for 2 hours at 100V. The reagents used for the SDS-PAGE are enlisted below and in 
Table 2.4.1. 
 
Table 2.4.1. Chemical reagents used for SDS-PAGE gel preparation. 
Reagent Resolving Gel (12.5%), 
Volume for 2x 0.75 mm gels 
Stacking gel (4%), Volume 
for 2x 0.75 mm gels 
Acrylamide/Bis 30:8 (w/v) 4.17 mL 650 µL 
1.5M Tris pH 8.8 2.5 mL 418 µL 
10% SDS 100 µL 50 µL 
d H2O 3.14 mL 3.9 mL 
10% APS 75 µL 37.5 µL 
TEMED 15 µL 7.5 µL 
 
SDS-PAGE Buffer Recipes:
1.5 M Tris pH8.8 (150ml): 
27.23 g Tris base  
add dH2O until ~80ml and adjust pH to 
8.8 with 6N HCl 
1.5 M Tris pH6.8 (100ml): 
18.17 g Tris base 
add dH2O until ~60ml and adjust pH to 
6.8 with 6N HCl 
 
 
 
 
 
 
6N HCl  
50ml dH2O + 50ml 37% HCl solution 
1x Running buffer: 
25 mM Tris base (3.03g/L) 
192 mM Glycine (14.4g/L) 
0.1% SDS 
Set pH to 8.3 (with HCl)
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2.4.4. EBNA1 Western Blot 
After the SDS-PAGE run was completed, the gel was removed from the chamber, incubated 
for 10 minutes in 1x Transfer buffer and blotted onto 0.45 µm nitrocellulose membrane 
(Biorad) for 1 hour at 10V. EBNA1 was detected by Western blot using 1:10 diluted EBNA1-
specific 5F12 hybridoma supernatant followed by 1:10 000 diluted goat-anti rabbit HRP-
labeled secondary antibody (Biorad). The signal was developed by SuperSignal WestPico 
Chemiluminescent Substrate (Pierce) and developed onto an Amersham Hyperfilm ECL film 
(GE Healthcare). 
 
Western Blot Buffer Recipes:  
10x Transfer buffer: 
250 mM Tris base (30.3 g/L) 
1920 mM  Glycine (144g/L) 
pH should be 8.3, do not adjust! 
1x Transfer buffer: 
20%  Methanol 
10% 10x transfer buffer 
70% distilled water 
 
 
2.4.5. TR-FRET High-Throughput Screening Assay 
300 nM of EBNA1458-641 were incubated together with 25 nM biotin-labeled DNA 
oligonucleotide (Biotin-TEG-5’-
GGGTAGCATATGCTATCTAGATAGCATATGCTACCC-3’), 2 nM Eu3+ Cryptate-
conjugated mouse monoclonal anti-6 His antibody, and 12.5 nM Streptavidin-d2. All 
components were mixed together in a total volume of 10 µl in reaction buffer comprising of 
200 mM NaCl, 20 mM Tris, 1 mM DTT, and 0.5% w/v BSA. The 384 well plates were 
incubated for 120 minutes at 30oC and read using Perkin Elmer EnVision reader at 340 nm 
excitation and 665 nm emission. The HTS assay was performed by the European Screening 
Port, a company specialized in establishing, optimizing, performing and analyzing HTS 
assays. 
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2.4.6. Chemical Libraries Used in HTS 
 
Table 2.4.2. Names of libraries, number and concentration of compounds used in the HTS. 
Library Number of compounds Concentration used for 
initial screening 
ChemBioNet 16 671 20 µM 
ComGenex 2 133 20 µM 
KiWiZ 140 20 µM 
UHH 421 20 µM 
ChemBridge 2 240 20 µM 
Analyticon Discovery 2 040 10 µM 
ENZO 640 4 µg/mL 
HYPHA Discovery 8 783 unknown 
 
 
2.4.7. HTS Hit Quality Control  
Optically interfering compounds were removed as follows: The average Eu signal intensity 
was calculated and compounds that had values of 2-times below the average were excluded as 
quenching compounds, while compounds that had a value 2-times higher than the average 
were excluded as fluorescent compounds.  
 
2.4.8. HTS Hit Profiling 
The identified Group 1 hits showing 30% or more inhibition of the TR-FRET signal were 
tested in 11-point dose response studies. ActivityBase XE analysis was used to calculate the 
fit of the compounds. DsDNA intercalating compounds were identified by the Quant-iT 
PicoGreen dsDNA Assay Kit (Invitrogen). Identification of cell cytotoxic molecules was 
performed by 11-point compound dose response with HEK 293 cells incubated with the 
compounds for 24h in 0.1% v/v DMSO concentration. The cells were then lysed and 
intracellular ATP was measured with CellTiter-Glo Kit (Promega) used according to the 
manufacturer’s recommendations. 
 
2.4.9. Virtual HTS Screen 
Virtual screen was performed with 1.1 M compounds from ZINC Lead-like library. TrixXBMI 
Software was used to analyze the binders through two different scoring functions (ChemScore 
and ScreenScore). 4 400 binding models were used for the visual analysis.  
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2.4.10. Electrophoretic Mobility Shift Assay (EMSA) 
120 µg/mL of EBNA1 were incubated for 30 minutes at 30oC with 12 nM of biotinylated 
oligonucleotide (as used in the HTS assay) in 100 µL of reaction buffer (200 mM NaCl, 20 
mM Tris, 1 mM DTT, and 0.5% w/v BSA). The reaction was the aliquoted into 8 tubes with 
15 µL volume to which 0, 10, 25, 50, 100, 500, 1 000, or 10 000 µL of Tilorone were added. 
The reactions were incubated at 30oC for additional 120 minutes. EBNA1 only and 
oligonucleotide only were used as controls and underwent the same procedure as the samples. 
Non-denaturing loading dye was added to the samples, which were then loaded on a 1.5mm 
6% non-denaturing polyacrylamide gel (4 mL 30% Acrylamide, 600 µL Glycerol, 15 mL 0.5 
TBE buffer, 300 µL 10% APS, 20 µL TEMED). Before the addition of the samples the gel 
was pre-run for 30 minutes at 100 V in cold 0.5 M TBE buffer. The gel was then run at 70V 
for 2 hours and then transferred for 45 minutes at 12V onto a Biodyne B positively charged 
Nylon membrane (Pall Corporation). The membrane was then immediately UV-cross-linked 
for 15 minutes and blocked overnight in 5% skimmed milk in PBS buffer. The 
oligonucleotide was then detected by incubation of the membrane with 1:1 000 diluted 
Streptavidin-HRP antibody (eBioscience) and the signal was detected by SuperSignal West 
Femto (Pierce) and developed onto an Amersham Hyperfilm ECL film (GE Healthcare).   
 
EMSA Running Buffer 
10X TBE Buffer Recipe  
1 M Tris 
0.9 M boric acid 
0.01 M EDTA 
 
 
2.4.11. Cell Line Culturing and Cytotoxicity Assay 
LCL and Ramos cell lines were cultured in R10 media (10% FCS, Penicillin/Streptomycin 
diluted 1:100 in RPMI) at an initial cell density of 0.3 x 106 cells per mL T75 flasks or 6-well 
plate. 0, 10, 15, 20, or 25 µM of Tilorone were added to the cultures. Respective volume of 
0.1% DMSO was added to the sample with 0 µM of Tilorone, which served as a no-treatment 
control. The samples were counted at least 3 times per week using Trypan Blue (Gybco), 
counting chamber and a microscope to discern dead cells. The samples that reached a cell 
density of 1 x 106 cells per mL or higher were split to the original cell density of 0.3 x 106 
cells per mL. The cultures were kept for at least 17 days and the cell splitting was taken into 
account for the final calculation of total cell numbers versus time of culture. 
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2.4.12. Cell Viability Assay 
Similarly to the cell cytotoxicity assay (above) the LCLs and L428 cell lines were incubated 
at an initial cell density of 0.3 x 106 cells per mL in 6-well plates and 0, 10, 15, 20, or 25 µM 
of Tilorone were added to the cultures. Respective volume of 0.1% DMSO was added to the 
sample with 0 µM of Tilorone, which served as a no-treatment control. Measurements were 
taken at day 1, 3, 5, and 7, stained with Live/Dead Fixable Death Cell Kit APC-Cy7 dye 
(Invitrogen), and the frequency of live cells from all cells was measured by flow cytometry on 
an LSR Fortessa (BD Biosciences). The frequency was then related to the frequency of live 
cells of the 0 µM Tilorone sample at the respective time points. 
 
2.4.13. Cell Proliferation Assay 
LCLs or L428 cells were stained with Cell Trace Violet (Invitrogen) at a final dye 
concentration of 1 µM. The cells were cultured as described in section 2.4.12. and stained 
with Live/Dead Fixable Death Cell Kit APC-Cy7 to eliminate dead cells. Cell Trace Violet 
was detected in the Pacific Blue channel by flow cytometry on an LSR Fortessa (BD 
Biosciences). The relative mean fluorescence intensity (MFI) of Cell Trace Violet was 
normalized to LCL or L428 conditions incubated with 0 µM Tilorone at the respective time 
point. Dilution of the Cell Trace Violet MFI signal signified proliferation of the cells.  
 
2.4.14. Annexin V Apoptosis Staining 
LCL and L428 cell lines were cultured and incubated with 0, 5, 10, 15, 20, or 25 µM Tilorone 
concentrations as described above (Section 2.4.12.). 24 hours later the cell samples were 
harvested, washed in PBS, resuspended in 1x Binding Buffer, and stained with 0.5 µl 
Annexin V (Biolegend) per 100 µl staining volume. 0.5 µl 7-AAD (Biolegend) per 100 µl 
staining volume was added to discern dead cells. The samples were then incubated for 30 
minutes at 4oC and measured within one hour by flow cytometry on an LSR Fortessa (BD 
Biosciences). Annexin V was detected in the APC channel while 7-AAD was detected in the 
PerCP channel.  
 
2.4.15. Caspase 3/7 Activation Assay 
Caspase-Glo 3/7 Assay (Promega) was used for measurement of apoptosis through the 
activation of Caspase 3 and 7. LCLs and L428 cells were resuspended in fresh R10 and 
seeded in 96-well plate at 15 000 cells per well in a total volume of 100 µL together with 0, 5, 
10, 15, 20, 25 µM Tilorone. The cells were incubated with the inhibitor for 3, 8 and 24 hours 
and the Caspase 3/7 activity was measured according to the manufacturer’s recommendation. 
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100 µM Ionamycin was used as positive control, while 0 µM Tilorone served as negative 
control of the assays.  
 
2.4.16. Lytic Infection Inhibition Assay 
AKBM cells that express GFP upon switch from latent to lytic EBV replication were grown 
in R10 media supplemented with Hygromycin. On the day of the assay the cells were washed 
in R10 media only to remove the Hygromycin from the cell culture. 200 µL of cell culture 
with a cell density of 4 x 106 per mL was distributed in 24-well plates and incubated for 2 
hours with 3.5 µL F(Ab) IgG cross-linking antibody at 37oC. As negative control, no F(Ab) 
IgG was added to the cultures. Concomitantly, Tilorone at a concentration of 0, 10, 15, 20 or 
25 µM was added to the cell cultures. After two hours of incubation, 800 µL of R10 was 
added to the wells and the cells were left overnight at 37oC. On the next day, the cells were 
stained with Live/Dead APC-Cy7 Fixable Death Cell Stain (Invitrogen). The GFP expression 
was used as a quantification marker of lytic reactivation. The flow cytometry analysis was 
performed on an LSR Fortessa (BD Biosciences). Beforehand, the cells were counted in a 
counting chamber to determine Tilorone- or induction-related cell death. 
  
2.4.17. Ex Vivo EBV Transformation of B Cells 
CD19+ cells were MACS separated from freshly isolated PBMCs and stained with Cell Trace 
Violet (Invitrogen) as described in Section 2.4.13. 2x105 CD19+ cells were plated per well in 
a U-bottom 96-well plate and infected with 0.5 MOI of EBV (1x105 RIU per well). Then 0, 1, 
10, and 20 µM of Tilorone we added to the cultures and the cellular proliferation was 
analyzed with FlowJo cell proliferation tool at day 4, 6, and 11 post infection. The relative 
frequency of divided cells was normalized to the frequency of cells incubated with 0 µM of 
Tilorone for four days. 
 
2.4.18. Luciferase Transduction of Cell Lines 
pLenti CMV Puro LUC (w168-1) (Addgene) supernatants were used for transfection of LCLs 
or L428 with firefly luciferase. LCLs were diluted at a 1:1 ratio in pLenti supernatant and 
R10 at a cell density of 0.5x106 per mL. The cells were then plated in 24-well plates at 2 mL 
per well. Puromycin antibiotic selection was started with 0.7 µg/mL and continued for at least 
14 days. Then serial dilution of cells was performed ranging from 1x103 to 1x105 cells per 
well in a 96-well plate. D-Luciferin (Caliper Lifesciences) was added to the cells and the 
luciferase signal was detected in Xenogen IVIS 100 (Caliper Lifesciences) imaging system. 
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The cells, LCL-luc or L428-luc, were then cultured without Puromycin selection in R10 
media and used for further experiments. 
 
2.4.19. Non-Reconstituted NSG Mouse Tumor Model 
Non-reconstituted NOD Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice (The Jackson Laboratory) 
were injected with 10x106 luciferase-expressing LCLs (LCL-luc) or control (L428-luc) cells 
i.v. into the tail vein. The mice were treated with 50 mg/kg Tilorone or PBS thrice a week for 
the continuation of four weeks. The weight and the general health status of the mice were 
observed thrice a week. Mice whose weight dropped below 15% of the highest weight were 
sacrificed. The proliferation and localization of the injected cells was measured weekly as 
follows: 150 mg/kg D-Luciferin (Caliper Lifesciences) was injected i.p. and the animals were 
anesthetized with 2% isofluran, and then transferred in the dark chamber of a Xenogen IVIS 
100 (Caliper Lifesciences) imaging system where the anesthesia was maintained via nose 
cones. The luminescence was recorded 10 minutes post the D-Luciferin injection. The photo 
flux was measured in a rectangular region of interest of the same size around the whole body 
of the individual mice using Living Image 2.5 software (Caliper Lifesciences).  
 
2.4.20. EBV Infection in Humanized NSG Mice 
Sublethally-irradiated NOD Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) or NSG HLA-A2 transgenic 
pups (The Jackson Laboratory) were injected intrahepatically with 1-2 x105 CD34+ MACS-
isolated hematopoietic progenitor cells derived from human fetal liver tissue (Advanced 
Bioscience Resources). The preparation of the human fetal tissue and the isolation of the 
CD34+ cells were performed as previously described by Strowig et al. [142]. The animal 
protocols were approved by the Cantonal Veterinary Office Zürich (protocol nos. 116/2008 
and 148/2011). Three months post injection, the mice were bled and the reconstitution of the 
human immune system compartments was analyzed with the flow cytometry panel presented 
in Table 2.4.3. 
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Table 2.4.3. Flow cytometry panel for determination of human lymphocyte subsets in reconstituted 
humanized NSG mice. 
Marker Fluorophore Clone Dilution Company 
Live/Dead Aqua - 1:1000 Invitrogen 
CD45 Pacific Blue HI30 1:200 Biolegend 
CD19 PE-Cy7 HIBI9 1:100 Biolegend 
CD3 PE-Cy5.5 S4.1 (7D6) 1:50 Invitrogen 
CD4 APC-Cy7 RPA-T4 1:50 Biolegend 
CD8 PerCP RPA-T8 1:100 BD Biosciences 
CD45RO AlexaFluo700 UCHL1 1:100 Biolegend 
HLA-DR FITC L243 1:200 Biolegend 
NKp46 APC 9E2 1:50 BD Biosciences 
 
 
The mice were then distributed in two cohorts so that the median reconstitution rates 
of the human lymphocyte subsets were comparable. The mice were pre-treated with 50 mg/kg 
Tilorone i.p. and 24 hours later infected i.p. with 1x105 Raji Infecting Units (RIU) GFP-EBV 
(B95-8); the titration of the virus was performed on Raji cells in serial dilutions and 
calculated as RIU using flow cytometry of GFP-positive Raji cells 3 days after cells infection.  
The mice were treated 3 times per week with 50 mg/kg Tilorone for the following 5 to 7 
weeks. The weight and general health state of the mice was monitored thrice a week, while 
the whole blood viral load and the lymphocyte composition was evaluated once a week. The 
mice were sacrifice 5 to 7 weeks post infection or when a mouse lost 15% or more of its 
highest weight. The spleens and livers of the mice were harvested and the lymphocytes 
isolated through Collagenase D (Roche) and DNase (Roche) digestion. The cells were 
counted and stained with the panel in Table 2.4.3. and analyzed on an LSR Fortessa (BD 
Bioscences).  
 
2.4.21. EBV Quantification from Tissue and Whole Blood 
Tissue pieces were measured and digested by QIAmp DNA mini kit (Qiagen) and the EBV 
viral load per mg of tissue was determined by the Medical Virology department at the 
University of Zurich as follows: DNA isolated from the organs was eluted in 50 μl Tris-
EDTA and stored at 4°C. Quantitative analysis of EBV DNA was performed by a TaqMan® 
(Applied Biosystems) real-time PCR technique [137] with modified primers for the BamHI 
W fragment (5’-CTTCTCAGTCCAGCGCGTTT-3’ and 5’-
TCTAGGGAGGGGGACCACTG-3’) and the fluorogenic probe (5′-(FAM)-
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CGTAAGCCAGACAGCAGCCAATTGTCAG-(TAMRA)-3′). PCRs of duplicate samples 
were performed using ABI Prism 7700 Sequence Detector (Applied Biosystems). 
 
2.4.22. Statistical Analysis 
Unless otherwise stated, all data was analyzed with two-tailed student’s t test. A P value of 
<0.05 was considered statistically significant. Prism software (GraphPad Software) was used 
for the statistical analysis and graphs generation. 
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3.	  RESULTS	  
 
3.1. Generation of Autoreactive Humoral and Cellular Immune Responses during 
Infectious Mononucleosis 
 
3.1.1. Demographics of IM Patients and Controls 
Since patients with a history of IM have 2.3 times higher relative risk of developing MS later 
in life [94], we hypothesized that during the fulminant phase of IM autoreactive cellular and 
humoral immune responses are generated that contribute to autoimmune pathologies later in 
life. To test this hypothesis we collected samples from IM patients taken at the time of first 
doctor visit post occurrence of IM symptoms. In our cohort of IM patients the onset of 
symptoms was between 3 and 21 days before first doctor visit. PBMCs and serum samples 
were collected from these patients and compared to adolescents who suffered from unrelated, 
i.e. non-inflammatory medical conditions or were healthy. The control patients visited doctors 
in the same hospital and suffered from the following conditions with the respective number of 
patients written in brackets: migraine (3), healthy (2), sunstroke (2), chronic headache (1), 
tonsillitis (1), Lumbago (1), congenital facial paralysis (1), Melkersson–Rosenthal syndrome 
(1), and vocal cord dysfunction (1). Table 3.1.1 presents the demographics of the IM patients 
and controls.  
 
Table 3.1.1. Demographics of IM patients and healthy controls.  
 Controls IM patients 
Number 13 13 
Gender (f/m) 9/4 5/8 
Average age 15 (SD = 4) 16 (SD = 8) 
Days with symptoms before doctor visit NA 3-21 
Symptoms (moderate/severe/ND) NA 3/9/1 
ND = Not determined, NA = Not available 
 
 
3.1.2. Serum Analysis for Hallmarks of EBV Infection 
To verify the infection status of the study participants we measured the EBV viral load in the 
serum of the patients and controls (Figure 3.1.1.). The serum viral load of the IM patients 
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varied between 200 and 35 700 viral particle per mL serum, while as expected none of the 
controls presented with detectable viral load in the serum. 
 
Figure 3.1.1. EBV viral load in the serum of control and IM patients. IM patients presented with high 
serum viral load with a variation between 200 and 35 700 viral particles per ml of serum, while no 
EBV viral load was detected in the control patients. 
 
 
To verify the EBV seropositivity of our study participants we, then, performed 
ELISA for detection of anti-VCA IgG antibodies, which are a hallmark of latent EBV 
infection (Figure 3.1.2.). Since we wanted to compare latent EBV carriers as controls to 
active IM patients we eliminated from our analysis four of the initial control samples that 
were negative for VCA antibodies. These four controls were also excluded from the patient 
demographics table (Table 3.1.1). In contrast, all IM patients presented with anti-VCA IgG 
antibodies the median of which, however, was lower than that of the control patients.  
Figure 3.1.2. Presence of anti-VCA IgG antibodies in the serum of latent non-IM control EBV carriers 
and IM patients.  
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3.1.3. Investigation of Humoral Autoreactive Immune Responses 
 
3.1.3.1. Reactivity Against Human MOG Antigen 
The myelin oligodendrocyte glycoprotein (MOG) is expressed on the outer layer of the 
myelin sheath and therefore is easily accessible to attack by autoreactive antibodies. This 
antigen has been implicated in the pathology of MS since it is confined to the CNS and 
antibodies against MOG have been detected in MS patient serum, cerebral fluid, and brain 
lesions [143], [144]. Moreover, the mouse model of MS, experimental autoimmune 
encephalomyelitis (EAE), can be generated by induction of anti-MOG antibodies that 
infiltrate the CNS and cause MS-like pathologies [145], [146]. 
 We investigated the presence of autoreactive anti-MOG antibodies in the control and 
IM patient sera by incubating the sera with an oligodendroglial cell line that constitutively 
expressed human MOG on its surface. The presence of bound serum antibodies was then 
determined through a secondary anti-human antibody bound to a fluorescent dye. A control 
oligodendroglial cell line transduced with a non-MOG lentivector was used to define the 
background fluorescence level. The anti-human MOG 818C5 antibody was used as positive 
control, and also to determine the detection limit of the assay (Figure 3.1.3.A). The MOG 
autoreactivity was measured as delta MFI of the MFI obtained by incubating the patient 
serum with the MOG-expressing cell line minus the MFI obtained with the non-MOG control 
cell line (Figure 3.1.3.B). Even though the median delta MFI of the IM patient group was 
higher than that of the control group, no statistical significance was observed. Interestingly, 
only one of the IM patients (IM15) but none of the controls had a delta MFI above the 
positivity threshold.  
 
Figure 3.1.3. Serum reactivity to human MOG antigen. (A) Titration of MOG reactivity assay with 
different concentrations of anti-human MOG antibody. (B) Anti-MOG reactivity of controls and IM 
patient sera. The positivity threshold, designated with a grey dotted line, was determined as three 
standard deviations above the mean of the control samples.  
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3.1.3.2. Detection of Autoreactivity through HEp2 Immunofluorescence 
Presence of anti-nuclear antibodies (ANA) is a hallmark of autoreactivity that is routinely 
tested in the clinic for diagnosis of autoimmune disease. In collaboration with the Clinical 
Immunology Department at the University Hospital Zurich, we analyzed the presence of 
autoantibodies by incubating control and IM patient sera with permeabilized HEp2 cells and 
performing immunofluorescence analysis to determine the binding pattern of potential 
autoreactive antibodies in the patient and control sera. 6 out of 13 IM patient samples were 
HEp2-staining negative, while 6 were borderline positive, and only 1 (IM12) was determined 
as positive. On the other hand, 11 out of 13 control samples were negative and 2 were 
considered as positive (CO9 and CO10). Interestingly, the HEp2 staining pattern observed for 
8 of the 13 (62%) IM patient samples was determined as reticular cytoplasmic pattern that is 
similar to staining obtained with anti-vimentin autoantibodies (Figure 3.1.4.). None of the 
controls had such a vimentin-like pattern but rather a dense cytoplasmic staining for one of 
the controls (CO9), and a dense, homogeneous nuclear staining for the second positive 
control (CO10). The vimentin-like antibodies were determined by differential use of anti-IgG 
and anti-IgM secondary antibodies to be of IgM isotype. 
 
Figure 3.1.4. HEp2 immunofluorescence for detection of autoreactive antibodies. (A) Example of 
HEp2-positive control sample with dense cytoplasmic staining. (B) Representative HEp2-positive 
vimentin-like staining of an IM patient. 
 
  
Additionally, we tested for presence of SS-A antibodies, characteristic of SLE, and 
citrullinated peptide antibodies (CCP2) that are typical for RA.  All IM patients were negative 
for SS-A antibodies and only one (IM15) had borderline CCP2 positivity. Due to limited 
availability of serum from some of the control samples not all of them were tested for 
presence of SS-A and CCP2 antibodies. None of the tested control samples was positive for 
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SS-A or CCP2 autoantibodies. A summary of the HEp2 staining results obtained from the IM 
patient sera is presented in Table 3.1.2. 
 
Table 3.1.2. Summary of HEp2 staining results with IM patient sera.  
For SS-A values >7 were considered negative, 7-10 borderline, and >10 positive. For CCP2 values >7 
were considered negative, 7-10 borderline, and >10 positive. Negative values are colored in green, 
borderline in orange, and positive in red. ND = Not determined 
 
 
3.1.3.3. Detection of Anti-Vimentin Autoantibodies 
To verify that the observed HEp2 staining pattern in the IM patietns is derived due to 
presence of anti-vimentin antibodies, we performed ELISA to detect and quantify the anti-
vimentin IgM and IgG antibodies in the control and IM patient sera (Figure 3.1.5.). Indeed, 
the IM patients had significantly higher levels of anti-vimentin IgM antibodies compared to 
the controls (p=0.002). 9 out of 13 (69%) IM patients were positive for vimentin, while only 1 
out of 13 (8%) control samples had an IgM anti-vimentin signal above the positivity threshold 
(Figure 3.1.5.A). Anti-vimentin IgG was detected in only 4 out of 13 (31%) IM patients, 
while none of the controls was positive. The difference between the two groups, however, did 
not reach statistical significance. We analyzed additionally one MS (n=18) and one MG 
Patient 
number 
SS-A CCP2 HEp2 
(ANA) 
quantitative 
HEp2 (ANA) 
qualitative 
HEp2 (ANA) binding 
pattern 
IM5 ND ND 40 Negative None 
IM6 1.8 6.1 160 Borderline Reticular cytoplasmic 
pattern, vimentin-like 
IM7 2.2 5.3 160 Borderline (1) Nuclear speckled; 
(2) Reticular cytoplasmic 
pattern, vimentin-like 
IM9 0.9 1.9 160 Borderline (1) Reticular cytoplasmic 
pattern, vimentin-like; 
(2) Faint nuclear fine 
speckled pattern 
IM10 0.2 1.7 160 Borderline Reticular cytoplasmic 
pattern, vimentin-like 
IM12 0.8 2.2 320 Positive Reticular cytoplasmic 
pattern, vimentin-like 
IM14 ND ND 40 Negative None 
IM15 1.1 7.6 160 Borderline Reticular cytoplasmic 
pattern, vimentin-like 
IM16 0.5 2.8 40 Negative Reticular cytoplasmic 
pattern, vimentin-like 
IM17 0.9 3 40 Negative Nuclear speckled 
IM18 0.4 2.8 40 Negative None 
IM19 0.7 1.7 40 Negative Faint nucleolar binding 
IM20 0.3 2.9 160 Borderline Reticular cytoplasmic 
pattern, vimentin-like 
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(n=12) patient cohorts for presence of anti-vimentin antibodies (Figure 3.1.5.A). The MS 
patient cohort was the same as described in Section 2.2.1., while the MG cohort was the same 
as described in Section 2.3.1. Interesting, 6 out of 18 (33%) of the MS patients were positive 
for anti-vimentin IgM, compared to only 1 MG patient out of 12 (8%). Similarly to our 
observation for the IM patients and controls, the IgG anti-vimentin reactivity was greatly 
decreased compared to the IgM responses. Only 1 MS patient (6%) and none of the MG 
patients had detectable IgG antibodies to vimentin (Figure 3.1.5.B). 
Figure 3.1.5. Detection of anti-vimentin IgM (A) and IgG (B) autoantibodies in control, IM patient, 
MS patient, and MG patient sera.  
 
 
3.1.3.4. Correlation Between EBV Viral Load and Humoral Autoreactivity Responses 
To determine whether there is a link between EBV viral load and humoral autoreactivity 
responses during acute IM, we correlated the serum viral load of the IM patients with their 
respective autoreactivity values to MOG, ANA, SS-A, CCP2, and the anti-vimentin IgM and 
IgG antibody levels (Figure 3.1.6.). Only MOG (Figure 3.1.6.A) and CCP2 (Figure 3.1.6.C) 
reactivity reached statistical significance. EBV viral load did not correlate with anti-vimentin 
IgM (Figure 3.1.6.E) or IgG (Figure 3.1.6.F) antibody levels. Curiously, the IM patients with 
the highest EBV viral load (IM15) presented with borderline positivity for CCP2 and ANA 
autoreactivity as well as the highest value for MOG reactivity. The IM patient with the second 
highest viral load (IM12) was clearly positive for ANA and had a relatively high but not 
above the positivity threshold value for MOG reactivity. These two patients were further 
analyzed for presence of autoreactive T cells. 
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Figure 3.1.6. Correlation analysis between EBV viral load and autoreactive antibody levels in IM 
patient sera. (A) EBV viral load correlated to MOG reactivity. (B) EBV viral load correlated to HEp2 
(ANA) reactivity. (C) EBV viral load correlated to CCP2 reactivity. (D) EBV viral load correlated to 
SS-A reactivity. (E) EBV viral load correlated to anti-vimentin IgM antibody levels. (F) EBV viral 
load correlated to anti-vimentin IgG antibody levels. 
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3.1.4. Investigation of Cellular Autoreactive Immune Responses 
 
3.1.4.1. Reactivity to EBV and Autoantigen Peptide Pools 
Next, we investigated the presence of autoreactive T cell responses during acute IM. Frozen 
PBMCs were thawn and stimulated with pools of 51 overlapping peptides of the C-terminal 
region of EBNA1, 5 lytic EBV peptides, 8 latent EBV peptides, 15 myelin peptides, or 15 
pro-insulin peptides. As a negative control and baseline response determinant we used 
unstimulated PBMCs, while PMA/Ionomycin stimulation served as positive control for the 
assay. The myelin peptide pool that was used comprised of peptides that have been described 
to be immunodominat in MS patients and encephalytogenic in mice [147]. The pro-insulin 
peptide pool served as a control autoimmune reponse peptide pool unrelated to MS 
pathogenesis. The IM patients had reduced reactivity to stimulation with EBV antigens, 
however that was not surprising since hypotetically this is due to T exhaustion and lowered 
thresold of responsiveness in the setting of fulminant infection. Nevertheless, the IM patients 
had augmented responses to lytic and to a lesser extend to the latent EBV peptide pool 
compared to the controls. However, the IM patients did not differ in their reactivity to myelin 
nor to the pro-insulin autoantigens (Figure 3.1.7.).  
 
Figure 3.1.7. IFN-γ ELISPOT with IM patient and control PBMCs. The cells were stimulated with 
peptide pools of EBNA1, lytic or latent EBV antigens, myelin, pro-insulin. PMA/Ionomycin served as 
positive control, while no stimulation served as a negatice control. The baseline of IFN-γ response for 
each patient set was determined based on the SFU in the non-stimulated condition (wo). The straight 
line represents the baseline of response of the control patients, while the dotted line represent the 
baseline of response of the IM paient group.  
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3.1.4.2. Cross-Reactivity Analysis of EBNA1-Reactive T Cells from IM Patients 
Since we did not find any signs of augmented autoreactivity to myelin or pro-insulin antigens 
in bulk PBMCs from acute IM patients, we deicded to chose the two patients with highest 
EBV viral load and to clone out EBNA1-reactive T cells in order to check whether these T 
cells would cross-react to autoantigens.  
 EBNA1-reactive T cells were expanded from bulk PBMCs and separated by cytokine 
capture assay, then single-cell seeded and outgrown. The cells were stimulated only with 
irradiated feeders and EBNA1 peptide pool, and supplemented with IL-2.  No unspecific 
phytohaemagglutinin (PHA) stimulation was used during the expansion and clone 
maintenance. 
34 EBNA1-reactive CD4+ T cell clone cultures were outgrown from patient IM12, 
while 10 EBNA1-reactive CD4+ T cell clone cultures could be outgrown from patient IM15. 
As control 5 EBNA1-reactive CD4+ T cell clone cultures were isolated from control patient 
CO15. 
 The reactivity of the clone cultures was measured by IFN-γ , GM-CSF, and IL-2 
cytokine production as well as expression of T cell activation markers, HLA-DR and CD69, 
post stimulation with 5 µM EBNA1 peptides, 5 and 25 µM of myelin peptide pool, or 5 and 
25 µM of pro-insulin peptide pool (Table 2.2.5.). Stimulation with medium alone was used to 
determine the baseline cytokine secretion and activation marker expression of the clone 
cultures. The EBNA1-reactive clones secreted IFN-γ, GM-CSF, but no IL-2, and upregulated 
HLA-DR and CD69 in response to EBNA1 peptide pool stimulation. None of the clone 
cultures stimulated with myelin or proinsulin peptide pool, however, was observed to 
significantly upregulate T cell activation markers or secrete IFN-γ, GM-CSF, nor IL-2. Figure 
3.18 presents IFN-γ production as result of stimulation with increasing concentrations of 
EBNA1, myelin, or proinsulin peptide pool stimulation.  
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Figure 3.1.8. IFN-γ secretion as result of EBNA1, myelin, or proinsulin peptide pool stimulations of 
six representative EBNA1-reactive clones from IM12 (A-F), and two representative clones from CO15 
(G-H).  
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3.2. EBV-Specific Immune Responses in Patients with Multiple Sclerosis Responding to 
IFN-β Therapy 
The following section is adapted from Comabella, Kakalacheva et al. Mult Scler. 2012 
May;18(5):605-9. 
3.2.1. Patient Demographics 
Symptomatic primary infection with the human γ-herpesvirus Epstein–Barr virus and 
elevated immune responses to EBV are associated with the development and progression of 
multiple sclerosis. Interferon-beta (IFN-β), first-line treatment for relapse-onset MS, exhibits 
complex immunoregulatory and antiviral activities. The objective of this study was to 
determine EBV-specific immune responses in patients with MS during IFN-β therapy. In 
order to do that we evaluated cellular and humoral immune responses to EBV- and 
cytomegalovirus (CMV)-encoded antigens in patients with MS before and 1 year after IFN-β 
treatment. Twenty-eight patients with MS who showed a clinical response to IFN-β as 
defined by the absence of relapses and lack of progression on the Expanded Disability Status 
Scale (EDSS) score during the first 2 years of treatment were included. Since paired 
peripheral blood mononuclear cells (PBMC) and serum samples were not available in all of 
the 28 patients included in this study, we determined antibody responses in a total of 24 
patients and cellular immune responses in a total of 18 patients. A summary of the 
demographic and baseline clinical characteristics is shown in Table 3.2.1.  
 
Table 3.2.1. Demographics and baseline clinical characteristics of MS patients treated with IFN-beta. 
(Table copied from Comabella, Kakalacheva et al. [148]) 
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3.2.2. Virus-Specific IgG Antibody Levels in Patients with MS Remain Unchanged 
before and during IFN-β Treatment 
We determined IgG responses specific for the EBV-encoded immunogenic C-terminal 
domain of the latent viral protein EBNA1 (p72) and towards pooled viral capsid antigens 
(VCA), expressed during productive viral replication. These responses were compared with 
IgG reactivity against lysates of the β-herpesvirus CMV. EBV-specific antibody responses 
were detectable in 96% (23/24) of the patients compared with a seropositivity rate of 50% 
(12/24) for CMV (Figure 3.2.1.). Antibody responses to EBNA1 tended to be lower after 1 
year of therapy (median of 9062 U/mL before treatment compared with 5804 U/mL during 
treatment). However, this difference did not reach statistical significance (p = 0.2296). 
Humoral immune responses to lytic VCA antigens remained unchanged during IFN-β 
treatment, whereas IgG responses to CMV lysates slightly decreased (median of antibody 
index: 1.29 U/mL before treatment compared with 1.18 U/mL during treatment, p = 0.007). 
Neutralizing antibody (NAb) data at baseline and after 12 and 24 months of treatment 
were available in 16 patients (57.2%). Only one patient out of 16 (6.3%) developed low titre 
of NAbs at 12 and 24 months of treatment. Humoral and cellular immune responses in this 
patient did not differ from the NAb-negative cohort and patients from whom NAb 
determinations were missing. 
 
 
Figure 3.2.1. Virus-specific IgG antibody levels in patients with MS remained unchanged before and 
during IFN-β treatment. (A) Serum ELISA for IgG antibody responses to EBV-encoded nuclear 
antigen 1 (EBNA1). Median EBNA1 antibody concentration before treatment was 9062 U/mL, while 
after treatment 5804 U/mL. (B) Serum ELISA for IgG antibody responses to EBV-encoded lytic viral 
capsid antigens (VCA). Median VCA antibody concentration before treatment was 37.85 U/mL, while 
after treatment 36.21 U/mL. (C) Serum ELISA for IgG antibody responses to CMV lysates. Median 
CMV antibody index before treatment was 1.29, while after treatment 1.18. The frequencies of patients 
seropositive for the respective ELISAs are noted below the graphs. Seronegative individuals were 
excluded from the analysis. (Figure copied from Comabella, Kakalacheva et al. [148]) 
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3.2.3. Viral Antigen-Specific T Cell Proliferation Is Altered in Patients with MS before 
and during IFN-β Treatment 
Employing a multiparameter flow cytometry-based CFSE dilution assay, we next determined 
EBV- and CMV-specific CD4+ and CD8+ T cell responses in 18 patients before and during 
IFN-β therapy. PBMC were stimulated with either MHC class I-restricted epitopes from three 
latent (EBNA3A, EBNA3B, EBNA3C) and three lytic (BZLF1, BRLF1, BMLF1) antigens or 
an overlapping peptide library spanning the C-terminal domain of EBNA1 (400-641) [141]. 
The MHC class I-restricted T cell epitopes were selected based on their previous 
identification as immunodominant CD8+ T cell epitopes [149], [149], whereas EBNA1 was 
chosen as a dominant EBV-encoded CD4+ T cell antigen in healthy virus carriers [150]. MHC 
class I-restricted CMV pp65-derived peptides were used as control antigens [149]. IFN-β 
treatment was associated with a marked downregulation of EBNA1-specific CD4+ T cell 
responses (p = 0.0156) (Figure 3.2.2.). In contrast, CD8+ T cell responses towards other EBV-
encoded antigens expressed during both B cell transformation and lytic replication did not 
change significantly during treatment. Although we observed a slight decrease of CMV-
specific IgG levels (Figure 3.2.1.), CMV-specific proliferative CD8+ T cell responses 
remained unchanged during clinically effective IFN-β therapy (Figure 3.2.2.). 
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Figure 3.2.2. Viral antigen-specific T cell proliferation was altered in patients with MS before and 
during IFN-β treatment. (A) Antiviral T cell responses were quantified using a flow cytometry-based 
CFSE dilution assay. Peripheral blood mononuclear cells (PBMCs) were stimulated without or with 
EBNA1, EBV and CMV-derived peptides. The populations were pre-gated on single live CD3+ cells 
and CD4+ versus CFSE dilution is displayed in dot blots. Percentages in quadrants represent 
frequencies of CFSElow cells of the respective CD4-positive or CD4-negative populations. Data 
obtained from one representative patient before and after treatment is shown. (B) Percentage of 
proliferating CD4+ T cells after stimulation with EBNA1 before and during IFN-β treatment. (C) 
Percentage of proliferating CD8 T cells after stimulation with MHC class I-restricted EBV peptide mix 
before and during IFN-β treatment. (D) Percentage of proliferating CD8+ T cells after stimulation with 
CMV-pp65 before and during IFN-β treatment. 8/19, 11/19 and 12/19 patients showed proliferative 
responses to EBNA1, MHC-class I restricted EBV peptides and CMV pp65 peptides, respectively, at 
baseline. Patients not showing a proliferative T cell response were excluded from the analysis. (Figure 
copied from Comabella, Kakalacheva et al. [148]) 
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3.3. Intrathymic Epstein-Barr Virus Infection Is Not a Prominent Feature of 
Myasthenia Gravis 
The following section is adapted from Kakalacheva et al., Ann Neurol. 2011;70:508–514. 
3.3.1 Rarity of B Cells Containing EBV DNA in EOMG Thymi  
Recently, Cavalcante et al. reported presence of active EBV infection in thymi derived from 
Myasthenia Gravis patients [120]. The authors claimed that dysregulated EBV infection is 
common in the diseased thymi and could contribute to the immunological changes that 
initiate and/or perpetuate the disease [120]. To evaluate whether EBV infection is 
characteristic of early-onset Myasthenia Gravis (EOMG), we investigated thymus, plasma 
and PBMC samples from 16 patients. Thymic CD19+ B cell frequencies ranged from 6.2 to 
23.6%, of which 13 to 75% showed ‘memory-type’ CD27+ phenotype. 
 
Table 3.3.1. MG patient demographics at thymectomy. (Table copied from Kakalacheva et al. [1]) 
 
 
Real-time PCR was performed to quantify the content of genomic EBV DNA 
(BamHI W repeat region) in EOMG thymi. The lowest detection limit of the assay was 3 
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copies of BamHI-W-encoding plasmid as determined by serial plasmid dilutions (Figure 
3.3.1.A). This high sensitivity was further confirmed by detection of as few as 20 EBV-
positive Raji (human Burkitt’s lymphoma cell line) cells in 1x107 EBV-negative RAMOS 
cells (EBV-negative human Burkitt’s lymphoma cell line); the same sensitivity was observed 
with Lymphoid cell lines (LCLs) that had been infected and transformed with EBV in vitro 
(data not shown). 
 Even with this highly sensitive PCR reaction, EBV was not detected in the majority 
of EOMG thymi; signals of EBV positivity barely reached the detection limit of the assay 
(mean ± SD of 3 ± 1 copies) in only 4 of all 16 samples (Figure 3.3.1C). That corresponds to 
approximately one viral genome, since the BamHI-W sequence occurs in multiple repeats (5-
11) in EBV genomes [151]. In order to increase sensitivity of the assay, we used immuno-
magnetic beads to isolate CD19+ B cells, the site of persistent EBV infection, from 10 thymic 
suspensions. In addition, to further maximize frequencies of GC and stromal cells, we tested 
enzymatically-dispersed cells, available from 7 of these 10 cases. Nevertheless, low EBV 
DNA signal was observed in 3 of the B-cell sorted samples (mean ± SD of 9 ± 5 viral copies) 
(Figure 3.3.1D). Demographic and individual data for each patient is presented in Table 3.3.1. 
and Table 3.3.2., respectively. 
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Figure 3.3.1. Infrequent detection of Epstein-Barr virus (EBV) in EOMG thymic cells, using real-time 
polymerase chain reaction to quantify the presence of genomic EBV DNA (EBV BamHI-W repeat 
region). Plasmids encoding EBV BamHI-W repeat (A) and Bcl2 (B) were used to plot the standard 
curves and to calibrate the sensitivity of the assay. Levels of EBV DNA in total (C) or B cell enriched 
(D) EOMG thymic cell suspensions; 1 of the 3 positive cases had also been positive in C. The bars in C 
and D represent mean values; the dotted lines indicate the EBV BamHI-W detection limit as 
determined with its plasmid. Mononuclear cells isolated from tonsils from 2 different EBV carriers 
with persistent throat infection were used as positive controls and yielded 50-Ct (cycle threshold) 
values of 14.7 and 14.6, respectively. (Figure copied from Kakalacheva et al. [1]) 
 
 
3.3.2. Rarity of B Cells Expressing EBV Markers in EOMG Thymi  
Cryosections of the thymi samples from EOMG patients that presented with EBV-positive 
DNA signals in total thymi suspensions (n=3), and in CD19+-sorted samples (n=3), as well as 
one EBV PCR-negative sample were stained for CD20, EBER, and EBNA2. All investigated 
section had large numbers of CD20+ cells localized at foci (Figure 3.2.2.). However, no 
EBER or EBNA2 positive cells were found at regions of CD20+ cell foci. Occasionally, we 
found individual EBER or EBNA2 positive cells localizing in regions that resemble 
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capillaries. However, the frequency of such EBV-positive cells was extremely rare. No EBV-
positive cells were observed in the PCR-negative EOMG thymic section. Individual data for 
each patient is presented in Table 3.3.2. 
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Figure 3.3.3. Occasional detection of Epstein-Barr virus (EBV)-encoded nuclear antigen 2 (EBNA2)-
positive cells outside B cell follicles. EBV-encoded RNA (EBER) or EBNA2 signal was detected near 
high endothelial venules looping across this field, in thymic sections from patient MG2, who showed 
low but detectable viral DNA levels in thymic cell suspensions. No EBER- or EBNA2-positive signal 
was found in the polymerase chain reaction-negative early onset myasthenia gravis thymus. The bars 
correspond to 50 µm (left panel) and 200 µm (right). (Figure copied from Kakalacheva et al. [1]) 
 
 
3.3.3. No Evidence for Altered EBV-Specific Immune Responses in EOMG Patients 
We next checked for circulating antibodies to EBV antigens, using commercially available 
ELISA kits to determine the levels of IgG specific for the EBV-encoded immunogenic C-
terminal domain of EBNA1 (p72) and the lytic EBV viral capsid antigen (VCA). EBV-
specific IgG antibodies were compared to those against viral lysates of cells infected with the 
ubiquitous human cytomegalovirus (HCMV). No significant differences were observed 
between levels or prevalence of IgG reactivity in EOMG and healthy controls (Figure 
3.3.4.A). In order to investigate the occurrence of EBV reactivation, we measured IgM VCA 
antibodies in both the EOMG and healthy donor serum samples. Nevertheless, we could not 
detect any positive IgM VCA serum levels expect for one healthy donor who presented with 
borderline IgM VCA levels (data not shown).  
 Next, we investigated the presence of altered EBV and HCMV peptide-specific T cell 
responses, as measured by frequencies of IFN-γ-positive T lymphocytes by intracellular 
cytokine staining (ICS). No significant differences between EOMG patients and healthy 
controls were observed in response to EBNA1 or HCMV peptide pools (Figure 3.3.4.C). 
Moderate but not statistically significant elevation of IFN-γ-producing CD8+ T lymphocytes 
was observed after stimulation with MHC class I-restricted EBV-encoded peptides, as 
compared to healthy controls (Figure 3.3.4.C). 
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Figure 3.3.4. Epstein-Barr virus (EBV)-specific antibodies and T cell reactivity in patients with early 
onset myasthenia gravis (EOMG). (A) Circulating immunoglobulin IgG antibodies were determined in 
16 patients, and 15 age- and gender-matched healthy controls, against EBV-encoded nuclear antigen 1 
(EBNA1), the EBV-encoded viral capsid antigen (VCA), and human cytomegalovirus (HCMV). (B) 
Representative interferon IFN-γ intracellular cytokine staining dot plot data. Peripheral blood 
mononuclear cells were stimulated for 6 hours with a peptide library covering the immunogenic 
domain of the CD4+ T cell antigen EBNA1, as well as with major histocompatibility complex (MHC) 
class I-restricted epitopes derived from lytic and latent EBV proteins and from the HCMV-derived 
pp65 protein or phorbol myristate acetate/ionomycin (PMA/Ion.) as positive control. (C) Frequencies 
of IFN-γ-producing EBV-specific T cells. The moderate elevation of CD8+ T cell responses to MHC 
class I-restricted EBV peptides does not reach significance. Bars in A and C represent median values. 
(Figure copied from Kakalacheva et al. [1]) 
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 Table 3.3.2. Summary of Individual Results for all MG Patients. (Table copied from Kakalacheva et 
al. [1]) 
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3.4. Identification of a Novel Inhibitor of Latent EBV Infection 
 
3.4.1. Design of the High-Throughput Screening Assay  
In order to be able to identify inhibitors of latent EBV infection, we chose to target EBNA1, 
an essential viral protein involved in the maintenance and replication of latent EBV. Since 
EBNA1 does not have enzymatic activity, we targeted the protein’s ability to bind site-
specifically to DNA and subsequently initiate viral replication at OriP in dividing latently 
infected cells. For that purpose together with an HTS company we designed an assay based 
on time-resolved fluorescence energy transfer (TR-FRET) that included histidine (His)-
tagged C-terminal region of EBNA1 that is essential for the dimerization and DNA-binding 
function of the protein, and a 36-base pair biotinylated oligonucleotide with a sequence 
encoded on OriP that is specifically recognized by EBNA1. The His-tagged EBNA1 was 
recognized by anti-His mouse monoclonal antibody bound to Eu3+ Cryptate conjugate, while 
the biotinylated oligonucleotide was recognized by a streptavidin molecule bound to d2. In 
this assay format the Eu3+ Cryptate conjugate was the donor of the TR-FRET, while d2 
functioned as the acceptor. If a small molecule disrupted the EBNA1/oligonucleotide 
complex, reduction in the TR-FRET signal would be observed. A schematic representation of 
the assay is shown in Figure 3.4.1A, while the sequence of the oligonucleotide is represented 
in Figure 3.4.1B. Since EBNA1 binds only to double-stranded DNA it was essential that the 
oligonucleotide formed a hairpin or dimerized.  
 
 
Figure 3.4.1 High-throughput screening assay for identification of EBNA1/oligonucleotide complex 
inhibitors. (A) Schematic representation of the time-resolved resonance screening assay including the 
biotinylated oligonucleotide and the His-tagged recombinant C-terminus of EBNA1 together with their 
respective binding partners: Streptavidin-d4 and anti-His mouse monoclonal antibody bound to Eu3+ 
Cryptate conjugate. The excitation and emission wavelengths are given in brackets. (B) Sequence of 
the oligonucleotide that is specifically recognized by EBNA1 and was used in the HTS. 
A B 
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3.4.2 Expression of Recombinant EBNA1 
To perform the HTS assay, we expressed and purified the C-terminal region of EBNA1 (458-
641) tagged to 6 histidine residues. Protein fractions from a representative purification 
process were run on an SDS-PAGE and a Silver stain is presented in Figure 3.4.2 A, where 
EBNA1 can be observed at the size of 21kDa. An overexpressed band at the size of 21 kDa 
can be observed in the pre-purification fraction (lane 2). Similar amount of the overexpressed 
band can be observed in the flow-through during loading (lane 3) which signifies that high 
amounts of the EBNA1 protein were not bound to the column and lost in the flow-through. 
To minimize the loss of recombinant EBNA1, the flow-through was re-run on the column. 
During the wash steps 40 mM Imidazole solution was used to remove weakly bound proteins 
to the His-Trap column. No EBNA1 loss was observed during the wash steps demonstrating 
that the recombinant EBNA1 was tightly bound to the column. EBNA1 could be eluted with 
Imidazole concentrations of 300 mM or higher. When EBNA1 was eluted with 500 mM of 
Imidazole, a faint line of a 75 kDa proteins was observed which contaminated the purified 
EBNA1 fractions. However, the concentration of the impurities was below 90%, which was 
considered acceptable for execution of the high-throughput screen (HTS) assay. Western blot 
analysis with specific 5F12 antibodies directed against the C-terminus region of EBNA1 was 
used to verify that the bands were positive for EBNA1 and that no degradation fragments 
were observed on the gel (Figure 3.4.2B).  
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Figure 3.4.2. EBNA1 purification fractions (A) Silver stain post SDS-PAGE of recombinant EBNA1 
purification fractions including marker (lane 1), pre-purification E. coli extract (lane 2), flow-through 
during His-Trap column loading (lane 3), flow-through during 40 mM Imidazole wash steps (lanes 4-
8), elution fractions with 500 mM Imidazole (lanes 9-15). Elution fractions (lanes 9-13), designated 
with the purple line, were used for the high-throughput screening assay. (B) Western blot with 5F12 
antibody specific for the C-terminal region of EBNA1. 
 
 
3.4.3. High-Throughput Screening Outcome 
A total number of 24 285 unique compounds (Class I group) were used for the primary screen 
(Table 3.4.1). While 636 compounds with intrinsic auto-fluorescence or quenching 
characteristics were identified and removed from the analysis, 103 compounds yielded an 
EBNA1/oligonucleotide complex displacement of more than 30% and underwent 11-point 
dose response hit profiling. Out of these 15 curves could be fitted using the curve-fitting 
module of the IDBS ActivityBase software. Counter assays for DNA intercalation and 
cytotoxicity identified respectively 6 and 4 compounds with more than 50% displacement.  
Besides the Class I compounds, we investigated 8 783 compound mixtures generated 
from fermented fungi, termed HYPHA compounds (Class II group). 3.1% (266 compound 
mixtures) of the non-assay interfering 8 497 mixtures showed 30% displacement, while 1.3% 
(107 compound mixtures) presented with 50% HTS assay inhibition. This efficiency of hit 
finding is remarkably high compared to the efficiency observed for the Class I compounds, 
from which 0.7% of tested compounds had 30% HTS assay inhibition, while only 0.18% 
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yielded 50% inhibition. The top 5 best hits of the 50% displacement Class II compounds were 
selected for further fractionation since each mixture contained 20-30 different compounds. 
The fractionated samples were tested for activity through the HTS assay and the active 
fractions were further sub-fractionated. Several of these fractions were investigated in vitro. 
The one compound, P6, showed remarkable selective cytotoxicity to LCLs. Despite their 
great potential, the Class II compounds were not further investigated due to (1) complexity of 
the mixtures and need for identification of the component compounds, and (2) because of the 
complex legal issues concerning the intellectual property of the compounds. The following 
sections will only focus on the investigation of the Class I compounds with inhibitory 
potential.  
Along with the HTS, we performed virtual screen of more than 1 x 106 compounds of 
which the top 50 hits were further investigated. Of these 32 were available for purchase and 
were subsequently used in the TR-FRET assay setup. However, from all 32 tested compounds 
only 2 had partial activity and were not pursued further. 
 
 
Table 3.4.1 Class I and Class II compounds included in the primary high-throughput screening, hit 
profiling, and counter assays. 
Screening phase Class I compounds Class II compounds 
Primary screen 24 285 8 783 
Removal of assay interfering 
compounds 
23 649 8 497 
>30% TR-FRET 
displacement 
103 266 
Hit profiling (11-point dose 
response curve fitting) 
15 - 
Counter assay for DNA 
intercalation 
6/15 - 
Counter assay for 
cytotoxicity 
4/15 - 
 
 
3.4.4. In Vitro Profiling of the HTS Hits 
The chemical structure of the 15 top HTS hits is presented in Figure 3.4.3, while their activity 
on the HTS assay, cell viability and DNA intercalation counter assays is presented in Figure 
3.4.4.  
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Figure 3.4.3. Chemical structure of all 15 top HTS hit compounds. The compounds marked with an 
asterisk (*) were not available for purchase. 
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Figure 3.4.4. HTS assay results of the 10 available for purchase HTS hit compounds. The fitted 
displacement curves of the primary and the dose-response hit profiling HTS assays are shown together 
with the counter assays for cell viability to HEK cells and DNA intercalation. 
 
 
10 of all 15 top HTS hit compounds were available for purchase and were screened in 
vitro in our laboratory for cytotoxicity to EBV-transformed lymphoblastoid cell lines (LCLs) 
and as a control to the EBV-negative Burkitt lymphoma cell line (Ramos). Three different 
Cell$viability$ DNA$intercala1on$Primary$assay$Dose6response$second$assay$Compound$ Cell$viability$ DNA$interc la1on$Primary$assay$Dose6response$second$assay$Compound$
Compound Primary Assay Cell Viability DNA Intercalation 
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concentrations of the compounds were tested based on the inhibition curves obtained from the 
HTS. The majority of the tested compounds had either no effect on the viability of the LCLs 
or was cytotoxic to both the EBV-positive and EBV-negative cell lines. 
Tilorone, a compound with 30% displacement of the EBNA1/oligonucleotide 
complex in the HTS assay at 33µM concentration, showed remarkable toxicity towards the 
LCLs, while it had limited effect on the Ramos cell line (Figure 3.4.5.). Based on this 
observation the compound was chosen as our top HTS hit and its thorough characterization 
was further undertaken. 
Figure 3.4.5. Cell cytotoxicity to LCLs (A-C) and Ramos cell line (D-F) as determined by total cell 
counts in the course of 17 days of incubation with 1 µM (A and D), 10 µM (B and E) or 100µM (C and 
F) of Tilorone. 
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3.4.5. Confirmation of Tilorone’s Ability to Inhibit the EBNA1/DNA Interaction 
Tilorone was identified as the top hit of a HTS that selected compounds that inhibited the 
ability of EBNA1 to bind to its cognate DNA sequence on OriP. In order to confirm this 
suggested mechanism of action of Tilorone, we designed an Electrophoretic mobility shift 
assay (EMSA) that independently determined the dissociation of the EBNA1/oligonucleotide 
complex. The biotinylated oligonucleotide was either incubated alone or in the presence of 
the C-terminal domain of EBNA1 together with no or increasing concentrations of Tilorone 
(0 µM-1000µM). The mixtures were then run on a non-denaturing polyacrylamide gel and 
blotted onto positively charged Nylon membrane (Figure 3.4.6.A). That allowed for the clear 
separation between oligonucleotide that is in unbound form and ran faster on the non-
denaturing gel and the bound form of the oligonucleotide to EBNA1 that forms a complex 
with the protein that ran with a delay on the gel. Interestingly, we observed that two bands of 
EBNA1-bound oligonucleotide were present on the membrane, which might represent 
EBNA1 bound to the oligonucleotide in dimer and monomer forms. As expected we observed 
that Tilorone led to dose-dependent dissociation of the EBNA1/oligonucleotide complex that 
resulted in increasing concentrations of unbound oligonucleotide (Figure 3.4.6.). The EMSA 
and the HTS observation independently confirmed the ability of Tilorone to dissociate the 
EBNA1/oligonucleotide complex in a dose-dependent manner. Therefore, we decided to 
further characterize the compound in in vitro and in vivo models.  
 
 
Figure 3.4.6. Electrophoretic mobility shift assay (EMSA) of the EBNA1/oligonucleotide complex 
incubated with increasing concentrations of Tilorone. (A) Representative EMSA blot of the 
oligonucleotide in a free form with no EBNA1 (lane 1), bound to EBNA1 in the presence of no 
Tilorone (lane 2), and in the presence of EBNA1 together with increasing concentrations of Tilorone 
(lanes 3-9). (B) Quantification of relative density of the unbound oligonucleotide band from three 
independent EMSA experiments.  
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3.4.6. Characterization of the Effect of Tilorone In Vitro 
The EBV-transformed LCL cell line in vitro model system was chosen to further characterize 
the effect of Tilorone on EBV-infected cells. For that purpose we used distinct LCL types that 
were obtained from ex vivo EBV-transformed B cells from different healthy donors that were 
generated at different time points in our laboratory. These cells were considered suitable for 
our experiments since for their proliferation, the LCL require the persistence of the EBV 
genome. Four such LCL cell lines were used to quantify the cytotoxic effect of Tilorone. As a 
control we used the L428 EBV negative Hodgkin’s lymphoma cell line, which was suggested 
to have similar activation and proliferation status as the LCLs. The cells were incubated for 7 
days with various concentrations of Tilorone and the frequency of live cells as determined by 
flow cytometry was related to the frequency of live untreated cells at the respective time 
point. Tilorone reduced cell viability in a dose-dependent manner for all four types of LCLs. 
Incubation with 15 µM Tilorone led to reduction in cell viability of 35% on day 5 and 70% on 
day 7. This concentration had no effect on the L428 cell viability for the investigated time 
period. A Tilorone concentration of 20 µM led to reduction of LCL cell viability of 70% on 
day 5 and 94% at day 7. This Tilorone concentration had no effect on L428 cell viability on 
day 5 and only 12% cell viability reduction at day 7. However, while a concentration of 25 
µM of Tilorone led to 89 and 99% reduction of LCL viability on day 5 and 7 respectively, it 
also resulted in 22 and 60% reduction of L428 viability on day 5 and 7 respectively (Figure 
3.4.7.). This observation suggest that there is a limited range of concentrations at which 
Tilorone has a cytotoxic effect in an EBV-specific manner, however above a certain 
concentration the compound is cytotoxic also to EBV-negative cells. 
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Figure 3.4.7. Tilorone exhibits cytotoxic effect on EBV-positive, but not on EBV-negative cell lines.  
Four types of LCLs (A, C-E) and one control cell line (B) were incubated with increasing 
concentrations of Tilorone (5, 10, 15, 20, and 25 µM) for 7 days. The cells were analyzed by flow 
cytometry and the frequency of live cells is presented as ratio of the live cells with 0 µM Tilorone at 
the respective time points. 
 
 
Having seen that Tilorone exhibits cytotoxic effects on the LCLs, we decided to 
investigate whether that effect was due to reduction in cellular proliferation. In order to do 
that the LCL and L428 cell lines were stained with CellTrace Violet and incubated with 
increasing concentrations of Tilorone for 7 days. The dilution of the dye was used as a 
proliferation measure, and was analyzed by flow cytometry at 1, 3, 5, and 7 days of culture. 
Higher mean fluorescence intensity (MFI) signified less dye dilution that represented less cell 
proliferation. Tilorone led to dose-dependent inhibition of LCL proliferation that was 
observable as early as day 3 and was most pronounced at day 5 and 7 (Figure 3.4.8.A). The 
compound had little effect on the proliferation of the control cell line, L428. The only 
inhibition of L428 cell line proliferation was observed with the highest concentration of the 
compound (25 µM) at day 7 (Figure 3.4.8.B). This finding coincided with the 
abovementioned cytotoxic effect of Tilorone at high compound concentration that occurred in 
EBV-unrelated manner.   
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Figure 3.4.8. Tilorone inhibits proliferation of EBV-transformed LCLs. (A) EBV-positive cell line, 
LCL, and EBV-negative cell line, L428, were stained with CellTrace Violet and incubated with 
increasing concentrations of Tilorone for 7 days. The dilution of the dye, used as a proliferation 
measure, was analyzed by flow cytometry at 1, 3, 5, and 7 days of culture and presented as overlay of 
histograms. (B) Relative mean fluorescence intensity (MFI) of CellTrace Violet normalized to LCLs 
incubated with 0 µM Tilorone at the respective time point. (C) Relative mean fluorescence intensity 
(MFI) of CellTrace Violet normalized to L428 incubated with 0 µM Tilorone at the respective time 
point. 
 
 
Moreover, we investigated whether the cytotoxic and anti-proliferative effect of 
Tilorone were due to apoptosis induction. For this purpose we analyzed the presence of 
Annexin V positive cells post incubation with increasing concentrations of Tilorone (Figure 
3.4.9.A). In addition, we measured the activation of Caspase 3/7, as a direct marker of 
apoptosis initiation (Figure 3.4.9.B). The compound led to dose-dependent apoptosis 
induction as observed by both Annexin V expression and Caspase 3/7 activation. 
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Figure 3.4.9. Induction of apoptosis as a result of Tilorone treatment. (A) Frequency of Annexin V-
positive LCLs 24 hours post incubation with increasing concentrations of Tilorone. (B) Caspase 3 and 
7 activation in LCLs 3, 8, and 24 hours post incubation with increasing concentrations of Tilorone.  
 
 
Based on our in vitro findings we could conclude that Tilorone limited the 
proliferation and promoted cytotoxicity by inducing apoptosis in EBV-positive cell lines. 
These findings make the compound an interesting candidate for treatment of EBV-associated 
malignancies, therefore we decided to investigate it further with our mouse models.  
 
3.4.7. In Vivo Effect of Tilorone on EBV-Associated Tumor Burden  
Thanks to the abundant literature about the pharmacokinetics and pharmacodynamics of 
Tilorone in mice, we could determine that the compound would be well tolerated when 
applied through oral gavage or intraperitonealy (i.p.). The reported LD50 for oral application 
of Tilorone for mice was 959 mg/kg, while the LD50 for i.p. application was 145 mg/kg [152]. 
Since we had to apply the compound 3 times per week for the continuation of at least 4 
weeks, we decided to apply Tilorone i.p. in order to minimize the risk of tissue scarring and 
animal loss due to repeated gavaging. The compound was applied at a concentration of 50 
mg/kg 3 times per week and was well tolerated since no Tilorone-related weight loss was 
observed in our experiments (Figure 3.4.10.).  
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Figure 3.4.10. No weight changes observed due to treatment with Tilorone. Mouse weight change 
compared to initial weight in the course of 45 days of 3-times per week treatment with 50 mg/kg 
Tilorone. Representative experiment of three repeats including 5 mice in Tilorone-treated group and 4 
mice in the PBS-treated group. 
 
 
 To test the efficacy of Tilorone against EBV-associated tumors in vivo, we injected 
i.v. 10x106 luciferase-expressing LCLs (LCL-luc) or control (L428-luc) into NOD-SCID-
gamma-chain-deficient (NSG) mice and monitored the luminescence signal as a measure of 
cancer cell line proliferation in vivo for four weeks. Representative luminescence 
measurements are presented in Figure 3.4.11.A. One to two days after injection the 
luminescence signal was localized mainly in the lungs and reproductive organs of the 
animals. During week one most of the signal localized to the liver, while from week two on 
increase in the luminescence signal and formation of high-signal foci in the area that localized 
with the spleen were observed. 
Figure 3.4.11. summarizes the results obtained from one representative experiment 
from a total of 3 experiments per cell line. The mice, treated with Tilorone, showed 
significantly reduced tumor burden at week three and four post LCL injection compared to 
vehicle (PBS)-treated mice (Figure 3.4.11.B). Moreover, the percentage of mice presenting 
with spleen tumors was reduced from 100% (5/5 mice) in the vehicle-treated group to 14% 
(1/7 mice) in the Tilorone-treated group (Figure 3.4.11C). The compound had no effect on 
tumor proliferation (Figure 3.4.11C) or the tumor incidence (Figure 3.4.11.D) of an EBV-
negative Hodgkin’s lymphoma cell line, L428. It should be noted, however, that even though 
both cell lines have similar growth kinetic in vitro, the L428 cell line grew more aggressively 
in the NSG mice and led to tumor formations in the liver, rather than in the spleen as 
observed for the LCLs. In short, Tilorone successfully inhibited the proliferation and the 
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tumor incidence of an EBV-associated cancer cell line in immunodeficient mice, while it had 
no effect on the proliferation and tumor incidence of an EBV-negative cancer cell line. 
 
Figure 3.4.11. Tilorone effectively reduced EBV-associated tumor burden. NOD-SCID-gamma-chain-
deficient (NSG) mice were injected with luciferase-expressing EBV-positive (LCL-luc) or EBV-
negative (L428-luc) B cell lines. In vivo luciferase measurement was performed weekly to monitor 
tumor cell proliferation. (A) Representative luciferase measurements at week zero, one, and two post 
LCL-luc injection. (B) Luminescence measurement of vehicle- and Tilorone-treated mice post LCL-luc 
injection. One representative of three independent experiments with 5 mice in the control and 7 in the 
treatment group is shown. (C) Comparison between tumor incidences in the spleen of vehicle- and 
Tilorone-treated mice 4 weeks post LCL-luc injection. (D) Luminescence measurement of vehicle- and 
Tilorone-treated mice post L428-luc injection. One representative of three independent experiments 
with 5 mice in the control and 5 in the treatment group is shown. (E) Comparison between tumor 
incidences in the liver of vehicle- and Tilorone-treated mice 4 weeks post L428-luc injection.  
 
 
3.4.8. Tilorone Inhibits Ex Vivo Transformation of Human B Cells by EBV 
CD19+ B cells were MACS-isolated from human PBMCs, stained with CellTrace Violet, and 
infected with EBV in the presence of increasing concentrations of Tilorone. The compound 
led to dose-dependent inhibition of proliferation of the B cells implying that Tilorone 
inhibited the capacity of EBV to transform B cells. Based on our observations, not only was 
Tilorone able to induce the death of EBV-positive cell lines, but also the compound was able 
to limit transformation of non-infected human B cells by EBV.   
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Figure 3.4.11. Tilorone inhibited ex vivo transformation of human B cells by EBV. Human CD19+ B 
cells were MACS-isolated from PBMCs and stained with CellTrace Violet, a cell proliferation dye. 
The cells were then infected with 0.5 MOI of EBV and cultured in the presence of increasing 
concentrations of Tilorone. (A) CellTrace Violet dye dilution at day 4, 6, and 11 post EBV infection. 
The numbers above the histograms represent the number of cell divisions as calculated by FlowJo cell 
proliferation analysis tool. Representative proliferation histograms of 1 donor out of 6 tested. (B) The 
frequency of divided cells was determined with the FlowJo cell proliferation analysis tool. The relative 
frequency of divided cells is presented normalized to the frequency of cells incubated with 0 µM of 
Tilorone for four days. 
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3.4.9. Tilorone Reduces Lytic EBV Reactivation in AKBM Cells 
Having seen that Tilorone successfully reduces ex vivo transformation of B cells by EBV, we 
decided to investigate whether the compound has an effect on lytic reactivation. For that 
purpose we used the AKBM cell line, a cell line derived from the EBV-positive Burkitt's 
lymphoma cell line Akata. The cell line was transfected with a reporter to express an 
immuno-sortable surface (CD2) marker and GFP upon induction of the lytic cycle that was 
achieved through cross-linking of its BCR by anti-human IgG antibody. Upon induction of 
the lytic cycle the lytically switched cells would almost exclusively express CD2 and GFP 
and would upregulate the immediate early lytic EBV gene, BZLF1 [153].  
 AKBM cells were incubated with 0, 10, 15, 20, and 25 µM of Tilorone, while EBV 
lytic reactivation was induced through BCR cross-linking. The cells were harvested and 
analyzed for GFP expression by flow cytometry after 24 hours. 67% of the induced AKBM 
cells reactivated lytic EBV replication (Figure 3.4.12.A). The lytic reactivation was 
significantly reduced to 31% in the presence of 10 µM of Tilorone, while 25 µM of the 
compound led to nearly complete abrogation of lytic reactivation with only 3.6% GFP-
positive AKBM cells. That reduction in lytic reactivation was not due to cytotoxic effect of 
Tilorone. Even though the induction of reactivation led to loss of about 60% of the AKBM 
cells both in the Tilorone treated and non-treated conditions, the compound itself did not lead 
to reduction in absolute cell counts (Figure 3.4.12.B). 
  
Figure 3.4.12. Tilorone reduces lytic EBV reactivation in AKBM cells. (A) Frequency of GFP positive 
AKBM cells as a result of lytic viral reactivation. (B) Absolute cell counts of live AKBM cells in non-
induced and induced AKBM cells, treated with Tilorone.  
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3.4.11. Tilorone Leads to Marginal Reduction in Viral Load in EBV-Infected 
Humanized Mice 
The next intriguing question that we wanted to answer was whether Tilorone could inhibit 
EBV infection in vivo. Since EBV is a species-specific pathogen and infects human B cells 
but not murine lymphocytes, we had to generate NOD-SCID-gamma-chain-deficient (NSG) 
mice with reconstituted human immune system components. NSG newborns were 
reconstituted with human fetal liver-derived CD34+ cells. Three months later, the frequencies 
of the human lymphocytes were evaluated. The blood of the reconstituted mice typically 
comprised of 60-90% human CD45+ cells, about 60% of which were human CD19+, and 20-
40% were CD3+ with a 4:1 ratio of CD4+ to CD8+ T cells. NKp46+ NK cells represented 1-4% 
of all human CD45+ cells (Figure 3.4.13.).  
 
 
Figure 3.4.13. Reconstitution of human lymphocyte subsets in NOD-SCID-gamma-chain-deficient 
(NSG) mice from one representative cohort of humanized mice, split in subgroups for Tilorone or 
vehicle treatment.  
 
 
The HLA-A2-transgenic or non-transgenic reconstituted NSG mice were infected 
with 105 RIU B95-8 EBV virus particles. One day before the infection and thrice a week 
thereafter, the mice were treated either with vehicle or 50 mg/kg Tilorone. The treatment dose 
and frequency was comparable to the one used for the non-reconstituted NSG mice (Section 
3.4.7.). Similar to the non-reconstituted mice, the humanized NSG tolerated well the 
compound and responded with no treatment-specific weight loss (Figure 3.4.14.).  
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Figure 3.4.14. Tilorone does not lead to treatment-specific weight loss in humanized NSG mice. 
Weight changes compared to original weight in humanized NSG mice in the course of EBV infection 
with or without Tilorone treatment. 
 
 
EBV viral load in the whole blood of the animals could be observed starting from 
week two and was measured weekly thereafter. We performed two independent experiments 
with HLA-A2 transgenic (experiment duration: 5 weeks) and two independent experiments 
with non-HLA transgenic humanized NSG mice (experiment duration: 7 weeks). In all four 
experiments we observed at least one time point when the Tilorone treated mice had reduced 
EBV viral load compared to the vehicle-treated mice (Figure 3.4.15.). However, that 
difference was significant only for two of the experiments (Figure 3.4.15.A-B), while when 
we combined all data points the significance was lost (Figure 3.4.15.E). However, we could 
observe a trend for reduced viral load in the Tilorone-treated group at weeks four, five, and 
six. This observation could be due to the variability between the individual mice both in 
reconstitution level and EBV viral load, but also due to diverse blood Tilorone levels. 
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Figure 3.4.15. Tilorone led to marginally reduced EBV viral load in reconstituted humanized NSG 
mice. Two individual experiments conducted in non-HLA transgenic NSG mice (A-B) and two 
individual experiments in HLA-A2 transgenic NSG mice are presented (C-D). (E) EBV viral load 
changes as result of Tilorone treatment from all four experiments combined. The empty circles 
represent the vehicle-treated mice, while the filled squares represent the Tilorone-treated animals. 
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Despite the compound’s strong cytotoxic and anti-proliferative effect in vitro and its 
ability to limit ex vivo B cell transformation, lytic reactivation, and tumor burden in non-
reconstituted NSG mice, the complex environment of an NSG mouse reconstituted with 
human immune system components poses challenges to the efficiency of the treatment. 
Encouraging, however, is the fact that Tilorone does not affect the composition, both 
in frequency and absolute numbers, of the reconstituted human immune system in the NSG 
mice (Figure 3.4.16.). Both vehicle and Tilorone treated mice showed no changes in absolute 
counts of the human CD19+ cell subset (Figure 3.4.16.B), while the CD3+ subset was 
expanding in the course of the infection due to increase in both CD8+ (Figure 3.4.16.F) and 
CD4+ T cells (Figure 3.4.16.H). Moreover, expansion of activated T cells, CD3+ HLA-DR+ 
subset (Figure 3.4.16.J), was observed in the course of the infection. However, as already 
mentioned the treatment with Tilorone did not lead to significant changed in the counts of B 
cells, or expansion and activation status of the human T cells. 
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Figure 3.4.16. No change in reconstituted human lymphocyte subsets due to Tilorone treatment in 
humanized NSG mice. (A) Frequency and (B) absolute cell count of human CD19+ cells. (C) 
Frequency and (D) absolute cell count of human CD3+ cells. (E) Frequency and (F) absolute cell count 
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of human CD8+ cells. (G) Frequency and (H) absolute cell count of human CD8+ cells. (I) Frequency 
and (J) absolute cell count of human CD3+ HLA-DR+ cells. Data from one representative non-HLA-
transgenic cohort of humanized NSG mice is shown here. 
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4.	  DISCUSSION	  
 
4.1. Generation of Autoreactive Humoral and Cellular Immune Responses during 
Infectious Mononucleosis 
The aim of this study was to characterize the generation of autoreactive humoral and cellular 
immune responses during acute IM in order to better understand the well-described link 
between history of IM and autoimmune diseases such as multiple sclerosis. For that purpose 
we chose IM patients that underwent medical visit shortly after onset of IM symptoms. These 
patients were compared to age-matched patients that visited the same hospital however due to 
non-IM-related complaints. We considered this as the most appropriate control group as the 
patients in this group were not only matched for age, gender and demographic location, but 
also suffered from diverse conditions some of which were characterized by mild 
inflammation. Therefore, by comparing these two groups of patients one would be able to 
better eliminate autoimmune reactions that were rather due to not IM-specific inflammatory 
process, yet comparing the IM patients to other non-IM inflammatory disease patients would 
provide a more reliable control. 
Moreover, in order to have only EBV carriers in the control and IM patient cohorts, 
in our control group we chose only patients who were latent EBV carriers based on presence 
of anti-VCA IgG antibodies. Interestingly, the IM patient group had reduced median level of 
anti-VCA IgG compared to the control group. That could be explained by the fact that anti-
VCA IgG antibodies take about 2 weeks after onset of disease to develop [154]. 9 out of the 
13 IM patients had their first doctor visit and blood drawing in the first week after onset of 
symptoms, therefore their IgG responses towards the VCA antigen were not as fully 
developed as in the latent EBV carriers in the control group. 
 
4.1.1. Investigation of Humoral Autoreactive Immune Responses 
Fulminant inflammation processes have been long known to stimulate the transient 
production of autoreactive antibodies. Myriad of studies were published during the 60s and 
70s of the last century describing the occurrence of autoantibodies during acute IM. It was 
know that acute IM leads to augmented levels of immunoglobulins that persist for as long as 2 
years post infection [155], [156]. These antibodies were usually of IgM isotype and rarely 
converted to IgG [157]. Such antibodies included antinuclear antibodies (ANA) [158], [157], 
anti-IgG [158], anti-I or cold-agglutinin antibodies [155], anti-smooth muscle antibodies 
[159], anti-cyroprotein antibodies [160], and anti-tubulin antibodies. Nevertheless, these 
autoantibodies were not strongly associated with disease pathologies except for the anti-I 
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antibodies, which are though to lead to hemolysis during IM. The other autoantibodies are 
thought to potentially contribute to liver damage and rare complications such as 
thrombocytopenia and agranulocytosis [161].  
MS is a heterogeneous disease with complex pathology. Increasing evidence, 
however, points that antibody-mediated effector mechanisms could contribute to the 
immunopathogenesis of demyelination [143]. Such effector mechanisms include 
immunoglobulin deposition within white matter lesions [162], antibody-associated receptor 
mediated phagocytosis of myelin debris [163], and complement activation within the CNS 
[164], [143]. The CNS-confined MOG antigen was considered as a plausible target for the 
demyelinating immune response especially since animal models of MS, induced by 
immunization with CNS homogenates and complete Freund’s adjuvant, were characterized by 
the generation of MOG-specific antibodies that contributed to the disease pathology [145], 
[165]. Additionally, MOG was shown to contain an encephalitogenic T cell epitope which 
together with the humoral immune responses against MOG contributed to the demyelination 
of CNS neurons in rat, mouse, and marmoset models of MS [166], [167], [168]. The role of 
anti-MOG antibodies in human MS is, nonetheless, controversial. Several studies have 
confirmed the persistent presence of anti-MOG antibodies, predominantly of IgM isotype, in 
MS patients and transiently in patients with other inflammatory neurological disorders [143], 
[144]. These anti-MOG antibodies were determined to occur early in the event of the disease 
progression as well as to be good predictors of MS conversion of patients with clinically 
isolated syndrome [143], [169]. The later observation was, however, contested by a different 
group [170]. 
Interestingly, not much is known about the presence of anti-MOG antibodies during 
infectious mononucleosis. One case report describes a patient with infectious mononucleosis 
who also developed post-EBV encephalopathy. The patient was negative for traces of active 
EBV infection in the CNS, suggesting no active role of EBV in the disease pathology, but had 
high humoral (predominantly IgM) and T responses against MOG that decreased after the 
encephalopathy was resolved [171]. Yet, the generation and prevalence of MOG antibodies 
during IM is poorly defined. 
In our study we performed a novel assay for detection of anti-MOG antibodies by 
using human oligodendroglial cell line that stably expresses human MOG in its natural 
glycosylation form. We screened 13 IM and 13 control patient samples and detected anti-
MOG antibodies in only one IM patient. One should note however that our assay used goat 
anti-human IgG as secondary detection antibody. Therefore, with this assay we screened only 
for presence of anti-MOG IgG antibodies in our cohorts. Since IgM MOG antibodies seem to 
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be the predominant isotype found in MS patients, it would be of high interest to optimize the 
assay for detection of IgM anti-MOG antibodies. 
Besides through bystander activation in the course of fulminant inflammation, 
autoreactive antibodies can be produced due to EBV infection and immortalization of 
autoreactive B cells. We collaborated with Tracy et al. on a study that looked at autoreactivity 
of EBV-infected and EBV-negative B cells from acute IM patients. 56 EBV-positive and 69 
EBV-negative memory B cells were single-cell sorted, and the antibodies of these B cells 
were cloned, expressed, and used for self- and poly-reactivity assays [172]. One of the assays 
performed was the MOG assay that we used for characterization of IM patient sera. Tracy et 
al. found that EBV does persist within self- and poly-reactive B cells; however, infection with 
the virus does not favor the survival of autoreactive B cells. 
An interesting and unexpected finding from the HEp2 immunofluorescence analysis 
of the IM patient sera was the identification of vimentin-like autoantibodies in a large fraction 
of the patients. The cytoskeleton forms a complex network of filamentous proteins that are 
distributed throughout the cytoplasm. Autoantibodies against the three main types of 
filaments, microfilaments, microtubules, and intermediate filaments, have been described in 
numerous diseases such as anti-actin autoantibodies in liver diseases and anti-tubulin 
antibodies in infectious mononucleosis [173]. Vimentin is the most widely expressed 
intermediate filament protein. It is predominantly produced by mesenchymal cells and its 
main function is to facilitates cellular processes such as migration, protein trafficking and 
signal transduction by orchestrating protein complexes [174]. Antibodies against vimentin 
have been described in a number of diseases including connective tissue diseases such as 
SLE, RA, in Crohn’s disease, and lymphoproliferative diseases such as angioimmunoblastic 
lymphadenopathy [175]. 
Our observations of high prevalence of anti-vimentin IgM antibodies in 69% of the 
IM patients compared to only 8% in control patients are not the first ones to describe the 
occurrence of cytoskeletal autoantibodies in IM. Kataaha et al. showed that 92.5% of 40 IM 
patients were positive for IgM autoantibodies against cytoskeletal intermediate filaments of 
pre-keratin or vimentin type [176]. Surprisingly, the group compared 72 RA patients and 
found that 81.9% of these patients also had high titers of the vimentin-like antibodies, while 
only 26% of the 93 healthy donors had low titers of the antibodies.   
Interesting, several studies have shown that EBV infection led to upregulated 
expression of vimentin in the infected cells. Upon EBV infection vimentin was found to 
redistribute to patch-like inclusions in lipid rafts where it was associated with LMP1 [177]. 
When vimentin was chemically disrupted, LMP1 relocalized to the site where vimentin was 
redistributed, suggesting that the two proteins might form a complex [177]. A recent study by 
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Meckes et al. not only confirmed the association of the two proteins but also elucidated the 
functional significance of vimentin’s activity. The researchers evaluated the function of 
vimentin by short hairpin RNA knockdown, expression of dominant-negative vimentin 
protein, and use of chemical inhibitor to reveal the role of the protein in LMP1 signal 
transduction and transformation [174]. 
Despite the low number of IM and control patients used in this study, we found 
positive correlation between the EBV viral load and MOG IgG and CCP reactivity. 
Curiously, the IM patient with the highest viral load (IM15) also presented with the highest 
humoral response to MOG, borderline positivity to citrullinated proteins (CCP2), and IgM but 
not IgG responses to vimentin. The IM patient with the second highest viral load (IM12), was 
the only patient from the IM cohort that was positive for ANA, had a high MOG reactivity, 
and IgM but not IgG responses to vimentin. Due to the high viral load and high levels of 
autoreactivity of the serum of these patients we decided to look closer into the T cell 
responses of these patients. 
 
4.1.2. Investigation of Cellular Autoreactive Immune Responses 
The acute phase of EBV infection is characterized by considerable activation and expansion 
of CD8+ T cells. It is suggested that during this state of acute inflammation non-EBV-specific 
T cells also get activated through bystander activation or novel antigen availability due to 
release of cell material from copious cell death. Molecular mimicry could provide another 
mechanism for activation and expansion of autoreactive T cells. In the latter case, T cells that 
are reactive to viral epitopes have cross-reactivity potential to other antigens. The cross-
reactivity to secondary antigens might be of lower affinity, however in the event of an acute 
inflammation, the reactivity of these cells could be augmented. Once generated, such cross-
reactive T cells might convert to memory T cells and linger in the human body until they in 
combination with other environmental and genetic factors contribute to the development of 
autoimmune pathologies.  
 EBV-specific CD8+ and CD4+ T cells have been described to cross-react with 
allogeneic MHC molecules, self peptides, bacterial and other viral antigens [178], [179], 
[180], and [181]. In particular MBP-specific T cell clones isolated from MS patients have 
been shown to get activated by several viral and bacterial peptides, including common viruses 
such as EBV (peptide derived from the viral DNA polymerase) and influenza A, herpes 
simplex virus, and adenovirus [182]. A different study confirmed these findings by showing 
that MBP-specific T cell clones from MS patients can recognize a peptide from the EBV 
DNA polymerase protein, however in the context of a different MHC Class II molecule [183]. 
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Crystal structures of the two peptides in complex with their respective MHC molecules were 
shown to have a very close similarity and nearly identical TCR contact surface [183]. 
 Characteristic for MS patients is the presence of elevated humoral and cellular 
responses to certain EBV antigens. In particular, MS patients have been shown to possess 
enhanced T cell responses to EBNA1 owning to selectively expanded reservoirs of central 
memory CD4+ T helper 1 precursors and T helper 1 polarized effector memory cells [98]. 
Interestingly, these EBNA1-specific T cells have been shown to cross-react with myelin 
antigens and to produce IFN-γ and IL-2, and were speculated as contributors of CNS 
immunopathology [184]. 
 In this study we hypothesized that EBNA1-specific T cells that have the ability to 
cross-react to myelin antigens are generated during the acute phases of IM and can contribute 
to pathologies later in life.  
To address this hypothesis, we first analyzed responses of total PBMCs to EBV, 
myelin, and pro-insulin peptide pools (Figure 3.1.7.). Post EBV lytic peptide pool stimulation 
on average 19 versus 3 IFN-γ SFU per 2x105 PBMCs were detected from the IM patients 
compared to the controls, respectively. The higher response of the IM patients can be easily 
explained by the high availability of lytic antigens during active EBV infection. As expected, 
the controls were more reactive to the latent EBV peptide pool, than to the lytic ones, with an 
average of 8 SFU per 2x105 PBMCs. The IM patients had an average of 21 SFU per 2x105 
PBMCs to the latent EBV peptide pool which we speculate could be due to the presence of 
latent antigen-reactive CD8+ T cell clones, that were expanded during acute IM but decreased 
in numbers after resolution of the infection [138]. In general, one can see that the IFN-γ EBV 
peptide pool responses were rather close to the detection limit of the assay most probably due 
to the inflammatory state and the high activation status of the IM T cells. Such dysregulation 
of EBV-specific responses in IM patients has already been described [185]. Nevertheless, we 
could detect EBNA1 responses in the IM patient PBMCs. Presence of similar low but 
persistent EBNA1 CD4+ and CD8+ responses during acute IM have already been described by 
others [138]. On the other hand, myelin or pro-insulin IFN-γ responses could be detected 
neither in IM patients nor in control bulk PBMCs. 
We next cloned EBNA1-reactive T cells from acute IM patients to test their cross-
reactivity potential to autoantigens. For that purpose we chose the IM patients who presented 
with the highest level of serum autoimmunity and had the highest EBV viral load levels. 44 
EBNA1-reactive CD4-positive clonal cultures could be outgrown from these two IM patients. 
None of these clones, however, had detectable reactivity neither to the myelin nor to the 
proinsulin peptides. Our inability to identify cross-reactive clones could be either due to the 
mere lack of such clones during IM or due to the fact that the patients from whom these 
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clones were generated were not carriers of HLA-DR1*15, which is the strongest genetic risk 
factor associated with MS. 
In conclusion, despite the limited number of patients involved in this study, we 
observed enhanced autoreactivity to diverse self-antigens of the serum of IM patients. 
Moreover, this humoral autoreactivity correlated with the patient’s cell-free EBV viral load. 
Currently, we are analyzing a new cohort of IM patients and non-IM inflammatory controls to 
determine whether our observations from the first cohort can be confirmed.  
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4.2. EBV-Specific Immune Responses in Patients with Multiple Sclerosis Responding to 
IFN-β Therapy 
The following section is adapted from Comabella, Kakalacheva et al. Mult Scler. 2012 
May;18(5):605-9. 
Immune responses to EBNA1 are prominently increased in apparently healthy individuals 
who will develop MS, in patients with clinically isolated syndrome (CIS) suggestive of MS 
and in patients with clinically definite MS [99], [105], [102]. IgG responses to EBNA1 but 
not to lytic EBV antigens are reported to correlate with clinical and MRI-based markers of 
disease activity and progression, and to predict conversion to clinically definite MS in 
patients with CIS based on the 2005 revisions to the McDonald criteria [104], [102]. These 
changes in EBV-specific immunity appear not to be associated with an increase in viral 
replication or impaired immune control of EBV infection, since patients with clinically 
definite MS do not differ from healthy virus carriers in levels of cell-associated viral genomes 
in circulating blood cells and their ability to control EBV-infected B cell outgrowth in vitro 
[105], [106]. In line with these observations, we did not observe significant changes in T cell 
responses towards EBV-encoded antigens expressed during lytic infection and viral 
transformation in IFN-β-treated MS patients, further suggesting that the increase in EBNA1-
specific immune responses in patients with MS and its downregulation during IFN-β therapy 
are not primarily driven by viral replication. 
Elevated EBNA1-specific T cell responses in patients with MS display a phenotype 
indicative of frequent antigen recognition [184], and it has been suggested that these 
responses are maintained through restimulation by central nervous system-infiltrating and 
latently infected B cells or cross-reactivity with autoantigens [186], [106]. EBNA1 is the sole 
viral protein consistently expressed in latently infected proliferating B cells [187], and its 
transcription is regulated by IFN regulatory factors (IRFs) [188], [189], [190], [191], a family 
of transcription factors which is activated through IFN receptor signaling [192]. Thus, 
repression of EBNA1 transcription through IRFs leading to reduced antigen availability 
during systemic IFN-β treatment represents a hypothetical mechanism that could explain the 
observed downregulation of EBNA1-specific T cell responses. Due to the limited observation 
period of 1 year, we cannot exclude that IFN-β additionally affects immune responses to lytic 
EBV gene products or other viral antigens at later time points. Moreover, since T helper cell 
frequencies influence the generation and maintenance of IgG responses [193], we cannot 
exclude the possibility that antibody responses to EBNA1 decrease in patients responding to 
IFN-β therapy at a later time point. Nevertheless, our study shows that CD4+ T cell responses 
to EBNA1 are consistently reduced early after treatment initiation, and thus supports the 
notion that EBNA1 is a target antigen of the pathological immune response in MS. Although 
DISCUSSION 	  
	   112	  
further investigations will be necessary to clarify whether these changes are causally related 
to MS development and progression, our study suggests, if replicated in larger cohorts of 
patients and controls, that the magnitude of EBNA1-specifc immune responses is not only 
associated with disease activity and disability progression [104], [102], but also with the 
clinical response to IFN-β in MS. 
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4.3. Intrathymic Epstein-Barr Virus Infection Is Not a Prominent Feature of 
Myasthenia Gravis  
The following section is adapted from Kakalacheva et al., Ann Neurol. 2011;70:508–514. 
We found that the majority of EOMG thymi had undetectable levels of EBV DNA, even after 
real-time PCR analysis of isolated thymic B cells. Cryosections of EOMG thymi contained 
large numbers of CD20+ cells localized in foci, however, no EBER or EBNA2 positive cells 
were present where CD20+ cells localized. Furthermore, no significant alterations in EBV-
specific humoral or cellular immune responses were detected in EOMG patients versus 
healthy controls. 
 Investigating thymi from 17 MG patients including 12 with hyperplasia, Cavalcante et 
al. recently reported high frequencies of EBV-infected thymus-infiltrating B cells [120]. All 
their MG thymi showed evidence for active, i.e. replicative, EBV infection as defined by the 
presence of lytic and latent viral transcript and protein expression [120]. In sharp contrast, we 
could not confirm these high frequencies; even with highly sensitive and well established 
quantitative real-time PCR protocols for detecting genomic EBV [105], [194], [102], we 
found low viral DNA levels corresponding to single viral genomes in only 6 of 16 thymi. Nor 
could we detect presence of EBER or EBNA2 markers localizing with CD20-positive B cell 
foci in MG thymi. 
 The most obvious difference between these studies is that at least 14 of the 17 patients 
tested by Cavalcante et al. had been pre-treated with corticosteroids and/or other 
immunosuppressants (versus 1 of our 16) – which are known to impair immunosurveillance 
mechanisms of latent EBV infection [4]. In their remaining 3 cases, steroid or AChR antibody 
status is not reported, so they could derive from distinct MG subgroups. As suggested by 
Cavalcante et al., we checked for the systemic deregulation of host-EBV interactions reported 
for other autoimmune diseases such as MS [195]. Humoral as well as CD4+ and CD8+ T cell 
responses to immunodominant viral antigens expressed during B cell transformation, 
productive viral replication, and latent infection [4], [105], [141] proved to be unchanged in 
EOMG patients. These data are in line with the earlier screen for IgG antibody titers to EBV 
in patients with MG onset before age of 20 [196]. On the contrary, Csuka et al. claimed that 
EOMG patients are characterized by high titers of EBNA1 antibodies [197]. Their study 
compared the EBNA1 antibody levels in MG patients and controls and found no differences. 
However, when the authors quantified the frequency of high EBNA1 IgG producers, defined 
as more than 600AU/mL, they found that 16.3% of the healthy controls and 26.6% of the MG 
patients are positive (p=0.024), and therefore they deducted that high EBNA1 titers are 
characteristic of MG. Despite the high number of MG patients (n=158) included in their 
study, we believe that these percentages are too low to claim a strong association between the 
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disease and EBNA1 antibodies. Moreover, we found no difference in the level and titer of 
these antibodies in our cohort of EOMG patients. 
 Independently from our report two studies with similar findings were published in the 
last 2 years. Meyer et al. analyzed 25 EOMG thymi for histological signs of latent or lytic 
EBV infection and found no presence of EBV [198]. Moreover, Jing and colleagues analyzed 
30 thymi from MG patients with Chinese origin and found no histological signatures of EBV 
infection [199]. Yet our study provided the most comprehensive analysis of EBV responses in 
EOMG patients as we not only looked at histological markers of EBV infection, but also 
compared viral load and humoral and cellular immune responses. 
 After the publication of our and Meyer et al.’s studies, Cavalcante and colleagues 
claimed that the discrepancies in our observations are most probably due to differences in the 
sensitivities of our assays. Therefore, we have established communication with the Italian 
researchers and initiated exchange of samples so that we can cross-analyze them. However, 
this initiative has yet not led to a conclusion since Cavalcante and colleagues have not yet 
provided us with their MG thymi samples for EBV DNA quantification.  
 In conclusion, in EOMG thymi taken before immunosuppressive therapy (mostly 
within a few months of MG-onset), we detected only very low levels of EBV signals, which 
are to be expected in tissues infiltrated by peripheral B cells. Furthermore, EBV-specific 
immune responses were unchanged in these patients. These findings do not support a role for 
EBV infection in the initiation of EOMG. 
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4.4. Identification of a Novel Inhibitor of Latent EBV Infection 
With this study we aimed at identifying inhibitors of established EBV infection by targeting 
the essential interaction of EBNA1 with the viral episome. This protein/DNA complex has 
been well characterized as the crystal structure of the DNA-binding and dimerization domain 
of EBNA1 was solved in an unbound [38], and a form bound to a palindromic 18bp 
oligonucleotide encoded on OriP [39]. Curiously, the DNA binding domain of EBNA1 bares 
close structural similarity to the E2 protein of the papillomavirus despite their complete lack 
of sequence homology [39]. On the other side, the interaction of EBNA1 with the host DNA 
is less well characterized. Marechal et al. have identified the domains, CBS-1, -2, and -3, 
through which EBNA1 binds non-covalently to mitotic host chromosomes and therefore 
facilitates the almost equal separation of the viral episomes between the dividing daughter 
cells [200]. Since the interaction of EBNA1 with the episomal DNA sites has been much 
better characterized, we decided to use this interaction to design an HTS and screen for 
compounds that would dissociate the complex and subsequently would lead to abrogation of 
EBV infection. The sequence of the 36 bp oligonucleotide that we used in the HTS was 
constructed of the 18 bp nucleotide that Bochkarev et al. described joined to its 18 bp 
complementary strand. Inhibition of this interaction is supposed to interfere with the 
maintenance and the proliferation of the latent virus. This has been suggested by 
Nasimuzzaman et al. who substituted EBNA1 with a mutant EBNA1 form that could not bind 
to DNA. This mutant form exerted dominant negative effects on the maintenance of the viral 
episome and impaired the growth of a Burkitt lymphoma cell line [201]. Additionally, Kariya 
et al. showed that the presence of dominant-negative EBNA1 in the early stages of EBV 
infection led to inhibition of the positive feedback in the transcription of viral transforming 
genes and the subsequent eradication of EBV genomes in the sub-acute phases of the 
infection [202]. The observation that the abrogation of the functions of EBNA1 leads to 
reduced viral genome maintenance and decreased survival of EBV-infected cell lines has also 
been confirmed by Hong et al. who suppressed the expression of EBNA1 by RNA 
interference and observed reduced proliferation of Raji Burkitt lymphoma cell line [203]. 
Besides its essential role in episome maintenance and replication, EBNA1 is suggested to 
interact with other host factors and to support the survival of the infected cells as is the case 
for Burkitt’s lymphoma [204]. Many studies have suggested a direct role of EBNA1 in host 
gene regulation, however no study has yet unequivocally and compellingly been able to prove 
that [205]. 
Recently, we were not the first ones to target EBNA1 in an attempt to inhibit EBV 
infection. Kang and colleagues used a cell-based HTS assay through which they screened 40 
550 compounds for their ability to dissociate EBNA1 from OriP [206]. Roscovitine was 
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identified as an inhibitor of EBNA1 serine 393 phosphorylation that abrogated the interaction 
of the protein with OriP. This study elegantly elucidated the mechanisms of action of the 
compound, yet the authors evaluated the activity of the compound only against LCLs without 
providing an EBV-negative control cell line and did not at all look at the effect of roscovitine 
in vivo.  Four other such reports have characterized EBNA1 inhibitors, however none of the 
studies has evaluated the efficacy of the identified compounds in vivo [207], [208], [209], 
[210]. Thompson et al. concluded that even though the HTS used in their study identified 
inhibitors of the EBNA1/DNA interaction, these compounds are unlikely to be clinically 
relevant unless the appropriate chemical modifications are made [207]. 
The abundant literature strongly supports our choice to target EBNA1 in order to 
inhibit latent EBV infection. However, one concern should be noted here. Our HTS was 
designed to screen for compounds that would dissociate the EBNA1/DNA interaction; 
however, a positive readout in this assay would be obtained with any strong DNA intercalator 
irrespective of its ability to bind specifically to EBNA1. Some of the strongest dissociators of 
the complex that appeared among our top 15 hits were DNA binding molecules that are 
currently used for cancer chemotherapy (Figure 3.4.3., bottom line). It is doubtful that these 
molecules recognize specifically EBNA1, but rather by binding strongly to the 
oligonucleotide they inhibit the formation of the complex. As expected these compounds 
showed cytotoxic activity to both the EBV-positive and the control EBV-negative cell line 
and were not investigated further. In order to exclude hits that promiscuously bind DNA, one 
could suggest that the hit compounds were run on a control TR-FRET screen that included a 
different DNA binding protein and its cognate oligonucleotide. One such control DNA-
binding protein could be Proliferating cell nuclear antigen (PCNA). In order to determine 
which of our hit compounds interacted with DNA we used a PicoGreen counter-assay that 
identified dsDNA-binding compounds.  
Tilorone, was among the top 15 hit compounds and was the only compound that 
showed LCL-specific cytotoxic activity in vitro. At higher concentrations, however, the 
compound would promote cell killing of EBV-negative cell lines (Figure 3.4.7.B). Therefore, 
based on our observations we cannot claim that Tilorone specifically inhibits EBV-positive 
cells, however, we do see an effect of the compound on the stability of the 
EBNA1/oligonucleotide complex (Figure 3.4.6.) and subsequent cytotoxic (Figure 3.4.7.) and 
anti-proliferative (Figure 3.4.7.) effect on EBV-positive cell lines. Therefore, we were 
confident to continue with the thorough characterization of the compound and to suggest it as 
a potential lead compound to develop an inhibitor of EBV infection. Interestingly, a chemical 
derivative of Tilorone was also among the top 15 HTS hits (Figure 3.4.3., top row, second 
column). Unfortunately, this compound was not available for purchase. Nevertheless, one 
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should consider in the future the potential optimization of Tilorone with medicinal chemistry 
techniques that would enhance its activity and biological availability. Such attempts by others 
have already led to the successful optimization of the activity of the compound by 
modification of its fluorenone skeleton and its side chains [211]. Zhou et al. generated 22 
novel Tilorone analogs, 10 of which were shown to have better anticancer properties, defined 
as the compound’s cytotoxicity to a number of cancer cell lines [211]. 
Curiously, our top hit, Tilorone, was first described in the early 70s as a broad-
spectrum, orally active antiviral agent in mice [152]. The compounds was shown to 
effectively reduce the viral load of a number of RNA and DNA viruses including Semliki 
Forest virus, vesicular stomatitis virus, encephalomyocarditis, Mengo, vaccinia, herpes 
simplex virus and three strains of influenza among others [152], [212]. Yet, the 
efficaciousness of the compound in EBV infection has never been tested before. 
Even though the compound can be administered orally, we chose to deliver it 
intraperitonealy in order to minimize injuries and complications as a result of repeated gavage 
applications. 14C- and 3H-tilorone pharmacokinetics studies have shown that the compound 
distributes rapidly throughout the body post intravenous, intraperitoneal, and oral 
administration [213], [214]. The highest concentration of the compound through either 
application route was found in the liver and the kidneys of the injected mice, while the lowest 
concentration was detected in the plasma of the animals. Therefore, all three routes of 
administration provide similar biological distribution of the compound, however while the 
LD50 dose of a single intraperitonealy injection is 145 mg/kg, the LD50 for a single oral dose is 
959 mg/kg [152]. Therefore, one can apply orally 5 times higher concentration of Tilorone 
also taking into consideration that the hepatoportal system would eliminate about 21% of the 
orally administered Tilorone [214]. Hence, it would be of interested to explore the potential of 
application of a higher concentration of the compound through oral administration. Moreover, 
it would be advantageous to develop a chemical derivative of Tilorone that persist at higher 
concentrations in the blood if the compound is used for the treatment of EBV infection or 
EBV-associated lymphomas. 
After the discovery of the broad anti-viral properties of Tilorone, the compound was 
approved for medical use and commercialized under the name Amixin in a limited number of 
countries such as Ukraine and Russia. The drug is currently being used as a prophylactic 
against a number of viral infections including influenza, hepatitis, and herpes. Curiously, even 
though not the primary standard of care, the drug is also suggested for the treatment of 
multiple sclerosis. However, we were not able to find any clinical study reports describing the 
efficacy of the drug. Interestingly, we performed 2 independent EAE experiments where oral 
treatment with the compound led to decrease in disease onset, incidence, and severity (data 
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not shown). We did not, however, further characterize the mechanism through which this 
occurs.  
The mechanism of action described in the literature about the antiviral properties of 
Tilorone concerns the compound’s ability to induce IFN-α [215]. High serum titers of IFN-α 
were reported in mice post oral administration of the compound, with a peak at 24 hours, 
however the compound had reduced capacity to induce IFN-α production in other organisms 
such as rabbits, hamsters, ferrets, cats, dogs, and humans [216]. Tilorone has been shown to 
form a reversible molecular complex with DNA with a predilection for AT-rich sequence 
motifs [212]. A poorly understood interaction with the promoter region of IFN-α is suggested 
to be involved in the compound’s potential to induce the production of type I interferons. 
Nevertheless, the anti-proliferative effect of Tilorone on LCLs is most likely not due to the 
compound’s ability to induce IFN-α since we were not able to detect presence of IFN-α 
protein in the supernatant of treated LCLs (data not shown) and LCLs were suggested to be 
irresponsive to IFN-α since they lack the respective receptors. Moreover, we were not able to 
find IFN-α protein in the serum of Tilorone treated humanized NSG mice both 17 hours post 
injection and at the time of termination of the experiment between week 5 and 7 (data not 
shown).  
We hypothesis that due to its DNA intercalating abilities, Tilorone is able to bind to 
the AT-abundant sequence motif on OriP that EBNA1 recognizes and in doing so is able to 
interfere with the formation of the EBNA1/OriP complex which then leads to abrogation of 
the EBNA1 function to support the maintenance and the replication of latent EBV genomes. 
The activity of EBNA1 is mediated through binding of the protein on two distinct regions on 
OriP conveying two distinct functions (Figure 4.4.1.).  
 
Figure 4.4.1. Depiction of OriP and its EBNA1 binding sites. (Figure drawn based on Hammerschmidt 
et al. [16].) 
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The family of repeats (FR) is an array of 20 non-conserved tandem repeats of 30bp 
size that is located on the OriP and is essential for episomal maintenance [12]. EBNA1 can 
bind with high affinity as a dimer to the 20 motifs in the FR; however, only seven of the 20 
motifs need to be occupied by EBNA1 for efficient episomal maintenance to occur [12]. The 
dyad symmetry (DS), on the other hand, is a 65 bp region on OriP located about 1 kbps 
downstream of FR that is the minimal replicator element of episomal EBV. The region 
consists of two pairs of low affinity EBNA1-binding sites [12], [16]. The sites within one pair 
are spaced exactly 21 bp apart so that they fall in the same helical phase, a characteristic 
essential for their function as replicator that is not required for EBNA1 binding at the FR 
region [27].  Since the EBNA1 binding at the DS happens with low affinity and is highly 
sensitive to the helical turn of the DNA, we hypothesize that Tilorone is able to interfere with 
EBNA1 binding at the DS site due to the compound’s ability to bind to AT-rich DNA 
sequences and to change the topological structure of the DNA when bound. We do not have 
yet data to prove this hypothesis; however, we have seen that when we treat LCL-injected 
non-reconstituted NSG mice with Tilorone, we observed an inhibition of the proliferation of 
the LCLs but not complete eradication of the injected LCLs (Figure 3.4.11.). One should note 
here that one limitation of this mouse model is that the treatment with the compound is started 
2 days post intravenous injection of the LCLs and therefore this model is not a perfect 
representation of a solid tumor treatment in humans. Nevertheless, these data suggest that 
Tilorone inhibits strongly the proliferation of the latently infected cells, while it does not 
significantly influence the maintenance of the EBV episome. This differs from what we 
observed in vitro, where the compound not only inhibited the proliferation of latently infected 
cells, but also had cytotoxic effects and completely eradicated the LCLs (Figure 3.4.7. and 
3.4.8.). This discrepancy could be explained by the higher concentrations of the compound 
reaching the cell in vitro, which could possible result in higher level of DNA intercalation of 
the compound and eventual interference with the DNA replication processes of the cell. 
However, we have also not seen a decrease in EBV episome number in Tilorone treated LCLs 
(data not shown).  
Again we would propose that the compound should be optimized through medicinal 
chemistry in order to maximize its ability to dissociate the EBNA1/DNA complex not only at 
DS but also at the FR region. Then, we hypothesize that we would be able not only to 
interfere with the replication of latent EBV but also to efficiently abrogate EBV genome 
maintenance. That, however, raises the concern of EBV reinfection and subsequent IM-like 
complications of individuals who had cleared the infection post treatment. Since, however, 
EBV specific adaptive immune responses would be maintained after primary acute viral 
infections in memory T and B cell compartments, this would probably be less of a concern.  
DISCUSSION 	  
	   120	  
In conclusion, we have seen that Tilorone has strong cytotoxic and anti-proliferative 
effects on EBV-positive cells, while it significantly reduces ex vivo B cell transformation, 
lytic reactivation, and tumor burden in non-reconstituted NSG mice. The compound, 
however, has shown limited efficacy in reducing EBV viral load in EBV-infected humanized 
NGS mice. That most probably resulted from the potentially low Tilorone concentrations in 
the animal serum as suggested by pharmacokinetics studies with radio-labeled Tilorone [213], 
[214]. It would be interesting to evaluate the concentration of Tilorone in the mouse blood 
and correlate that to the viral load. More intriguing, however, would be to engineer the 
compound through medicinal chemistry to a form that is more readily available in the blood 
and efficacious against both EBV maintenance and proliferation. Further research and 
compound optimization could potentially lead to the development of a new treatment strategy 
against latent EBV infection and EBV-associated diseases.  
  
 REFERENCES 
	   121 
5.	  REFERENCES	  
  
 
 1. Kakalacheva, K., et al., Intrathymic Epstein-Barr virus infection is not a prominent feature of 
myasthenia gravis. Ann Neurol, 2011. 70(3): p. 508-14. 
2. de-The, G., The Epstein-Barr virus (EBV): a Rosetta Stone for understanding the role of 
viruses in immunopathological disorders and in human carcinogenesis. Biomed 
Pharmacother, 1985. 39(2): p. 49-51. 
3. Pellet P., R.B., Herpesviridae: A Brief Introduction. In Fields Virology. Vol. 5th edition, 
2007. 
4. Hislop, A., et al., Cellular responses to viral infection in humans: Lessons from Epstein-Barr 
virus. Annu Rev of Immunol, 2007. 25: p. 587-617. 
5. Baer, R., et al., DNA sequence and expression of the B95-8 Epstein-Barr virus genome. 
Nature, 1984. 
6. Miller, G., et al., Epstein-Barr virus: transformation, cytopathic changes, and viral antigens 
in squirrel monkey and marmoset leukocytes. Proc Natl Acad Sci U S A, 1972. 69(2): p. 383-
387. 
7. Parker, B.D., et al., Sequence and transcription of Raji Epstein-Barr virus DNA spanning the 
B95-8 deletion region. Virology, 1990. 179(1): p. 339-346. 
8. Zimber, U., et al., Geographical prevalence of two types of Epstein-Barr virus. Virology, 
1986. 154(1): p. 56-66. 
9. Abdel-Hamid, M., et al., EBV strain variation: geographical distribution and relation to 
disease state. Virology, 1992. 190(1): p. 168-175. 
10. Fingeroth, J., Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2. 
Proc Natl Acad Sci U S A, 1984. 81(14 I): p. 4510-4514. 
11. Tugizov, S.M., J.W. Berline, and J.M. Palefsky, Epstein-Barr virus infection of polarized 
tongue and nasopharyngeal epithelial cells. Nat Med, 2003. 9(3): p. 307-14. 
12. Yates, J.L., Epstein-Barr virus DNA replication. DNA replication in eukaryotic cells. Cold 
Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1996: p. 751-773. 
13. Bloss, T.A. and B. Sugden, Optimal lengths for DNAs encapsidated by Epstein-Barr virus. J 
Virol, 1994. 68(12): p. 8217-8222. 
14. Gibson, W. and B. Roizman, compartmentalization of spermine and spermidine in herpes 
simplex virion. Proc Natl Acad Sci U S A, 1971. 68(11): p. 2818. 
15. Hammerschmidt, W. and B. Sugden, Identification and characterization of oriLyt, a lytic 
origin of DNA replication of Epstein-Barr virus. Cell, 1988. 55(3): p. 427-433. 
16. Hammerschmidt, W. and B. Sugden, Replication of Epstein-Barr Viral DNA. Cold Spring 
Harbor Perspectives in Biology, 2013. 5(1): p. a013029-a013029. 
17. Liao, G.L., F.Y. Wu, and S.D. Hayward, Interaction with the Epstein-Barr virus helicase 
targets Zta to DNA replication compartments. J Virol, 2001. 75(18): p. 8792-8802. 
REFERENCES 	  
	   122	  
18. Liao, G.L., et al., The Epstein-Barr virus replication protein BBLF2/3 provides an origin-
tethering function through interaction with the zinc finger DNA binding protein ZBRK1 and 
the KAP-1 corepressor. J Virol, 2005. 79(1): p. 245-256. 
19. Takagi, S., K. Takada, and T. Sairenji, Formation of intranuclear replication compartments of 
Epstein-Barr-Virus with redistribution of BZLF1 And BMRF1 gene-products. Virology, 1991. 
185(1): p. 309-315. 
20. Nakayama, S., et al., Epstein-Barr Virus Polymerase Processivity Factor Enhances BALF2 
Promoter Transcription as a Coactivator for the BZLF1 Immediate-Early Protein. J Biol 
Chem, 2009. 284(32): p. 21557-21568. 
21. Pfuller, R. and W. Hammerschmidt, Plasmid-like replicative intermediates of the Epstein-
Barr virus lytic origin of DNA replication. J Virol, 1996. 70(6): p. 3423-3431. 
22. Daikoku, T., et al., Postreplicative mismatch repair factors are recruited to Epstein-Barr 
virus replication compartments. J Biol Chem, 2006. 281(16): p. 11422-11430. 
23. Kudoh, A., et al., Homologous Recombinational Repair Factors Are Recruited and Loaded 
onto the Viral DNA Genome in Epstein-Barr Virus Replication Compartments. J Virol, 2009. 
83(13): p. 6641-6651. 
24. Sugimoto, A., et al., Spatiotemporally Different DNA Repair Systems Participate in Epstein-
Barr Virus Genome Maturation. J Virol, 2011. 85(13): p. 6127-6135. 
25. Miyazaki, I., R.K. Cheung, and H.-M. Dosch, Viral interleukin 10 is critical for the induction 
of B cell growth transformation by Epstein-Barr virus. J Exp Med, 1993. 178(2): p. 439-447. 
26. Nanbo, A., A. Sugden, and B. Sugden, The coupling of synthesis and partitioning of EBV 
plasmid replicon is revealed in live cells. The EMBO Journal, 2007. 26(19): p. 4252-4262. 
27. Bashaw, J.M. and J.L. Yates, Replication from oriP of Epstein-Barr Virus Requires Exact 
Spacing of Two Bound Dimers of EBNA1 Which Bend DNA. J Virol, 2001. 75(22): p. 10603-
10611. 
28. Yates, J.L., S.M. Camiolo, and J.M. Bashaw, The Minimal Replicator of Epstein-Barr Virus 
oriP. J Virol, 2000. 74(10): p. 4512-4522. 
29. Julien, M.D., Z. Polonskaya, and J. Hearing, Protein and sequence requirements for the 
recruitment of the human origin recognition complex to the latent cycle origin of DNA 
replication of Epstein-Barr virus oriP. Virology, 2004. 326(2): p. 317-328. 
30. Deng, Z., et al., Telomeric proteins regulate episomal maintenance of Epstein-Barr virus 
origin of plasmid replication. Molecular Cell, 2002. 9(3): p. 493-503. 
31. Lindner, S.E., et al., The affinity of EBNA1 for its origin of DNA synthesis is a determinant of 
the origin&apos;s replicative efficiency. J Virol, 2008. 82(12): p. 5693-5702. 
32. Kirchmaier, A.L. and B. Sugden, Rep*: a viral element that can partially replace the origin of 
plasmid DNA synthesis of Epstein-Barr virus. J Virol, 1998. 72(6): p. 4657-4666. 
33. Wang, J.D., et al., Essential elements of a licensed, mammalian plasmid origin of DNA 
synthesis. Mol Cell Biol, 2006. 26(3): p. 1124-1134. 
34. Wensing, B., et al., Variant chromatin structure of the oriP region of Epstein-Barr virus and 
regulation of EBER1 expression by upstream sequences and oriP. J Virol, 2001. 75(13): p. 
6235-6241. 
 REFERENCES 
	   123 
35. Tempera, I. and P.M. Lieberman, Chromatin organization of gammaherpesvirus latent 
genomes. BBA - Gene Regul Mech, 2010. 1799(3-4): p. 236-245. 
36. Frappier, L. and M. Odonnell, Overproduction, Purification, and Characterization of Ebna1, 
the Origin Binding-Protein of Epstein-Barr-Virus. J Biol Chem, 1991. 266(12): p. 7819-7826. 
37. Chen, M.R., J.M. Middeldorp, and S.D. Hayward, Separation of the Complex DNA-Binding 
Domain of EBNA-1 into DNA Recognition and Dimerization Subdomains of Novel Structure. J 
Virol, 1993. 67(8): p. 4875-4885. 
38. Bochkarev, A., et al., Crystal structure of the DNA-binding domain of the Epstein-Barr virus 
origin-binding protein EBNA 1. Cell, 1995. 83(1): p. 39-46. 
39. Bochkarev, A., et al., Crystal structure of the DNA-binding domain of the Epstein-Barr virus 
origin-binding protein, EBNA1, bound to DNA. 1996. p. 791-800. 
40. Hegde, R.S., et al., Crystal-structure at 1.7-angstrom of the Bovine Papillomavirus-1 e2 DNA-
binding domain bound to its DNA target. Nature, 1992. 359(6395): p. 505-512. 
41. Altmann, M., et al., Transcriptional activation by EBV nuclear antigen 1 is essential for the 
expression of EBV transforming genes. Proc Natl Acad Sci U S A, 2006. 103(38): p. 14188-
14193. 
42. Aras, S., et al., Zinc Coordination Is Required for and Regulates Transcription Activation by 
Epstein-Barr Nuclear Antigen 1. PLoS Pathogens, 2009. 5(6). 
43. Avolio-Hunter, T.M. and L. Frappier, EBNA1 efficiently assembles on chromatin containing 
the Epstein-Barr virus latent origin of replication. Virology, 2003. 315(2): p. 398-408. 
44. Middleton, T. and B. Sugden, EBNA1 Can Link the Enhancer Element to the Initiator Element 
of the Epstein-Barr-Virus Plasmid Origin of DNA-Replication. J Virol, 1992. 66(1): p. 489-
495. 
45. Sears, J., et al., The amino terminus of Epstein-Barr virus (EBV) nuclear antigen 1 contains 
AT hooks that facilitate the replication and partitioning of latent EBV genomes by tethering 
them to cellular chromosomes. J Virol, 2004. 78(21): p. 11487-11505. 
46. Levitskaya, J., Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-
Ala repeat domain of the Epstein-Barr virus nuclear antigen 1. Proc Natl Acad Sci U S A, 
1997. 94(23): p. 12616-12621. 
47. Yin, Y., B. Manoury, and R. Fahraeus, Self-inhibition of synthesis and antigen presentation by 
Epstein-Barr virus-encoded EBNA1. Science, 2003. 301(5638): p. 1371-1374. 
48. Paludan, C., et al., Endogenous MHC class II processing of a viral nuclear antigen after 
autophagy. Science, 2005. 307(5709): p. 593-596. 
49. Caldwell, R., Epstein-Barr virus LMP2A drives B cell development and survival in the 
absence of normal B cell receptor signals. Immunity, 1998. 9(3): p. 405-411. 
50. Gires, O., et al., Latent membrane protein 1 of Epstein-Barr virus mimics a constitutively 
active receptor molecule. EMBO Journal, 1997. 16(20): p. 6131-6140. 
51. Mosialos, G., et al., The Epstein-Barr-virus transforming protein LMP1 engages signaling 
proteins for the tumor-necrosis-factor receptor family. Cell, 1995. 80(3): p. 389-399. 
52. Kilger, E., et al., Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent 
membrane protein 1, which simulates an activated CD40 receptor. EMBO Journal, 1998. 
17(6): p. 1700-1709. 
REFERENCES 	  
	   124	  
53. Zimber-Strobl, U., et al., Epstein-Barr virus latent membrane protein (LMP1) is not sufficient 
to maintain proliferation of B cells but both it and activated CD40 can prolong their survival. 
EMBO J, 1996. 15(24): p. 7070-8. 
54. Beaufils, P., et al., The (YXXL/I)2 signalling motif found in the cytoplasmic segments of the 
bovine leukaemia virus envelope protein and Epstein-Barr virus latent membrane protein 2A 
can elicit early and late lymphocyte activation events. EMBO J, 1993. 12(13): p. 5105-12. 
55. Williams, H., et al., The immune response to primary EBV infection: a role for natural killer 
cells. Br J Haematol, 2005. 129(2): p. 266-74. 
56. Strowig, T., et al., Tonsilar NK Cells Restrict B Cell Transformation by the Epstein-Barr 
Virus via IFN-γ. PLoS Pathogens, 2008. 4(2): p. e27. 
57. Pappworth, I.Y., E.C. Wang, and M. Rowe, The switch from latent to productive infection in 
Epstein-Barr virus-infected B cells is associated with sensitization to NK cell killing. J Virol, 
2007. 81(2): p. 474-82. 
58. Steven, N.M., et al., Immediate early and early lytic cycle proteins are frequent targets of the 
Epstein-Barr virus-induced cytotoxic T cell response. J Exp Med, 1997. 185(9): p. 1605-17. 
59. Steven, N.M., et al., Epitope focusing in the primary cytotoxic T cell response to Epstein-Barr 
virus and its relationship to T cell memory. J Exp Med, 1996. 184(5): p. 1801-13. 
60. Callan, M.F., et al., CD8(+) T-cell selection, function, and death in the primary immune 
response in vivo. J Clin Invest, 2000. 106(10): p. 1251-61. 
61. Hislop, A.D., et al., Epitope-specific evolution of human CD8(+) T cell responses from 
primary to persistent phases of Epstein-Barr virus infection. J Exp Med, 2002. 195(7): p. 893-
905. 
62. Dunne, P.J., et al., Epstein-Barr virus-specific CD8(+) T cells that re-express CD45RA are 
apoptosis-resistant memory cells that retain replicative potential. Blood, 2002. 100(3): p. 
933-40. 
63. Faint, J.M., et al., Memory T cells constitute a subset of the human CD8+CD45RA+ pool with 
distinct phenotypic and migratory characteristics. J Immunol, 2001. 167(1): p. 212-20. 
64. Hislop, A.D., et al., EBV-specific CD8+ T cell memory: relationships between epitope 
specificity, cell phenotype, and immediate effector function. J Immunol, 2001. 167(4): p. 
2019-29. 
65. Keating, S., et al., The lytic cycle of Epstein-Barr virus is associated with decreased 
expression of cell surface major histocompatibility complex class I and class II molecules. J 
Virol, 2002. 76(16): p. 8179-88. 
66. Maini, M.K., et al., Clonal expansions in acute EBV infection are detectable in the CD8 and 
not the CD4 subset and persist with a variable CD45 phenotype. J Immunol, 2000. 165(10): p. 
5729-37. 
67. Amyes, E., et al., Characterization of the CD4+ T cell response to Epstein-Barr virus during 
primary and persistent infection. J Exp Med, 2003. 198(6): p. 903-11. 
68. Precopio, M.L., et al., Differential kinetics and specificity of EBV-specific CD4+ and CD8+ T 
cells during primary infection. J Immunol (Baltimore, Md : 1950), 2003. 170(5): p. 2590-
2598. 
 REFERENCES 
	   125 
69. Ressing, M.E., et al., Interference with T cell receptor-HLA-DR interactions by Epstein-Barr 
virus gp42 results in reduced T helper cell recognition. Proc Natl Acad Sci U S A, 2003. 
100(20): p. 11583-8. 
70. Luzuriaga, K. and J.L. Sullivan, Infectious mononucleosis. New Engl J Med, 2010. 362(21): p. 
1993-2000. 
71. Nagy, N. and E. Klein, Deficiency of the proapoptotic SAP function in X-linked 
lymphoproliferative disease aggravates Epstein-Barr virus (EBV) induced mononucleosis and 
promotes lymphoma development. Immunol Lett, 2010. 130(1-2): p. 13-8. 
72. Epstein, M.A., B.G. Achong, and Y.M. Barr, Virus particles in cultured lymphoblasts from 
Burkitts lymphoma. Lancet, 1964. 1(733): p. 702. 
73. Carbone, A., A. Gloghini, and G. Dotti, EBV-associated lymphoproliferative disorders: 
classification and treatment. Oncologist, 2008. 13(5): p. 577-585. 
74. Young, L.S. and A.B. Rickinson, Epstein-Barr virus: 40 years on. Nat Rev Cancer, 2004. p. 
757-768. 
75. Kennedy, G., J. Komano, and B. Sugden, Epstein-Barr virus provides a survival factor to 
Burkitt's lymphomas. Proc Natl Acad Sci U S A, 2003. 100(24): p. 14269-14274. 
76. Chou, J., et al., Nasopharyngeal carcinoma—Review of the molecular mechanisms of 
tumorigenesis. Head and Neck, 2008. 30(7): p. 946-963. 
77. Kakalacheva, K., C. Munz, and J.D. Lunemann, Viral triggers of multiple sclerosis. Biochim 
Biophys Acta, 2011. 1812(2): p. 132-40. 
78. Hemmer, B., et al., Identification of high potency microbial and self ligands for a human 
autoreactive class II-restricted T cell clone. J Exp Med, 1997. p. 1651-1659. 
79. Hemmer, B., et al., Identification of candidate T-cell epitopes and molecular mimics in 
chronic Lyme disease. Nat Med, 1999. 5(12): p. 1375-1382. 
80. Hemmer, B., et al., Contribution of individual amino acids within MHC molecule or antigenic 
peptide to TCR ligand potency. of J Immunol, 2000. 164(2): p. 861-871. 
81. McRae, B.L., et al., Functional evidence for epitope spreading in the relapsing pathology of 
experimental autoimmune encephalomyelitis. J Exp Med, 1995. 182(1): p. 75-85. 
82. Yu, M., J.M. Johnson, and V.K. Tuohy, A predictable sequential determinant spreading 
cascade invariably accompanies progression of experimental autoimmune encephalomyelitis: 
a basis for peptide-specific therapy after onset of clinical disease. J Exp Med, 1996. p. 1777-
1788. 
83. Katz-Levy, Y., et al., Endogenous presentation of self myelin epitopes by CNS-resident APCs 
in Theiler's virus-infected mice. J Clin Invest, 1999. p. 599-610. 
84. Kaufman, D.L., et al., Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in 
murine insulin-dependent diabetes. Nature, 1993. 366(6450): p. 69-72. 
85. Lurquin, C., et al., Contrasting frequencies of antitumor and anti-vaccine T cells in metastases 
of a melanoma patient vaccinated with a MAGE tumor antigen. J Exp Med, 2005. 201(2): p. 
249-257. 
86. Miller, S.D., et al., Persistent infection with Theiler's virus leads to CNS autoimmunity via 
epitope spreading. Nat Med, 1997. p. 1133-1136. 
REFERENCES 	  
	   126	  
87. Olson, J.K., J. Ludovic Croxford, and S.D. Miller, Innate and adaptive immune requirements 
for induction of autoimmune demyelinating disease by molecular mimicry. Mol Immunol, 
2004. 40(14-15): p. 1103-1108. 
88. Longnecker, R., et al., Deletion of DNA encoding the first five transmembrane domains of 
Epstein-Barr virus latent membrane proteins 2A and 2B. J Virol, 1993. 67(8): p. 5068-5074. 
89. Pender, M., Infection of autoreactive B lymphocytes with EBV, causing chronic autoimmune 
diseases. Trends Immunol, 2003. 24(11): p. 584-588. 
90. Operskalski, E.A., et al., A case-control study of multiple sclerosis. Neurology, 1989. p. 825-
829. 
91. Lindberg, C., et al., Epidemiological investigation of the association between infectious 
mononucleosis and multiple sclerosis. Neuroepidemiology, 1991. 10(2): p. 62-65. 
92. Nielsen, T.R., Multiple sclerosis after infectious mononucleosis. Arch Neurol, 2007. p. 72-75. 
93. Ramagopalan, S.V., et al., Association of infectious mononucleosis with multiple sclerosis. A 
population-based study. Neuroepidemiology, 2009. 32(4): p. 257-262. 
94. Nielsen, T.R., et al., Effects of infectious mononucleosis and HLA-DRB1*15 in multiple 
sclerosis. Mult Scler, 2009. 15(4): p. 431-436. 
95. Thacker, E., Infectious mononucleosis and risk for multiple sclerosis: A meta-analysis. Ann 
Neurol, 2006. 59(3): p. 499-503. 
96. Alotaibi, S., Epstein-Barr Virus in Pediatric Multiple Sclerosis. JAMA, 2004. p. 1875-1879. 
97. Pohl, D., et al., High seroprevalence of Epstein-Barr virus in children with multiple sclerosis. 
Neurology, 2006. p. 2063-2065. 
98. Lünemann, J.D., et al., Broadened and elevated humoral immune response to EBNA1 in 
pediatric multiple sclerosis. Neurology, 2008. p. 1033-1035. 
99. Levin, L.I., et al., Temporal relationship between elevation of Epstein-Barr virus antibody 
titers and initial onset of neurological symptoms in multiple sclerosis. JAMA, 2005. p. 2496-
2500. 
100. Ascherio, A., et al., Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective 
study. JAMA, 2001. p. 3083-3088. 
101. DeLorenze, G.N., et al., Epstein-Barr virus and multiple sclerosis: evidence of association 
from a prospective study with long-term follow-up. Arch Neurol, 2006. 63(6): p. 839-844. 
102. Lünemann, J.D., et al., Elevated Epstein-Barr virus-encoded nuclear antigen-1 immune 
responses predict conversion to multiple sclerosis. Ann Neurol, 2010. p. 159-169. 
103. Jilek, S., et al., Strong EBV-specific CD8+ T-cell response in patients with early multiple 
sclerosis. Brain, 2008. 131: p. 1712-1721. 
104. Farrell, R.A., et al., Humoral immune response to EBV in multiple sclerosis is associated with 
disease activity on MRI. Neurology, 2009. 73(1): p. 32-8. 
105. Lünemann, J.D., et al., Increased frequency and broadened specificity of latent EBV nuclear 
antigen-1-specific T cells in multiple sclerosis. Brain, 2006. p. 1493-1506. 
 REFERENCES 
	   127 
106. Lünemann, J.D., et al., EBNA1-specific T cells from patients with multiple sclerosis cross 
react with myelin antigens and co-produce IFN-gamma  and IL-2. J Exp Med, 2008. 205(8): 
p. 1763-1773. 
107. Harkiolaki, M., et al., T cell-mediated autoimmune disease due to low-affinity crossreactivity 
to common microbial peptides. Immunity, 2009. 30(3): p. 348-357. 
108. Lang, H., A functional and structural basis for TCR cross-reactivity in multiple sclerosis. Nat 
Immunol, 2002. 3(10): p. 940-943. 
109. Olson, J.K., et al., A virus-induced molecular mimicry model of multiple sclerosis. J Clin 
Invest, 2001. 108(2): p. 311-318. 
110. Thorley-Lawson, D.A., Epstein-Barr virus: Exploiting the immune system. Nat Rev Immunol, 
2001. p. 75-82. 
111. Serafini, B., Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. The J 
Exp Med, 2007. 204(12): p. 2899-2912. 
112. Willis, S.N., et al., Epstein-Barr virus infection is not a characteristic feature of multiple 
sclerosis brain. Brain, 2009. 132: p. 3318-3328. 
113. Peferoen, L.A., et al., Epstein Barr virus is not a characteristic feature in the central nervous 
system in established multiple sclerosis. Brain, 2010. 133: p. e137. 
114. Sargsyan, S.A., et al., Absence of Epstein-Barr virus in the brain and CSF of patients with 
multiple sclerosis. Neurology, 2010. 74(14): p. 1127-1135. 
115. Vincent, A., Unravelling the pathogenesis of myasthenia gravis. Nat Rev Immunol, 2002. 
2(10): p. 797-804. 
116. Hohlfeld, R. and H. Wekerle, Reflections on the "intrathymic pathogenesis" of myasthenia 
gravis. J Neuroimmunol, 2008. 201-202: p. 21-7. 
117. Shiono, H., et al., Scenarios for autoimmunization of T and B cells in myasthenia gravis. Ann 
N Y Acad Sci, 2003. 998: p. 237-56. 
118. Aoki, T., et al., Attempts to implicate viruses in myasthenia gravis. Neurology, 1985. 35(2): p. 
185-92. 
119. Klavinskis, L.S., et al., Attempted isolation of viruses from myasthenia gravis thymus. J 
Neuroimmunol, 1986. 11(4): p. 287-99. 
120. Cavalcante, P., et al., Epstein-Barr virus persistence and reactivation in myasthenia gravis 
thymus. Ann Neurol, 2010. 67(6): p. 726-738. 
121. Esen, B.A., et al., Serologic response to Epstein-Barr virus antigens in patients with systemic 
lupus erythematosus: a controlled study. Rheumatol Int, 2012. 32(1): p. 79-83. 
122. Chen, D.Y., et al., Polymyositis/dermatomyositis and nasopharyngeal carcinoma: the Epstein-
Barr virus connection? J Clin Virol, 2010. 49(4): p. 290-5. 
123. Yadav, P., et al., Antibodies Elicited in Response to EBNA-1 May Cross-React with dsDNA. 
PloS One, 2011. 6(1). 
124. Sundar, K., et al., Expression of the Epstein-Barr virus nuclear antigen-1 (EBNA-1) in the 
mouse can elicit the production of anti-dsDNA and anti-Sm antibodies. J Autoimmun, 2004. 
23(2): p. 127-140. 
REFERENCES 	  
	   128	  
125. Kang, I., Defective Control of Latent Epstein-Barr Virus Infection in Systemic Lupus 
Erythematosus. J  Immunol, 2004. p. 1287-1294. 
126. Larsen, M., et al., Exhausted Cytotoxic Control of Epstein-Barr Virus in Human Lupus. PLoS 
Pathogens, 2011. 7(10). 
127. Ulff-Moller, C.J., et al., Epstein-Barr virus-associated infectious mononucleosis and risk of 
systemic lupus erythematosus. Rheumatology, 2010. 49(9): p. 1706-1712. 
128. Toussirot, E. and J. Roudier, Epstein-Barr virus in autoimmune diseases. Best Pract Res Clin 
Rheumatol, 2008. p. 883-896. 
129. Baboonian, C., et al., Cross reaction of antibodies to a glycine/alanine repeat sequence of 
Epstein-Barr virus nuclear antigen-1 with collagen, cytokeratin, and actin. Ann Rheum Dis, 
1991. 50(11): p. 772-775. 
130. Saal, J.G., et al., Synovial Epstein-Barr virus infection increases the risk of rheumatoid 
arthritis in individuals with the shared HLA-DR4 epitope. Arthritis Rheum, 1999. 42(7): p. 
1485-1496. 
131. Epstein, M.A., et al., Protection of cottontop tamarins against Epstein-Barr virus-induced 
malignant lymphoma by a prototype subunit vaccine. Nature, 1985. 318(6043): p. 287-289. 
132. Cadavid, L.F., B.E. Mejía, and D.I. Watkins, MHC class I genes in a New World primate, the 
cotton-top tamarin (Saguinus oedipus), have evolved by an active process of loci turnover. 
Immunogenetics, 1999. 49(3): p. 196-205. 
133. Cohen, J.I., et al., The need and challenges for development of an Epstein-Barr virus vaccine. 
Vaccine, 2013. 31: p. B194-B196. 
134. Sashihara, J., et al., Soluble Rhesus Lymphocryptovirus gp350 Protects against Infection and 
Reduces Viral Loads in Animals that Become Infected with Virus after Challenge. PLoS 
Pathogens, 2011. 7(10): p. e1002308. 
135. Gu, S.Y., et al., First EBV vaccine trial in humans using recombinant vaccinia virus 
expressing the major membrane antigen. Dev Biol Stand, 1995. 84: p. 171-177. 
136. Sokal, E.M., et al., Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, 
randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, 
and efficacy of an Epstein-Barr virus vaccine in healthy young adults. J Infect Dis, 2007. 
196(12): p. 1749-1753. 
137. Berger, C., et al., Dynamics of Epstein‐Barr virus DNA levels in serum during EBV‐
associated disease. J Med Virol, 2001. 64(4): p. 505-512. 
138. Scherrenburg, J., et al., Detailed analysis of EpsteinBarr virus-specific CD4 and CD8 T cell 
responses during infectious mononucleosis. Clin Exp Immunol, 2008. 153(2): p. 231-239. 
139. Lünemann, J., et al., Increased frequency of EBV-specific effector memory CD8+ T cells 
correlates with higher viral load in rheumatoid arthritis. J Immunol, 2008. 181(2): p. 991-
1000. 
140. Willcox, H.N., J. Newsom-Davis, and L.R. Calder, Greatly increased autoantibody 
production in myasthenia gravis by thymocyte suspensions prepared with proteolytic enzymes. 
Clin Exp Immunol, 1983. 54(2): p. 378-86. 
141. Lünemann, J.D., et al., Increased frequency of EBV-specific effector memory CD8+ T cells 
correlates with higher viral load in rheumatoid arthritis. J Immunol, 2008. 181(2): p. 991-
1000. 
 REFERENCES 
	   129 
142. Strowig, T., et al., Human NK cells of mice with reconstituted human immune system 
components require preactivation to acquire functional competence. Blood, 2010. 116(20): p. 
4158-67. 
143. Reindl, M., et al., Antibodies against the myelin oligodendrocyte glycoprotein and the myelin 
basic protein in multiple sclerosis and other neurological diseases: a comparative study. 
Brain, 1999. 122: p. 2047-2056. 
144. Egg, R., et al., Anti-MOG and anti-MBP antibody subclasses in multiple sclerosis. Mult Scler, 
2001. 7(5): p. 285-289. 
145. Lebar, R., et al., The M2 autoantigen of central-nervous-system myelin, a glycoprotein present 
in oligodendrocyte membrane. Clin Exp Immunol, 1986. 66(2): p. 423-434. 
146. Baranzini, S., et al., B cell repertoire diversity and clonal expansion in multiple sclerosis 
brain lesions. J Immunol, 1999. 163(9): p. 5133-5144. 
147. Bielekova, B., et al., Expansion and functional relevance of high-avidity myelin-specific 
CD4+ T cells in multiple sclerosis. J Immunol, 2004. p. 3893-3904. 
148. Comabella, M., et al., EBV-specific immune responses in patients with multiple sclerosis 
responding to IFNbeta therapy. Mult Scler, 2012. 18(5): p. 605-9. 
149. Currier, J.R., et al., A panel of MHC class I restricted viral peptides for use as a quality 
control for vaccine trial ELISPOT assays. J Immunol Methods, 2002. 260(1-2): p. 157-72. 
150. Münz, C., et al., Human CD4(+) T lymphocytes consistently respond to the latent Epstein-
Barr virus nuclear antigen EBNA1. J Exp Med, 2000. 191(10): p. 1649-1660. 
151. Jones, M.D. and B.E. Griffin, Clustered repeat sequences in the genome of Epstein Barr virus. 
Nucleic Acids Res, 1983. 11(12): p. 3919-37. 
152. Krueger, R.E. and G.D. Mayer, Tilorone hydrochloride: an orally active antiviral agent. 
Science, 1970, 169(951): p. 1213-1214. 
153. Ressing, M.E., et al., Impaired transporter associated with antigen processing-dependent 
peptide transport during productive EBV infection. J Immunol, 2005. 174(11): p. 6829. 
154. Epstein, M.A. and B.G. Achong, Pathogenesis of infectious mononucleosis. Lancet, 1977. 
2(8051): p. 1270-1273. 
155. Wollheim, F.A. and R.C. Williams, Jr., Studies on the macroglobulins of human serum. I. 
Polyclonal immunoglobulin class M (IgM) increase in infectious mononucleosis. N Engl J 
Med, 1966. 274(2): p. 61-7. 
156. Sutton, R.N., et al., The occurrence of autoantibodies in infectious mononucleosis. Clin Exp 
Immunol, 1974. 17(3): p. 427-436. 
157. Carter, R.L., Antibody formation in infectious mononucleosis. I. Some immunochemical 
properties of the Paul-Bunnell antibody. Br J Haematol, 1966. 12(3): p. 259-67. 
158. Holborow, E.J., et al., Antinuclear factor and other antibodies in blood and liver diseases. Br 
Med J, 1963. 1(5331): p. 656-8. 
159. Holborow, E.J., E.H. Hemsted, and S.V. Mead, Smooth muscle autoantibodies in infectious 
mononucleosis. Br Med J, 1973. 3(5875): p. 323-5. 
160. Kaplan, M.E. and E.M. Tan, Antinuclear antibodies in infectious mononucleosis. Lancet, 
1968. 1(7542): p. 561-563. 
REFERENCES 	  
	   130	  
161. Carter, R.L., Proceedings: Infectious mononucleosis. Immunopathology. J Clin Pathol, 1973. 
26(12): p. 987-8. 
162. Prineas, J.W., The neuropathology of multiple sclerosis. Handbook Clin Neurol. Vol. 47. 
1985. 213-257. 
163. Prineas, J.W. and J.S. Graham, Multiple-sclerosis - capping of surface immunoglobulin-G on 
macrophages engaged in myelin breakdown. Ann Neurol, 1981. 10(2): p. 149-158. 
164. Gay, D. and M. Esiri, Blood-brain-barrier damage in acute multiple-sclerosis plaques - an 
immunocytological study. Brain, 1991. 114: p. 557-572. 
165. Linington, C. and H. Lassmann, Antibody-responses in chronic relapsing experimental 
allergic encephalomyelitis - correlation of serum demyelinating activity with antibody titer to 
the myelin oligodendrocyte glycoprotein (MOG). J Neuroimmunol, 1987. 17(1): p. 61-69. 
166. Adelmann, M., et al., The N-terminal domain of the myelin oligodendrocyte glycoprotein 
(MOG) induces acute demyelinating experimental autoimmune encephalomyelitis in the Lewis 
rat. J Neuroimmunol, 1995. 63(1): p. 17-27. 
167. Amor, S., et al., Identification of epitopes of myelin oligodendrocyte glycoprotein for the 
induction of experimental allergic encephalomyelitis in SJL and Biozzi AB/H mice. J 
Immunol, 1994. 153(10): p. 4349-4356. 
168. Genain, C.P., et al., Antibody facilitation of multiple sclerosis-like lesions in a nonhuman 
primate. J Clin Invest, 1995. 96(6): p. 2966-2974. 
169. Berger T., et al., Antimyelin Antibodies as a Predictor of Clinically Definite Multiple 
Sclerosis. N Engl J Med. 2003: p. 1-7. 
170. Kuhle, J., Lack of association between antimyelin antibodies and progression to multiple 
sclerosis. New Engl J Med, 2007. 356(4): p. 371-378. 
171. Jilek, S., et al., Severe post-EBV encephalopathy associated with myelin oligodendrocyte 
glycoprotein-specific immune response. J Neuroimmunol, 2007. 192(1-2): p. 192-197. 
172. Tracy, S.I., et al., Persistence of Epstein-Barr Virus in Self-Reactive Memory B Cells. J Virol, 
2012. 86(22): p. 12330-12340. 
173. Whitehouse, J.M., N. Ferguson, and G.A. Currie, Autoantibody to microtubules in infectious 
mononucleosis. Clin Exp Immunol, 1974. 17(2): p. 227-35. 
174. Meckes, D.G., Jr., N.F. Menaker, and N. Raab-Traub, Epstein-Barr virus LMP1 modulates 
lipid raft microdomains and the vimentin cytoskeleton for signal transduction and 
transformation. J Virol, 2013. 87(3): p. 1301-11. 
175. Alcover, A., et al., Antibodies to vimentin intermediate filaments in sera from patients with 
SLE and RA: quantitation by solid phase radioimmunoassay. J Rheumatol, 1985. 12(2): p. 
233-6. 
176. Kataaha, P.K., et al., Anti-intermediate filament antibodies, antikeratin antibody, and 
antiperinuclear factor in rheumatoid arthritis and infectious mononucleosis. Ann Rheum Dis, 
1985. 44(7): p. 446-449. 
177. Liebowitz, D., et al., An Epstein-Barr virus transforming protein associates with vimentin in 
lymphocytes. Mol Cell Biol, 1987. 7(7): p. 2299-308. 
 REFERENCES 
	   131 
178. Strang, G. and A.B. Rickinson, Multiple HLA class I-dependent cytotoxicities constitute the 
"non-HLA-restricted" response in infectious mononucleosis. Eur J Immunol, 1987. 17(7): p. 
1007-13. 
179. Burrows, S.R., et al., An alloresponse in humans is dominated by cytotoxic T lymphocytes 
(CTL) cross-reactive with a single Epstein-Barr virus CTL epitope: implications for graft-
versus-host disease. J Exp Med, 1994. 179(4): p. 1155-1161. 
180. Misko, I.S., et al., Crossreactive recognition of viral, self, and bacterial peptide ligands by 
human class I-restricted cytotoxic T lymphocyte clonotypes: implications for molecular 
mimicry in autoimmune disease. Proc Natl Acad Sci U S A, 1999. 96(5): p. 2279-2284. 
181. Clute, S.C., Cross-reactive influenza virus-specific CD8+ T cells contribute to 
lymphoproliferation in Epstein-Barr virus-associated infectious mononucleosis. J Clin Invest, 
2005. 115(12): p. 3602-3612. 
182. Wucherpfennig, K. and J. Strominger, Molecular mimicry in T cell-mediated autoimmunity: 
Viral peptides activate human T cell clones specific for myelin basic protein. Cell, 1995. 
80(5): p. 695-705. 
183. Lang, H.L.E., et al., A functional and structural basis for TCR cross-reactivity in multiple 
sclerosis. Nat Immunol, 2002. 3(10): p. 940-943. 
184. Lünemann, J.D., et al., EBNA1-specific T cells from patients with multiple sclerosis cross 
react with myelin antigens and co-produce IFN-gamma and IL-2. J Exp Med, 2008. p. 1763-
1773. 
185. Borysiewicz, L.K., et al., Epstein Barr virus-specific immune defects in patients with 
persistent symptoms following infectious mononucleosis. Q J Med, 1986. 58(226): p. 111-121. 
186. Lünemann, J. and C. Münz, EBV in MS: guilty by association? Trends Immunol. 2009. 30(6): 
p.243-248. 
187. Hochberg, D., Demonstration of the Burkitt's lymphoma Epstein-Barr virus phenotype in 
dividing latently infected memory cells in vivo. Proc Natl Acad Sci U S A. 2004. 101(1): 
p.239-244. 
188. Zhang, Q., et al., The Epstein-Barr virus (EBV) DNA polymerase accessory protein, BMRF1, 
activates the essential downstream component of the EBV oriLyt. Virology, 1997. 230(1): p. 
22-34. 
189. Nonkwelo, C., I.K. Ruf, and J. Sample, Interferon-independent and -induced regulation of 
Epstein-Barr virus EBNA-1 gene transcription in Burkitt lymphoma. J Virol, 1997. 71(9): p. 
6887-6897. 
190. Zhang, L. and J.S. Pagano, Interferon regulatory factor 2 represses the Epstein-Barr virus 
BamHI Q latency promoter in type III latency. Mol Cell Biol, 1999. 19(4): p. 3216-3223. 
191. Zang, Y.C., et al., Immunoregulation and blocking antibodies induced by interferon beta 
treatment in MS. Neurology, 2000. 55(3): p. 397-404. 
192. Tamura, T., et al., The IRF family transcription factors in immunity and oncogenesis. Annu 
Rev Immunol, 2008. 26: p. 535-84. 
193. Freer, G., et al., Role of T helper cell precursor frequency on vesicular stomatitis virus 
neutralizing antibody responses in a T cell receptor beta chain transgenic mouse. Eur J 
Immunol, 1995. 25(5): p. 1410-6. 
REFERENCES 	  
	   132	  
194. Strowig, T., et al., Priming of protective T cell responses against virus-induced tumors in mice 
with human immune system components. J Exp Med, 2009. 206(6): p. 1423-1434. 
195. Münz, C., et al., Antiviral immune responses: triggers of or triggered by autoimmunity? Nat 
Rev Immunol, 2009. 9(4): p. 246-258. 
196. Klavinskis, L.S., et al., Antivirus antibodies in myasthenia gravis. Neurology, 1985. 35(9): p. 
1381-4. 
197. Csuka, D., et al., High anti-EBNA-1 IgG levels are associated with early-onset myasthenia 
gravis. Eur J Neurol, 2012. 19(6): p. 842-846. 
198. Meyer, M., et al., Lack of evidence for epstein‐barr virus infection in myasthenia gravis 
thymus. Ann Neurol, 2011. 70(3): p. 515-518. 
199. Jing, F., et al., Lack of Epstein-Barr virus infection in Chinese myasthenia gravis patients. 
Acta Neurol Scand, 2013. 
200. Marechal, V., et al., Mapping EBNA-1 domains involved in binding to metaphase 
chromosomes. J Virol, 1999. 73(5): p. 4385-4392. 
201. Nasimuzzaman, M., et al., Eradication of Epstein-Barr virus episome and associated 
inhibition of infected tumor cell growth by adenovirus vector-mediated transduction of 
dominant-negative EBNA1. Mol Ther, 2005. 11(4): p. 578-590. 
202. Kariya, Y., et al., Dominant-negative derivative of EBNA1 represses EBNA1-mediated 
transforming gene expression during the acute phase of Epstein-Barr virus infection 
independent of rapid loss of viral genome. Cancer Sci, 2010. 101(4): p. 876-81. 
203. Wang, H., et al., EBV latent membrane protein 2A induces autoreactive B cell activation and 
TLR hypersensitivity. 2006. p. 2793-2802. 
204. Kennedy, G. and B. Sugden, EBNA-1, a bifunctional transcriptional activator. Mol Cell Biol, 
2003. 23(19): p. 6901-6908. 
205. Smith, D. and B. Sugden, Potential Cellular Functions of Epstein-Barr Nuclear Antigen 1 
(EBNA1) of Epstein-Barr Virus. Viruses, 2013. 5(1): p. 226-240. 
206. Kang, M.S., et al., Roscovitine inhibits EBNA1 serine 393 phosphorylation, nuclear 
localization, transcription, and episome maintenance. J Virol, 2011. 85(6): p. 2859-68. 
207. Thompson, S., et al., Development of a high-throughput screen for inhibitors of Epstein-Barr 
virus EBNA1. J Biomol Screen, 2010. 15(9): p. 1107-1115. 
208. Li, N., et al., Discovery of selective inhibitors against EBNA1 via high throughput in silico 
virtual screening. PLoS One. 2010 5(4). 
209. Kim, S.Y., et al., Small molecule and peptide-mediated inhibition of Epstein-Barr virus 
nuclear antigen 1 dimerization. Biochem Bioph Res Co, 2012: p. 1-6. 
210. Arvey, A., et al., An Atlas of the Epstein-Barr Virus Transcriptome and Epigenome Reveals 
Host-Virus Regulatory Interactions. Cell Host Microbe, 2012. 12(2): p. 233-245. 
211. Zhou, D., et al., Synthesis and activity evaluation of tilorone analogs as potential anticancer 
agents. Eur J Med Chem, 2013. 64(C): p. 432-441. 
212. Chandra, P. and G.J. Wright, Tilorone hydrochloride: the drug profile. Top Curr Chem , 1977. 
72: p. 125-148. 
 REFERENCES 
	   133 
213. Wacker, A., et al., Distribution of C-14 Tilorone in Mice. Naturwissenschaften, 1972. 59(11): 
p. 520. 
214. Zinkovsky, V.G., O.V. Zhuk, and S.K. Sumriy, Pharmacokinetics of a synthetic interferon 
inducer amixin in mice. Pharmacol Rep, 2007. 59(6): p. 739-751. 
215. Kleinschmidt, W.J., Biochemistry of interferon and its inducers. Ann Rev Biochem, 1972. 
41(10): p. 517-542. 
216. Mannering, G.J. and L.B. Deloria, The pharmacology and toxicology of the interferons: an 
overview. Ann Rev Pharmacol Toxicol, 1986. 26: p. 455-515. 
 
 
 
	  	   134	  
ACKNOWLEDGEMENTS 	  
	   135 
ACKNOWLEDGEMENTS	  
 
First and foremost, I would like to thank my supervisor, Jan Lünemann, for giving me the 
opportunity to perform my doctoral studies in his laboratory. That enabled me to contribute to 
a variety of projects, many of which were successfully published, to establish international 
collaborations, and to participate at local and international conferences and student programs, 
all of which have provided a tremendous boost to my professional as well as personal 
development.  
I would also like to thank Christian Münz for the constant support, scientific advice, 
supervision, and inspiration throughout the last four years.  
For the invaluable opportunity to work with the humanized mouse model I would like 
to express my gratitude to all people involved in the arduous task of generating and taking 
care of the mice: Sonja Meixlsperger-Rämer, Patrick Rämer, Obinna Chijioke, Carol Leung, 
Olga Antsiferova, Ana Raykova, Donal McHugh, Cornelia Gujer, Vanessa Landtwing, Bithi 
Chatterjee, Debora Häfeli, and the rest of the mouse house team. 
My warmest gratitude to our collaborators who contributed to the experimental data 
used in this thesis: Fabienne Brilot-Turville (University of Sydney) for providing us with 
complete protocols and materials for the MOG serum reactivity assay; Walter Bossart and 
Riccarda Capaul (Medical Virology, UZH) for EBV quantification; Stefan Regenass (Clinical 
Immunology, USZ) for HEp2 staining, CCP and SS-A detection, Nick Willcox (University of 
Oxford) and Björn Tackenberg (University of Marburg) for MG patient samples; Manuel 
Comabella (Hospital Universitari Vall d'Hebron) for MS patient samples; Silke Wiesmayr 
and Kevin Rostasy (University Hospital Innsbruck), Tarik Azzi and David Nadal 
(Experimental Infectious Diseases and Cancer Research, UZH) for IM and control patient 
samples; Silvia Behnke (Sophistolab) for tissue histology, European Screening Port for HTS 
assay expertise. 
I would also like to thank Burkhard Becker and Burkhard Ludewig for agreeing to 
take part in my PhD committee and for providing me with scientific guidance and 
encouragement.  
My four years at the Institute of Experimental Immunology would have not been the 
amazing time they were without the great friendships that I made. Most importantly, thanks to 
Michael Maurer, Patrick Weber, Christina Sina, Isaak Quast, Christian Keller, Flavio Cueni, 
and Deeqa Osman for the great time in the Lünemann lab and the advice, support and help 
with experimental troubleshooting. Many thanks to Heike Nowag, Olga Antsiferova, Rosa 
Barreira, Ana Raykova, Vanessa Landtwing, and Donal McHugh for their friendship and 
support through the common PhD ups-and-downs. Credits to Carol Leung, Susana Romao, 
ACKNOWLEDGEMENTS 	  
	   136	  
Sonja Meixlsperger-Rämer, Patrick Rämer, Monique Ghannage, Obinna Chijioke, 
Bithi Chatterjee, and Cornelia Gujer for their expert advice on experiments and life in 
general; and to Patrick Weber, Anne Müller, Danusia Vanoaica, and Brady Messmer for 
keeping the lab up and running. Greatly appreciated are also all the other members of the 
Institute of Experimental Immunology, and all the born and born-to-be lab babies who kept 
the rumors and excitement in the institute alive. 
Next, I would like to express my tremendous gratitude to my family for encouraging 
me to pursue my dreams away from my home country, for their invaluable support and 
motivation throughout the years. 
Last but not least, I would like to thank Christian Beeler for making my time in 
Switzerland an unforgettable and life-changing experience, and for providing the balance that 
made it possible to successfully surmount the difficulties I am encountering on my way. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  	   137 
CURRICULUM VITAE 
 
 
Name: Kristina Kakalacheva 
Work Email: kristina.kakalacheva@uzh.ch 
Private Email: k.kakalacheva@gmail.com  
 
Date of Birth:  May 16th, 1986  
Nationality:  Bulgarian  
 
 
EDUCATION  
 
10/2009 – to date  University of Zurich, Switzerland 
  PhD in Immunology 
 
 09/2008 – 09/2009  University of Oxford, UK 
  MSc in Integrated Immunology 
 
09/2005 – 05/2008  Jacobs University Bremen, Germany  
 BSc in Biochemistry and Cell Biology 
   
09/2001 – 05/2005  High School Vasil Levski, Bulgaria  
Graduated with diploma in Natural Sciences and Mathematics    
 
 
PRACTICAL EXPERIENCE  
 
10/2009 – to date Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland 
Doctoral thesis conducted in the laboratory of Prof. Jan Lünemann on Epstein-Barr 
virus: environmental trigger and therapeutic target in autoimmune diseases. Member 
of the Microbiology and Immunology track of the Life Sciences Graduate School. 
 
04/2009 – 09/2009 Jenner Institute, Oxford, UK 
 Master thesis conducted in the group of Prof. Adrian Hill on the Induction of 
Indoleamine 2,3-dioxygenase by tuberculosis vaccines and its impact on vaccine 
immunogenicity. 
 
07/2008 – 09/2008 Swiss Federal Institute of Technology (ETH), Zurich, Switzerland 
Participant in the International Biology Undergraduate Summer School, including a 
two-month research project in the group of Prof. Martin Lössner on the 
Characterization of recombinase protein of a novel L. monocytogenes bacteriophage.   
 
01/2008 – 02/2008 Max Planck Institute for Marine Microbiology, Bremen, Germany 
 Guided research in the group of Prof. Antje Boetius on the Identification of the 
phylogeny of giant sulfide-oxidizing bacteria.   
 
09/2007 – 12/2007 Jacobs University Bremen, Bremen, Germany 
 Guided research in the group of Prof. Klaudia Brix on the Determination of the role of 
lipoprotein receptor-related protein 1 in binding cathepsin B on the surface of 
migrating keratynocytes.  
 
07/2007 – 09/2007 Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK 
Internship in the group of Dr. Zoia Larin Monaco on the Development of human 
artificial chromosomes for gene therapy.   
 
06/2006 – 09/2006 Applied Biocatalysis Research Center, Graz, Austria 
 Internship in the group of Prof. Anton Glieder on Cloning and expression of bacterial 
cytochrome P450 enzymes. 
 
	  	   138	  
AWARDS AND HONORS 
  
08/2012 Merck Serono Innovation Cup 
Winner of competition for most innovative business plan on a novel autoimmune 
disease treatment strategy  
 
06/2012 RIKEN Research Center for Allergy and Immunology 
Awarded funding to attend a summer research program for young scientists in Japan  
 
09/2008 – 09/2009  Integrated Immunology Bursary Fund  
Granted to pursue a Master’s degree at the University of Oxford 
 
05/2007 – 05/2008 Annual Academic Life Steps Financial Grant, American Standard Foundation 
Awarded for outstanding academic performance 
 
09/2005 – 05/2008 Merit-Based Academic Scholarship from Jacobs University Bremen  
Granted to pursue a Bachelor‘s degree 
 
 
COURSES AND ACTIVITIES 
 
08/2013 Science and Technology Leadership Association (STeLA) Forum 
Workshop aiming at developing leadership skills for students in science and 
engineering, and facilitating multicultural dialogue on global issues 
 
02/2013 – 06/2013 Challenges in Drug Discovery and Development, Swiss Biotech Association  
Six-module course taught by leaders in the pharmaceutical and biotech industries 
 
08/2012 Merck Serono Innovation Cup 
 Challenging competition for development of an innovative business plan involving 
collaborative teamwork, successful presentation, and proposal defense in front of 
Merck Serono managers 
 
02/2012 – 06/2012 Entrepreneurship Course Venture Challenge, ETH Zurich 
Lectures by leading entrepreneurs and start-up coaches involving extensive teamwork 
on the founding of a biotech start-up 
  
08/2011  Novartis International Biotechnology Leadership Camp (BioCamp) 
 Workshop on the trends and challenges facing the pharmaceutical industry including 
teamwork and presentation of a case study on transforming a research finding into a 
start-up idea 
 
 
CONFERENCES 
 
04/2013   Roche Nature Medicine Immunology Symposium, Buonas, Switzerland 
  Poster presentation 
 
03/2013   Young Investigators Meeting, Grindelwald, Switzerland 
   Oral presentation 
 
04/2013  RIKEN RCAI International Summer Program, Yokohama, Japan 
 Poster and oral presentation 
 
04/2013  7th ENII Immunology Spring School, Sardinia, Italy  
   Poster presentation 
 
01/2012  Swiss Academy of Sciences Workshop on “How to Improve Animal 
Experimentation”, Rigi Kulm, Switzerland 
 Poster and oral presentation 
 
 
 
	  	   139 
04/2011   XXII Meeting of the Swiss Immunology PhD Students, Schloss Wolfsberg, 
Switzerland 
Oral presentation 
 
03/2011   Young Investigators Meeting, Crans-Montana, Switzerland 
   Oral presentation 
 
09/2010  Microbiology and Immunology Life Sciences Graduate School PhD Program 
Retreat, Ascona, Switzerland 
  Oral presentation 
 
 
PUBLICATIONS 
 
Tracy SI, Kakalacheva K, Lünemann JD, Luzuriaga K, Middeldorp J, Thorley-Lawson 
DA. Persistence of Epstein-Barr virus in self-reactive memory B cells. J Virol. 2012 
Nov;86(22):12330-40.  
 
Jelcić I, Hsu KC, Kakalacheva K, Breiden P, Dupont B, Uhrberg M, Martin R, Münz 
C, Lünemann JD. Killer immunoglobulin-like receptor locus polymorphisms in 
multiple sclerosis. Mult Scler. 2012 Jul;18(7):951-8.  
 
Comabella M, Kakalacheva K, Río J, Münz C, Montalban X, Lünemann JD. EBV-
specific immune responses in patients with multiple sclerosis responding to IFNβ 
therapy. Mult Scler. 2012 May;18(5):605-9.  
 
Kakalacheva K, Maurer MA, Tackenberg B, Münz C, Willcox N, Lünemann 
JD.Intrathymic Epstein-Barr virus infection is not a prominent feature of 
myasthenia gravis. Ann Neurol. 2011 Sep;70(3):508-14.  
 
Kakalacheva K, Lünemann JD. Environmental triggers of multiple sclerosis. FEBS 
Lett. 2011 Dec 1;585(23):3724-9. 
 
Kakalacheva K, Comabella M. Epstein-Barr virus and multiple sclerosis: causation 
or association? Future Microbiol. 2010 Nov;5(11):1617-9.  
 
Kakalacheva K, Münz C, Lünemann JD. Viral triggers of multiple sclerosis. Biochim 
Biophys Acta. 2011 Feb;1812(2):132-40.  
 
Comabella M, Montalban X, Kakalacheva K, Osman D, Nimmerjahn F, Tintoré M, 
Lünemann JD. B cell expression of the inhibitory Fc gamma receptor is unchanged 
in early MS. J Neuroimmunol. 2010 Jun;223(1-2):135-7. 
 
Comabella M, Montalban X, Horga A, Messmer B, Kakalacheva K, Strowig T, 
Caballero E, Münz C, Lünemann JD. Antiviral immune response in patients with 
multiple sclerosis and healthy siblings. Mult Scler. 2010 Mar;16(3):355-8. 
 
